

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12383166
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Desborough; Lane et al.

Insulin delivery system and methods with risk-based set points

Abstract

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

Inventors:	Desborough; Lane (Milpitas, CA), Mazlish; Bryan (Milpitas, CA)
Applicant:	Insulet Corporation (Acton, MA)
Family ID:	60329203
Assignee:	Insulet Corporation (Acton, MA)
Appl. No.:	15/601282
Filed:	May 22, 2017

Prior Publication Data

Document Identifier	Publication Date
US 20170332952 A1	Nov. 23, 2017

Related U.S. Application Data

us-provisional-application US 62340469 20160523

Publication Classification

Int. Cl.: G16H40/63 (20180101); A61B5/00 (20060101); A61B5/145 (20060101); A61M5/00 (20060101); A61M5/142 (20060101); A61M5/172 (20060101); G16H20/17 (20180101)

U.S. Cl.:

CPC A61B5/14532 (20130101); A61B5/7275 (20130101); A61M5/003 (20130101); A61M5/14244 (20130101); A61M5/14248 (20130101); A61M5/14276 (20130101); A61M5/1723 (20130101); G16H20/17 (20180101); G16H40/63 (20180101); A61B5/0031 (20130101); A61B5/4836 (20130101); A61M2005/14268 (20130101); A61M2005/14296 (20130101); A61M2205/3569 (20130101); A61M2205/3584 (20130101); A61M2205/50 (20130101); A61M2205/502 (20130101); A61M2205/52 (20130101); A61M2205/8206 (20130101); A61M2230/201 (20130101)

Field of Classification Search

CPC: A61B (5/14532); A61B (5/7275); A61B (5/4836); A61B (5/4839); A61B (5/4848); G16H (20/17); G16H (50/30); G16H (20/10)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
303013	12/1883	Horton	N/A	N/A
445545	12/1890	Crane	N/A	N/A
588583	12/1896	Lade	N/A	N/A
1441508	12/1922	Marius et al.	N/A	N/A
2283925	12/1941	Harvey	N/A	N/A

2797149	12/1956	Skeggs	N/A	N/A
2886529	12/1958	Guillaud	N/A	N/A
3413573	12/1967	Nathanson et al.	N/A	N/A
3574114	12/1970	Monforte	N/A	N/A
3614554	12/1970	Shield et al.	N/A	N/A
3631847	12/1971	Hobbs	N/A	N/A
3634039	12/1971	Brondy	N/A	N/A
3812843	12/1973	Wootten et al.	N/A	N/A
3841328	12/1973	Jensen	N/A	N/A
3885662	12/1974	Schaefer	N/A	N/A
3963380	12/1975	Thomas et al.	N/A	N/A
3983077	12/1975	Fuller et al.	N/A	N/A
4055175	12/1976	Clemens et al.	N/A	N/A
4108177	12/1977	Pistor	N/A	N/A
4146029	12/1978	Ellinwood, Jr.	N/A	N/A
4151845	12/1978	Clemens	N/A	N/A
4245634	12/1980	Albisser et al.	N/A	N/A
4268150	12/1980	Chen	N/A	N/A
4295176	12/1980	Wittwer	N/A	N/A
4313439	12/1981	Babb et al.	N/A	N/A
4368980	12/1982	Aldred et al.	N/A	N/A
4373527	12/1982	Fischell	N/A	N/A
4400683	12/1982	Eda et al.	N/A	N/A
4403984	12/1982	Ash et al.	N/A	N/A
4424720	12/1983	Bucchianeri	N/A	N/A
4435173	12/1983	Siposs et al.	N/A	N/A
4464170	12/1983	Clemens et al.	N/A	N/A
4469481	12/1983	Kobayashi	N/A	N/A
4475901	12/1983	Kraegen et al.	N/A	N/A
4498843	12/1984	Schneider et al.	N/A	N/A
4507115	12/1984	Kambara et al.	N/A	N/A
4523170	12/1984	Huth, III	N/A	N/A
4526568	12/1984	Clemens et al.	N/A	N/A
4526569	12/1984	Bernardi	N/A	N/A
4529401	12/1984	Leslie et al.	N/A	N/A
4551134	12/1984	Slavik et al.	N/A	N/A
4559033	12/1984	Stephen et al.	N/A	N/A
4559037	12/1984	Franetzki et al.	N/A	N/A
4562751	12/1985	Nason et al.	N/A	N/A
4573968	12/1985	Parker	N/A	N/A
4585439	12/1985	Michel	N/A	N/A
4601707	12/1985	Albisser et al.	N/A	N/A
4624661	12/1985	Arimond	N/A	N/A
4633878	12/1986	Bombardieri	N/A	N/A
4634427	12/1986	Hannula et al.	N/A	N/A
4646038	12/1986	Wanat	N/A	N/A
4657529	12/1986	Prince et al.	N/A	N/A
4678408	12/1986	Nason et al.	N/A	N/A
4684368	12/1986	Kenyon	N/A	N/A
4685903	12/1986	Cable et al.	N/A	N/A
4731726	12/1987	Allen, III	N/A	N/A
4743243	12/1987	Vaillancourt	N/A	N/A
4755169	12/1987	Sarnoff et al.	N/A	N/A
4755173	12/1987	Konopka et al.	N/A	N/A
4759120	12/1987	Bernstein	N/A	N/A
4781688	12/1987	Thoma et al.	N/A	N/A
4781693	12/1987	Martinez et al.	N/A	N/A
4808161	12/1988	Kamen	N/A	N/A
4854170	12/1988	Brimhall et al.	N/A	N/A
4859492	12/1988	Rogers et al.	N/A	N/A
4880770	12/1988	Mir et al.	N/A	N/A
4886499	12/1988	Cirelli et al.	N/A	N/A
4898578	12/1989	Rubalcaba, Jr.	N/A	N/A
4898579	12/1989	Groshong et al.	N/A	N/A
4900292	12/1989	Berry et al.	N/A	N/A
4919596	12/1989	Slate et al.	N/A	N/A
4925444	12/1989	Orkin et al.	N/A	N/A
4940527	12/1989	Kazlauskas et al.	N/A	N/A
4944659	12/1989	Labbe et al.	N/A	N/A
4967201	12/1989	Rich, III	N/A	N/A

4969874	12/1989	Michel et al.	N/A	N/A
4975581	12/1989	Robinson et al.	N/A	N/A
4976720	12/1989	Machold et al.	N/A	N/A
4981140	12/1990	Wyatt	N/A	N/A
4994047	12/1990	Walker et al.	N/A	N/A
5007286	12/1990	Malcolm et al.	N/A	N/A
5007458	12/1990	Marcus et al.	N/A	N/A
5061424	12/1990	Karimi et al.	N/A	N/A
5062841	12/1990	Siegel	N/A	N/A
5084749	12/1991	Losee et al.	N/A	N/A
5097834	12/1991	Skrabal	N/A	N/A
5102406	12/1991	Arnold	N/A	N/A
5109850	12/1991	Blanco et al.	N/A	N/A
5125415	12/1991	Bell	N/A	N/A
5130675	12/1991	Sugawara	N/A	N/A
5134079	12/1991	Cusack et al.	N/A	N/A
5139999	12/1991	Gordon et al.	N/A	N/A
5153827	12/1991	Coutre et al.	N/A	N/A
5154973	12/1991	Imagawa et al.	N/A	N/A
5165406	12/1991	Wong	N/A	N/A
5176662	12/1992	Bartholomew et al.	N/A	N/A
5178609	12/1992	Ishikawa	N/A	N/A
5189609	12/1992	Tivig et al.	N/A	N/A
5198824	12/1992	Poradish	N/A	N/A
5205819	12/1992	Ross et al.	N/A	N/A
5207642	12/1992	Orkin et al.	N/A	N/A
5213483	12/1992	Flaherty et al.	N/A	N/A
5217754	12/1992	Santiago-Aviles et al.	N/A	N/A
5219377	12/1992	Poradish	N/A	N/A
5232439	12/1992	Campbell et al.	N/A	N/A
5237993	12/1992	Skrabal	N/A	N/A
5244463	12/1992	Cordner et al.	N/A	N/A
5254096	12/1992	Rondelet et al.	N/A	N/A
5257980	12/1992	Van et al.	N/A	N/A
5261882	12/1992	Sealfon	N/A	N/A
5263198	12/1992	Geddes et al.	N/A	N/A
5272485	12/1992	Mason et al.	N/A	N/A
5273517	12/1992	Barone et al.	N/A	N/A
5281202	12/1993	Weber et al.	N/A	N/A
5281808	12/1993	Kunkel	N/A	N/A
5299571	12/1993	Mastrototaro	N/A	N/A
5308982	12/1993	Ivaldi et al.	N/A	N/A
5342298	12/1993	Michaels et al.	N/A	N/A
5346476	12/1993	Elson	N/A	N/A
5364342	12/1993	Beuchat et al.	N/A	N/A
5377674	12/1994	Kuestner	N/A	N/A
5380665	12/1994	Cusack et al.	N/A	N/A
5385539	12/1994	Maynard	N/A	N/A
5389078	12/1994	Zalesky et al.	N/A	N/A
5403797	12/1994	Ohtani et al.	N/A	N/A
5411889	12/1994	Hoots et al.	N/A	N/A
5421812	12/1994	Langley et al.	N/A	N/A
5427988	12/1994	Sengupta et al.	N/A	N/A
5433710	12/1994	VanAntwerp et al.	N/A	N/A
5456945	12/1994	McMillan et al.	N/A	N/A
5468727	12/1994	Phillips et al.	N/A	N/A
5478610	12/1994	Desu et al.	N/A	N/A
5505709	12/1995	Funderburk et al.	N/A	N/A
5505828	12/1995	Wong et al.	N/A	N/A
5507288	12/1995	Boecker et al.	N/A	N/A
5513382	12/1995	Agahi-Kesheh et al.	N/A	N/A
5533389	12/1995	Kamen et al.	N/A	N/A
5535445	12/1995	Gunton	N/A	N/A
5536249	12/1995	Castellano et al.	N/A	N/A
5540772	12/1995	McMillan et al.	N/A	N/A
5543773	12/1995	Evans et al.	N/A	N/A
5558640	12/1995	Pfeiler et al.	N/A	N/A
5569186	12/1995	Lord et al.	N/A	N/A
5582593	12/1995	Hultman	N/A	N/A
5584053	12/1995	Kommrusch et al.	N/A	N/A

5584813	12/1995	Livingston et al.	N/A	N/A
5590387	12/1995	Schmidt et al.	N/A	N/A
5609572	12/1996	Lang	N/A	N/A
5614252	12/1996	McMillan et al.	N/A	N/A
5625365	12/1996	Tom et al.	N/A	N/A
5635433	12/1996	Sengupta	N/A	N/A
5637095	12/1996	Nason et al.	N/A	N/A
5665065	12/1996	Colman et al.	N/A	N/A
5665070	12/1996	Mcphee	N/A	N/A
5678539	12/1996	Schubert et al.	N/A	N/A
5685844	12/1996	Marttila	N/A	N/A
5685859	12/1996	Kornerup	N/A	N/A
5693018	12/1996	Kriesel et al.	N/A	N/A
5697899	12/1996	Hillman et al.	N/A	N/A
5700695	12/1996	Yassinzadeh et al.	N/A	N/A
5703364	12/1996	Rosenthal	N/A	N/A
5707459	12/1997	Itoyama et al.	N/A	N/A
5707715	12/1997	Derochemont et al.	N/A	N/A
5713875	12/1997	Tanner, II	N/A	N/A
5714123	12/1997	Sohrab	N/A	N/A
5716343	12/1997	Kriesel et al.	N/A	N/A
5722397	12/1997	Eppstein	N/A	N/A
5733259	12/1997	Valcke et al.	N/A	N/A
5741228	12/1997	Lambrecht et al.	N/A	N/A
5746217	12/1997	Erickson et al.	N/A	N/A
5747350	12/1997	Sattler	N/A	N/A
5747870	12/1997	Pedder	N/A	N/A
5748827	12/1997	Holl et al.	N/A	N/A
5755682	12/1997	Knudson et al.	N/A	N/A
5758643	12/1997	Wong et al.	N/A	N/A
5759923	12/1997	McMillan et al.	N/A	N/A
5764189	12/1997	Lohninger	N/A	N/A
5771567	12/1997	Pierce et al.	N/A	N/A
5776103	12/1997	Kriesel et al.	N/A	N/A
5779676	12/1997	Kriesel et al.	N/A	N/A
5785688	12/1997	Joshi et al.	N/A	N/A
5797881	12/1997	Gadot	N/A	N/A
5800397	12/1997	Wilson et al.	N/A	N/A
5800405	12/1997	McPhee	N/A	N/A
5800420	12/1997	Gross et al.	N/A	N/A
5801057	12/1997	Smart et al.	N/A	N/A
5804048	12/1997	Wong et al.	N/A	N/A
5807075	12/1997	Jacobsen et al.	N/A	N/A
5817007	12/1997	Fodgaard et al.	N/A	N/A
5820622	12/1997	Gross et al.	N/A	N/A
5823951	12/1997	Messerschmidt	N/A	N/A
5839467	12/1997	Saaski et al.	N/A	N/A
5840020	12/1997	Heinonen et al.	N/A	N/A
D403313	12/1997	Peppel	N/A	N/A
5848991	12/1997	Gross et al.	N/A	N/A
5851197	12/1997	Marano et al.	N/A	N/A
5854608	12/1997	Leisten	N/A	N/A
5858005	12/1998	Kriesel	N/A	N/A
5858239	12/1998	Kenley et al.	N/A	N/A
5859621	12/1998	Leisten	N/A	N/A
5865806	12/1998	Howell	N/A	N/A
5871470	12/1998	Mcwha	N/A	N/A
5879310	12/1998	Sopp et al.	N/A	N/A
5889459	12/1998	Hattori et al.	N/A	N/A
5891097	12/1998	Saito et al.	N/A	N/A
5892489	12/1998	Kanba et al.	N/A	N/A
5897530	12/1998	Jackson	N/A	N/A
5902253	12/1998	Pfeiffer et al.	N/A	N/A
5903421	12/1998	Furutani et al.	N/A	N/A
5906597	12/1998	McPhee	N/A	N/A
5911716	12/1998	Rake et al.	N/A	N/A
5919167	12/1998	Mulhauser et al.	N/A	N/A
5931814	12/1998	Alex et al.	N/A	N/A
5932175	12/1998	Knute et al.	N/A	N/A
5933121	12/1998	Rainhart et al.	N/A	N/A

5935099	12/1998	Peterson et al.	N/A	N/A
5945963	12/1998	Leisten	N/A	N/A
5947911	12/1998	Wong et al.	N/A	N/A
5957890	12/1998	Mann et al.	N/A	N/A
5961492	12/1998	Kriesel et al.	N/A	N/A
5965848	12/1998	Altschul et al.	N/A	N/A
5971941	12/1998	Simons et al.	N/A	N/A
5993423	12/1998	Choi	N/A	N/A
5997501	12/1998	Gross et al.	N/A	N/A
6005151	12/1998	Herrmann et al.	N/A	N/A
6017318	12/1999	Gauthier et al.	N/A	N/A
6019747	12/1999	McPhee	N/A	N/A
6023251	12/1999	Koo et al.	N/A	N/A
6024539	12/1999	Blomquist	N/A	N/A
6027826	12/1999	Derochemont et al.	N/A	N/A
6028568	12/1999	Asakura et al.	N/A	N/A
6031445	12/1999	Marty et al.	N/A	N/A
6032059	12/1999	Henning et al.	N/A	N/A
6036924	12/1999	Simons et al.	N/A	N/A
6040578	12/1999	Malin et al.	N/A	N/A
6040805	12/1999	Huynh et al.	N/A	N/A
6046707	12/1999	Gaughan et al.	N/A	N/A
6049727	12/1999	Crothall	N/A	N/A
6050978	12/1999	Orr et al.	N/A	N/A
6052040	12/1999	Hino	N/A	N/A
6058934	12/1999	Sullivan	N/A	N/A
6066103	12/1999	Duchon et al.	N/A	N/A
6071292	12/1999	Makower et al.	N/A	N/A
6072180	12/1999	Kramer et al.	N/A	N/A
6077055	12/1999	Scott	N/A	N/A
6090092	12/1999	Fowles et al.	N/A	N/A
6101406	12/1999	Hacker et al.	N/A	N/A
6102872	12/1999	Doneen et al.	N/A	N/A
6111544	12/1999	Dakeya et al.	N/A	N/A
6115673	12/1999	Malin et al.	N/A	N/A
6123827	12/1999	Wong et al.	N/A	N/A
6124134	12/1999	Stark	N/A	N/A
6126637	12/1999	Kriesel et al.	N/A	N/A
6128519	12/1999	Say	N/A	N/A
6142939	12/1999	Eppstein et al.	N/A	N/A
6143164	12/1999	Heller et al.	N/A	N/A
6143432	12/1999	De et al.	N/A	N/A
6154176	12/1999	Fathy et al.	N/A	N/A
6157041	12/1999	Thomas et al.	N/A	N/A
6161028	12/1999	Braig et al.	N/A	N/A
6162639	12/1999	Douglas	N/A	N/A
6174300	12/2000	Kriesel et al.	N/A	N/A
6176004	12/2000	Rainhart et al.	N/A	N/A
6181297	12/2000	Leisten	N/A	N/A
6188368	12/2000	Koriyama et al.	N/A	N/A
6190359	12/2000	Heruth	N/A	N/A
6195049	12/2000	Kim et al.	N/A	N/A
6196046	12/2000	Braig et al.	N/A	N/A
6200287	12/2000	Keller et al.	N/A	N/A
6200293	12/2000	Kriesel et al.	N/A	N/A
6200338	12/2000	Solomon et al.	N/A	N/A
6204203	12/2000	Narwankar et al.	N/A	N/A
6208843	12/2000	Huang et al.	N/A	N/A
6214629	12/2000	Freitag et al.	N/A	N/A
6222489	12/2000	Tsuru et al.	N/A	N/A
6226082	12/2000	Roe	N/A	N/A
6244776	12/2000	Wiley	N/A	N/A
6261065	12/2000	Nayak et al.	N/A	N/A
6262798	12/2000	Shepherd et al.	N/A	N/A
6266020	12/2000	Chang	N/A	N/A
6270455	12/2000	Brown	N/A	N/A
6271045	12/2000	Douglas et al.	N/A	N/A
6280381	12/2000	Malin et al.	N/A	N/A
6285448	12/2000	Kuenstner	N/A	N/A
6300894	12/2000	Lynch et al.	N/A	N/A

6309370	12/2000	Ben-Haim et al.	N/A	N/A
6312888	12/2000	Wong et al.	N/A	N/A
6320547	12/2000	Fathy et al.	N/A	N/A
6323549	12/2000	Derochemont et al.	N/A	N/A
6334851	12/2001	Hayes et al.	N/A	N/A
6363609	12/2001	Pickren	N/A	N/A
6375627	12/2001	Mauze et al.	N/A	N/A
6375638	12/2001	Nason et al.	N/A	N/A
6379301	12/2001	Worthington et al.	N/A	N/A
6402689	12/2001	Scarantino et al.	N/A	N/A
6413244	12/2001	Bestetti et al.	N/A	N/A
6461331	12/2001	Van Antwerp	N/A	N/A
6470279	12/2001	Samsoondar	N/A	N/A
6474219	12/2001	Klitmose et al.	N/A	N/A
6475196	12/2001	Vachon	N/A	N/A
6477065	12/2001	Parks	N/A	N/A
6477901	12/2001	Tadigadapa et al.	N/A	N/A
6484044	12/2001	Lilienfeld-Toal	N/A	N/A
6485461	12/2001	Mason et al.	N/A	N/A
6485462	12/2001	Kriesel	N/A	N/A
6491656	12/2001	Morris	N/A	N/A
6492949	12/2001	Breglia et al.	N/A	N/A
6496149	12/2001	Birnbaum et al.	N/A	N/A
6501415	12/2001	Viana et al.	N/A	N/A
6512937	12/2002	Blank et al.	N/A	N/A
6520936	12/2002	Mann	N/A	N/A
6525509	12/2002	Petersson et al.	N/A	N/A
6527744	12/2002	Kriesel et al.	N/A	N/A
6528809	12/2002	Thomas et al.	N/A	N/A
6537249	12/2002	Kriesell et al.	N/A	N/A
6540260	12/2002	Tan	N/A	N/A
6540672	12/2002	Simonsen et al.	N/A	N/A
6541820	12/2002	Bol	N/A	N/A
6544212	12/2002	Galley et al.	N/A	N/A
6546268	12/2002	Ishikawa et al.	N/A	N/A
6546269	12/2002	Kurnik	N/A	N/A
6551276	12/2002	Mann et al.	N/A	N/A
6552693	12/2002	Leisten	N/A	N/A
6553841	12/2002	Blouch	N/A	N/A
6554798	12/2002	Mann et al.	N/A	N/A
6556850	12/2002	Braig et al.	N/A	N/A
D474778	12/2002	Barnes	N/A	N/A
6558351	12/2002	Steil et al.	N/A	N/A
6559735	12/2002	Hoang et al.	N/A	N/A
6560471	12/2002	Heller et al.	N/A	N/A
6561978	12/2002	Conn et al.	N/A	N/A
6562001	12/2002	Lebel et al.	N/A	N/A
6562014	12/2002	Lin et al.	N/A	N/A
6569115	12/2002	Barker et al.	N/A	N/A
6569125	12/2002	Jepson et al.	N/A	N/A
6572542	12/2002	Houben et al.	N/A	N/A
6572545	12/2002	Knobbe et al.	N/A	N/A
6574490	12/2002	Abbink et al.	N/A	N/A
6575905	12/2002	Knobbe et al.	N/A	N/A
6580934	12/2002	Braig et al.	N/A	N/A
6583699	12/2002	Yokoyama	N/A	N/A
6595956	12/2002	Gross et al.	N/A	N/A
6599281	12/2002	Struys et al.	N/A	N/A
6605072	12/2002	Struys et al.	N/A	N/A
6611419	12/2002	Chakravorty	N/A	N/A
6618603	12/2002	Varalli et al.	N/A	N/A
6620750	12/2002	Kim et al.	N/A	N/A
6633772	12/2002	Ford et al.	N/A	N/A
6635958	12/2002	Bates et al.	N/A	N/A
6639556	12/2002	Baba	N/A	N/A
6642908	12/2002	Pleva et al.	N/A	N/A
6645142	12/2002	Braig et al.	N/A	N/A
6648821	12/2002	Lebel et al.	N/A	N/A
6650303	12/2002	Kim et al.	N/A	N/A
6653091	12/2002	Dunn et al.	N/A	N/A

6656158	12/2002	Mahoney et al.	N/A	N/A
6662030	12/2002	Khalil et al.	N/A	N/A
6669663	12/2002	Thompson	N/A	N/A
6670497	12/2002	Tashino et al.	N/A	N/A
6678542	12/2003	Braig et al.	N/A	N/A
6680700	12/2003	Hilgers	N/A	N/A
6683576	12/2003	Achim	N/A	N/A
6686406	12/2003	Tomomatsu et al.	N/A	N/A
6690336	12/2003	Leisten et al.	N/A	N/A
6697605	12/2003	Atokawa et al.	N/A	N/A
6699218	12/2003	Flaherty et al.	N/A	N/A
6699221	12/2003	Vaillancourt	N/A	N/A
6718189	12/2003	Rohrscheib et al.	N/A	N/A
6720926	12/2003	Killen et al.	N/A	N/A
6721582	12/2003	Trepagnier et al.	N/A	N/A
6723072	12/2003	Flaherty et al.	N/A	N/A
6727785	12/2003	Killen et al.	N/A	N/A
6728560	12/2003	Kollias et al.	N/A	N/A
6731244	12/2003	Killen et al.	N/A	N/A
6731248	12/2003	Killen et al.	N/A	N/A
6733890	12/2003	Imanaka et al.	N/A	N/A
6740059	12/2003	Flaherty	N/A	N/A
6740072	12/2003	Starkweather et al.	N/A	N/A
6741148	12/2003	Killen et al.	N/A	N/A
6742249	12/2003	Derochemont et al.	N/A	N/A
6743744	12/2003	Kim et al.	N/A	N/A
6750740	12/2003	Killen et al.	N/A	N/A
6750820	12/2003	Killen et al.	N/A	N/A
6751490	12/2003	Esenaliev et al.	N/A	N/A
6753745	12/2003	Killen et al.	N/A	N/A
6753814	12/2003	Killen et al.	N/A	N/A
6758835	12/2003	Close et al.	N/A	N/A
6762237	12/2003	Glatkowski et al.	N/A	N/A
6780156	12/2003	Haueter et al.	N/A	N/A
6787181	12/2003	Uchiyama et al.	N/A	N/A
6791496	12/2003	Killen et al.	N/A	N/A
6799149	12/2003	Hartlaub	N/A	N/A
6810290	12/2003	Lebel et al.	N/A	N/A
6826031	12/2003	Nagai et al.	N/A	N/A
6827702	12/2003	Lebel et al.	N/A	N/A
6830623	12/2003	Hayashi et al.	N/A	N/A
6837858	12/2004	Cunningham et al.	N/A	N/A
6837988	12/2004	Leong et al.	N/A	N/A
6846288	12/2004	Nagar et al.	N/A	N/A
6853288	12/2004	Ahn et al.	N/A	N/A
6858892	12/2004	Yamagata	N/A	N/A
6862534	12/2004	Sterling et al.	N/A	N/A
6864848	12/2004	Sievenpiper	N/A	N/A
6865408	12/2004	Abbink et al.	N/A	N/A
6871396	12/2004	Sugaya et al.	N/A	N/A
6872200	12/2004	Mann et al.	N/A	N/A
6873268	12/2004	Lebel et al.	N/A	N/A
6878871	12/2004	Scher et al.	N/A	N/A
6883778	12/2004	Newton et al.	N/A	N/A
6890291	12/2004	Robinson et al.	N/A	N/A
6905989	12/2004	Ellis et al.	N/A	N/A
6906674	12/2004	McKinzie et al.	N/A	N/A
6914566	12/2004	Beard	N/A	N/A
6919119	12/2004	Kalkan et al.	N/A	N/A
6928298	12/2004	Furutani et al.	N/A	N/A
6936029	12/2004	Mann et al.	N/A	N/A
6943430	12/2004	Kwon	N/A	N/A
6943731	12/2004	Killen et al.	N/A	N/A
6949081	12/2004	Chance	N/A	N/A
6958809	12/2004	Sterling et al.	N/A	N/A
6963259	12/2004	Killen et al.	N/A	N/A
6979326	12/2004	Mann et al.	N/A	N/A
6989891	12/2005	Braig et al.	N/A	N/A
6990366	12/2005	Say et al.	N/A	N/A
6997920	12/2005	Mann et al.	N/A	N/A

7002436	12/2005	Ma et al.	N/A	N/A
7008404	12/2005	Nakajima	N/A	N/A
7009180	12/2005	Sterling et al.	N/A	N/A
7016713	12/2005	Gardner et al.	N/A	N/A
7018360	12/2005	Flaherty et al.	N/A	N/A
7025743	12/2005	Mann et al.	N/A	N/A
7025744	12/2005	Utterberg et al.	N/A	N/A
7027848	12/2005	Robinson et al.	N/A	N/A
7043288	12/2005	Davis et al.	N/A	N/A
7047637	12/2005	Derochemont et al.	N/A	N/A
7060059	12/2005	Keith et al.	N/A	N/A
7060350	12/2005	Takaya et al.	N/A	N/A
7061593	12/2005	Braig et al.	N/A	N/A
7066910	12/2005	Bauhahn et al.	N/A	N/A
7096124	12/2005	Sterling et al.	N/A	N/A
7109878	12/2005	Mann et al.	N/A	N/A
7115205	12/2005	Robinson et al.	N/A	N/A
7116949	12/2005	Irie et al.	N/A	N/A
7128727	12/2005	Flaherty et al.	N/A	N/A
7133329	12/2005	Skyggebjerg et al.	N/A	N/A
7137694	12/2005	Ferran et al.	N/A	N/A
7139593	12/2005	Kavak et al.	N/A	N/A
7139598	12/2005	Hull et al.	N/A	N/A
7144384	12/2005	Gorman et al.	N/A	N/A
7160272	12/2006	Eyal et al.	N/A	N/A
7171252	12/2006	Scarantino et al.	N/A	N/A
7179226	12/2006	Crothall et al.	N/A	N/A
7190988	12/2006	Say et al.	N/A	N/A
7204823	12/2006	Estes et al.	N/A	N/A
7220240	12/2006	Struys et al.	N/A	N/A
7230316	12/2006	Yamazaki et al.	N/A	N/A
7248912	12/2006	Gough et al.	N/A	N/A
7267665	12/2006	Steil et al.	N/A	N/A
7271912	12/2006	Sterling et al.	N/A	N/A
7278983	12/2006	Ireland et al.	N/A	N/A
7291107	12/2006	Hellwig et al.	N/A	N/A
7291497	12/2006	Holmes et al.	N/A	N/A
7291782	12/2006	Sager et al.	N/A	N/A
7303549	12/2006	Flaherty et al.	N/A	N/A
7303622	12/2006	Loch et al.	N/A	N/A
7303922	12/2006	Jeng et al.	N/A	N/A
7354420	12/2007	Steil et al.	N/A	N/A
7388202	12/2007	Sterling et al.	N/A	N/A
7402153	12/2007	Steil et al.	N/A	N/A
7404796	12/2007	Ginsberg	N/A	N/A
7405698	12/2007	De Rochemont	N/A	N/A
7429255	12/2007	Thompson	N/A	N/A
7460130	12/2007	Salganicoff	N/A	N/A
7481787	12/2008	Gable et al.	N/A	N/A
7491187	12/2008	Van et al.	N/A	N/A
7500949	12/2008	Gottlieb et al.	N/A	N/A
7509156	12/2008	Flanders	N/A	N/A
D590415	12/2008	Ball et al.	N/A	N/A
7522124	12/2008	Smith et al.	N/A	N/A
7547281	12/2008	Hayes et al.	N/A	N/A
7553512	12/2008	Kodas et al.	N/A	N/A
7564887	12/2008	Wang et al.	N/A	N/A
7569030	12/2008	Lebel et al.	N/A	N/A
7595623	12/2008	Bennett	N/A	N/A
7608042	12/2008	Goldberger et al.	N/A	N/A
7651845	12/2009	Doyle, III et al.	N/A	N/A
7652901	12/2009	Kirchmeier et al.	N/A	N/A
7680529	12/2009	Kroll	N/A	N/A
D614634	12/2009	Nilsen	N/A	N/A
7704226	12/2009	Mueller et al.	N/A	N/A
7714794	12/2009	Tavassoli Hozouri	N/A	N/A
7734323	12/2009	Blomquist et al.	N/A	N/A
7763917	12/2009	De Rochemont	N/A	N/A
7766829	12/2009	Sloan et al.	N/A	N/A
7771391	12/2009	Carter	N/A	N/A

7785258	12/2009	Braig et al.	N/A	N/A
7785313	12/2009	Mastrototaro	N/A	N/A
7806853	12/2009	Wittmann et al.	N/A	N/A
7806854	12/2009	Damiano et al.	N/A	N/A
7806886	12/2009	Kanderian et al.	N/A	N/A
7812774	12/2009	Friman et al.	N/A	N/A
7815602	12/2009	Mann et al.	N/A	N/A
7819843	12/2009	Mann et al.	N/A	N/A
7850641	12/2009	Lebel et al.	N/A	N/A
7918825	12/2010	O'Connor et al.	N/A	N/A
7946985	12/2010	Mastrototaro et al.	N/A	N/A
D640269	12/2010	Chen	N/A	N/A
7967812	12/2010	Jasperson et al.	N/A	N/A
7972296	12/2010	Braig et al.	N/A	N/A
7976492	12/2010	Brauker et al.	N/A	N/A
8062249	12/2010	Wilinska et al.	N/A	N/A
8066805	12/2010	Zuercher et al.	N/A	N/A
8069690	12/2010	Desantolo et al.	N/A	N/A
8088098	12/2011	Yodfat et al.	N/A	N/A
8105268	12/2011	Lebel et al.	N/A	N/A
8114489	12/2011	Nemat-Nasser et al.	N/A	N/A
8152789	12/2011	Starkweather et al.	N/A	N/A
8178457	12/2011	De Rochemont	N/A	N/A
8193873	12/2011	Kato et al.	N/A	N/A
8206350	12/2011	Mann et al.	N/A	N/A
8208984	12/2011	Blomquist et al.	N/A	N/A
8221345	12/2011	Blomquist	N/A	N/A
8226556	12/2011	Hayes et al.	N/A	N/A
8251907	12/2011	Sterling et al.	N/A	N/A
8267893	12/2011	Moberg et al.	N/A	N/A
8267921	12/2011	Yodfat et al.	N/A	N/A
8273052	12/2011	Damiano et al.	N/A	N/A
8350657	12/2012	Derochemont	N/A	N/A
8352011	12/2012	Van et al.	N/A	N/A
8354294	12/2012	De et al.	N/A	N/A
D677685	12/2012	Simmons et al.	N/A	N/A
8417311	12/2012	Rule	N/A	N/A
8439834	12/2012	Schmelzeisen-Redeker et al.	N/A	N/A
8439897	12/2012	Yodfat et al.	N/A	N/A
8449524	12/2012	Braig et al.	N/A	N/A
8452359	12/2012	Rebec et al.	N/A	N/A
8454576	12/2012	Mastrototaro et al.	N/A	N/A
8460231	12/2012	Brauker et al.	N/A	N/A
8467980	12/2012	Campbell et al.	N/A	N/A
8478557	12/2012	Hayter et al.	N/A	N/A
8480655	12/2012	Jasperson et al.	N/A	N/A
D688686	12/2012	Rhee et al.	N/A	N/A
8547239	12/2012	Peatfield et al.	N/A	N/A
8548544	12/2012	Kircher et al.	N/A	N/A
8551045	12/2012	Sie et al.	N/A	N/A
8560082	12/2012	Wei	N/A	N/A
8560131	12/2012	Haueter et al.	N/A	N/A
8562587	12/2012	Kovatchev et al.	N/A	N/A
D693837	12/2012	Bouchier	N/A	N/A
8579879	12/2012	Palerm et al.	N/A	N/A
8585591	12/2012	Sloan et al.	N/A	N/A
8585637	12/2012	Wilinska et al.	N/A	N/A
8585638	12/2012	Blomquist	N/A	N/A
8593819	12/2012	De Rochemont	N/A	N/A
D695757	12/2012	Ray et al.	N/A	N/A
8597274	12/2012	Sloan et al.	N/A	N/A
8615366	12/2012	Galley et al.	N/A	N/A
8622988	12/2013	Hayter	N/A	N/A
8694115	12/2013	Goetz et al.	N/A	N/A
8706691	12/2013	McDaniel et al.	N/A	N/A
8715839	12/2013	De Rochemont	N/A	N/A
8718949	12/2013	Blomquist et al.	N/A	N/A
8721585	12/2013	Brauker et al.	N/A	N/A
8727982	12/2013	Jennewine	N/A	N/A
8734428	12/2013	Blomquist	N/A	N/A

8747315	12/2013	Brauker et al.	N/A	N/A
8756043	12/2013	Albisser et al.	N/A	N/A
8768673	12/2013	Albisser et al.	N/A	N/A
8777896	12/2013	Starkweather et al.	N/A	N/A
8784369	12/2013	Starkweather et al.	N/A	N/A
8784370	12/2013	Lebel et al.	N/A	N/A
D710879	12/2013	Elston et al.	N/A	N/A
8795224	12/2013	Starkweather et al.	N/A	N/A
8810394	12/2013	Kalpin	N/A	N/A
D714822	12/2013	Capua et al.	N/A	N/A
D715315	12/2013	Wood	N/A	N/A
D715815	12/2013	Bortman et al.	N/A	N/A
8876755	12/2013	Taub et al.	N/A	N/A
D718779	12/2013	Hang et al.	N/A	N/A
D720366	12/2013	Hiltunen et al.	N/A	N/A
D720765	12/2014	Xie et al.	N/A	N/A
8939935	12/2014	O'Connor et al.	N/A	N/A
8945094	12/2014	Nordh	N/A	N/A
8977504	12/2014	Hovorka	N/A	N/A
8992475	12/2014	Mann et al.	N/A	N/A
D726760	12/2014	Yokota et al.	N/A	N/A
D727928	12/2014	Allison et al.	N/A	N/A
D730378	12/2014	Xiong et al.	N/A	N/A
D733175	12/2014	Bae	N/A	N/A
9056165	12/2014	Steil et al.	N/A	N/A
9061097	12/2014	Holt et al.	N/A	N/A
D734356	12/2014	Xiong et al.	N/A	N/A
D736811	12/2014	Teichner et al.	N/A	N/A
D737305	12/2014	Scazafavo et al.	N/A	N/A
D737831	12/2014	Lee	N/A	N/A
D737832	12/2014	Lim et al.	N/A	N/A
D738901	12/2014	Amin	N/A	N/A
D740301	12/2014	Soegiono et al.	N/A	N/A
D740308	12/2014	Kim et al.	N/A	N/A
D740311	12/2014	Drozd et al.	N/A	N/A
D741354	12/2014	Lee et al.	N/A	N/A
D741359	12/2014	Ji-Hye et al.	N/A	N/A
9171343	12/2014	Fischell et al.	N/A	N/A
D743431	12/2014	Pal et al.	N/A	N/A
D743991	12/2014	Pal et al.	N/A	N/A
9180224	12/2014	Moseley et al.	N/A	N/A
9180244	12/2014	Anderson et al.	N/A	N/A
9192716	12/2014	Jugl et al.	N/A	N/A
D744514	12/2014	Shin et al.	N/A	N/A
D744517	12/2014	Pal et al.	N/A	N/A
D745032	12/2014	Pal et al.	N/A	N/A
D745034	12/2014	Pal et al.	N/A	N/A
D745035	12/2014	Pal et al.	N/A	N/A
D746827	12/2015	Jung et al.	N/A	N/A
D746828	12/2015	Arai et al.	N/A	N/A
D747352	12/2015	Lee et al.	N/A	N/A
9233204	12/2015	Booth et al.	N/A	N/A
D749097	12/2015	Zou et al.	N/A	N/A
D749118	12/2015	Wang	N/A	N/A
D751100	12/2015	Lindn et al.	N/A	N/A
D752604	12/2015	Zhang	N/A	N/A
D753134	12/2015	Vazquez	N/A	N/A
D754718	12/2015	Zhou	N/A	N/A
9320471	12/2015	Hayes et al.	N/A	N/A
D755193	12/2015	Sun et al.	N/A	N/A
D755799	12/2015	Finnis et al.	N/A	N/A
D755820	12/2015	Wang	N/A	N/A
D756387	12/2015	Chang et al.	N/A	N/A
D757032	12/2015	Sabia et al.	N/A	N/A
D757035	12/2015	Raskin et al.	N/A	N/A
9333298	12/2015	Kim et al.	N/A	N/A
D758391	12/2015	Suarez	N/A	N/A
D758422	12/2015	Zhao	N/A	N/A
D759032	12/2015	Amin et al.	N/A	N/A
D759078	12/2015	Iwamoto	N/A	N/A

D759678	12/2015	Jung et al.	N/A	N/A
D759687	12/2015	Chang et al.	N/A	N/A
D761812	12/2015	Motamedi	N/A	N/A
D763308	12/2015	Wang et al.	N/A	N/A
D763868	12/2015	Lee et al.	N/A	N/A
D765110	12/2015	Liang	N/A	N/A
D765124	12/2015	Minks-Brown et al.	N/A	N/A
9402950	12/2015	Dilanni et al.	N/A	N/A
9415157	12/2015	Mann et al.	N/A	N/A
D765707	12/2015	Gomez	N/A	N/A
D766286	12/2015	Lee et al.	N/A	N/A
D767586	12/2015	Kwon et al.	N/A	N/A
D768154	12/2015	Kim et al.	N/A	N/A
D768188	12/2015	Li et al.	N/A	N/A
D768660	12/2015	Wielgosz	N/A	N/A
D768685	12/2015	Lee et al.	N/A	N/A
D769315	12/2015	Scotti	N/A	N/A
9474855	12/2015	McCann et al.	N/A	N/A
D770507	12/2015	Umezawa et al.	N/A	N/A
D770515	12/2015	Cho et al.	N/A	N/A
D771073	12/2015	Choi et al.	N/A	N/A
D771076	12/2015	Butcher et al.	N/A	N/A
D771690	12/2015	Yin et al.	N/A	N/A
D772911	12/2015	Lee et al.	N/A	N/A
9480796	12/2015	Starkweather et al.	N/A	N/A
9486172	12/2015	Cobelli et al.	N/A	N/A
9486571	12/2015	Rosinko	N/A	N/A
9486578	12/2015	Finan et al.	N/A	N/A
D773531	12/2015	Toth et al.	N/A	N/A
D775184	12/2015	Song et al.	N/A	N/A
D775196	12/2015	Huang et al.	N/A	N/A
9520649	12/2015	De Rochemont	N/A	N/A
D775658	12/2016	Luo et al.	N/A	N/A
D776126	12/2016	Lai et al.	N/A	N/A
D776687	12/2016	Wick et al.	N/A	N/A
D777191	12/2016	Polimeni	N/A	N/A
D777758	12/2016	Kisselev et al.	N/A	N/A
9579456	12/2016	Budiman et al.	N/A	N/A
D781323	12/2016	Green et al.	N/A	N/A
D781781	12/2016	Schimmoeller, Jr.	N/A	N/A
D781877	12/2016	Ko et al.	N/A	N/A
D781878	12/2016	Butcher et al.	N/A	N/A
D781879	12/2016	Butcher et al.	N/A	N/A
D781903	12/2016	Reichle et al.	N/A	N/A
D781905	12/2016	Nakaguchi et al.	N/A	N/A
D782506	12/2016	Kim et al.	N/A	N/A
D783672	12/2016	Rajasankar et al.	N/A	N/A
D785010	12/2016	Bachman et al.	N/A	N/A
D785656	12/2016	Bramer et al.	N/A	N/A
D786278	12/2016	Motamedi	N/A	N/A
D786898	12/2016	Hall	N/A	N/A
D788126	12/2016	Evnin et al.	N/A	N/A
9656017	12/2016	Greene	N/A	N/A
D788621	12/2016	Shallice et al.	N/A	N/A
D788652	12/2016	Mutsuro et al.	N/A	N/A
D789402	12/2016	Dye et al.	N/A	N/A
D789967	12/2016	Kaplan et al.	N/A	N/A
D789982	12/2016	Christiana et al.	N/A	N/A
D790560	12/2016	Inose et al.	N/A	N/A
D791781	12/2016	Donarski et al.	N/A	N/A
D791805	12/2016	Segars	N/A	N/A
D791812	12/2016	Bistoni et al.	N/A	N/A
D793412	12/2016	Chaudhri et al.	N/A	N/A
D795886	12/2016	Ng et al.	N/A	N/A
D795891	12/2016	Kohan et al.	N/A	N/A
D795900	12/2016	Bischoff et al.	N/A	N/A
D795906	12/2016	Butrick	N/A	N/A
D795927	12/2016	Bischoff et al.	N/A	N/A
9743224	12/2016	San et al.	N/A	N/A
D796530	12/2016	McMillan et al.	N/A	N/A

D796540	12/2016	McClean et al.	N/A	N/A
D797116	12/2016	Chapman et al.	N/A	N/A
D797763	12/2016	Kim et al.	N/A	N/A
D797774	12/2016	Park et al.	N/A	N/A
D797797	12/2016	Gandhi et al.	N/A	N/A
D798310	12/2016	Golden et al.	N/A	N/A
D798311	12/2016	Golden et al.	N/A	N/A
D799536	12/2016	Eder	N/A	N/A
D800765	12/2016	Stoksik	N/A	N/A
D800769	12/2016	Hennessey et al.	N/A	N/A
D801383	12/2016	Park et al.	N/A	N/A
D802011	12/2016	Friedman et al.	N/A	N/A
D802088	12/2016	Bos et al.	N/A	N/A
D803232	12/2016	Leigh et al.	N/A	N/A
D803242	12/2016	Mizono et al.	N/A	N/A
D804502	12/2016	Amini et al.	N/A	N/A
D805525	12/2016	Dascola et al.	N/A	N/A
D806716	12/2017	Pahwa et al.	N/A	N/A
D807376	12/2017	Mizono et al.	N/A	N/A
D807400	12/2017	Lagreca	N/A	N/A
D807910	12/2017	Graham et al.	N/A	N/A
D807918	12/2017	Cohen et al.	N/A	N/A
D807919	12/2017	Cohen et al.	N/A	N/A
D808423	12/2017	Jiang et al.	N/A	N/A
D808974	12/2017	Chiappone et al.	N/A	N/A
D808983	12/2017	Narinedhat et al.	N/A	N/A
9857090	12/2017	Golden et al.	N/A	N/A
D810116	12/2017	McClean et al.	N/A	N/A
D810771	12/2017	Gandhi et al.	N/A	N/A
9907515	12/2017	Doyle et al.	N/A	N/A
D815131	12/2017	Thompson et al.	N/A	N/A
D816090	12/2017	Stonecipher et al.	N/A	N/A
D817339	12/2017	Nanjappan et al.	N/A	N/A
D818491	12/2017	Timmer et al.	N/A	N/A
D819057	12/2017	Huang	N/A	N/A
D819059	12/2017	O'Toole	N/A	N/A
9980140	12/2017	Spencer et al.	N/A	N/A
9984773	12/2017	Gondhalekar et al.	N/A	N/A
D820311	12/2017	Cabrera et al.	N/A	N/A
D820862	12/2017	Alfonzo et al.	N/A	N/A
D822034	12/2017	Clymer et al.	N/A	N/A
D822677	12/2017	Weaver et al.	N/A	N/A
D822684	12/2017	Clausen-Stuck et al.	N/A	N/A
D822692	12/2017	Loychik et al.	N/A	N/A
D823862	12/2017	Chung et al.	N/A	N/A
D824400	12/2017	Chang et al.	N/A	N/A
D824951	12/2017	Kolbrener et al.	N/A	N/A
D826956	12/2017	Pillalamarri et al.	N/A	N/A
D826957	12/2017	Pillalamarri et al.	N/A	N/A
D828381	12/2017	Lee et al.	N/A	N/A
D829732	12/2017	Jeffrey et al.	N/A	N/A
D830374	12/2017	Leonard et al.	N/A	N/A
D830384	12/2017	Lepine et al.	N/A	N/A
D830385	12/2017	Lepine et al.	N/A	N/A
D830407	12/2017	Kisielius et al.	N/A	N/A
D831033	12/2017	Leonard et al.	N/A	N/A
10102344	12/2017	Rees et al.	N/A	N/A
D833469	12/2017	Coleman et al.	N/A	N/A
D834601	12/2017	Felt	N/A	N/A
D835132	12/2017	Ito et al.	N/A	N/A
D835145	12/2017	Cashner et al.	N/A	N/A
D835147	12/2017	Kisielius et al.	N/A	N/A
D835651	12/2017	Bao	N/A	N/A
D835666	12/2017	Saleh et al.	N/A	N/A
D836123	12/2017	Pillalamarri et al.	N/A	N/A
D837807	12/2018	Baber et al.	N/A	N/A
D838731	12/2018	Pillalamarri et al.	N/A	N/A
D840418	12/2018	Saad et al.	N/A	N/A
D840419	12/2018	Saad et al.	N/A	N/A
10195343	12/2018	Kamen et al.	N/A	N/A

D844022	12/2018	Amin	N/A	N/A
D845317	12/2018	Wellmeier et al.	N/A	N/A
10248839	12/2018	Levy et al.	N/A	N/A
D848459	12/2018	Li	N/A	N/A
D851099	12/2018	Uppala et al.	N/A	N/A
D851658	12/2018	Pillalamarri et al.	N/A	N/A
10307538	12/2018	Desborough et al.	N/A	N/A
10335464	12/2018	Michelich et al.	N/A	N/A
10391242	12/2018	Agrawal et al.	N/A	N/A
D865795	12/2018	Koo	N/A	N/A
10500334	12/2018	Mazlish et al.	N/A	N/A
D872746	12/2019	Laborde	N/A	N/A
D874471	12/2019	Pillalamarri et al.	N/A	N/A
D875114	12/2019	Clediere	N/A	N/A
10583250	12/2019	Mazlish et al.	N/A	N/A
D880498	12/2019	Shahidi et al.	N/A	N/A
10610644	12/2019	Mazlish et al.	N/A	N/A
D888070	12/2019	Yusupov et al.	N/A	N/A
10737024	12/2019	Schmid	N/A	N/A
D904426	12/2019	Paul	N/A	N/A
10881793	12/2020	Mazlish et al.	N/A	N/A
D911353	12/2020	Sanchez et al.	N/A	N/A
D914031	12/2020	Ding et al.	N/A	N/A
D916729	12/2020	Gabriel et al.	N/A	N/A
D916870	12/2020	Hemsley	N/A	N/A
D916878	12/2020	Kim et al.	N/A	N/A
10987468	12/2020	Mazlish et al.	N/A	N/A
D918261	12/2020	Ramamurthy et al.	N/A	N/A
D920351	12/2020	Zhang	N/A	N/A
D923033	12/2020	Smith et al.	N/A	N/A
11027063	12/2020	Mazlish et al.	N/A	N/A
11033682	12/2020	Mazlish et al.	N/A	N/A
D927533	12/2020	Clymer	N/A	N/A
11116900	12/2020	Haider et al.	N/A	N/A
D938447	12/2020	Holland	N/A	N/A
11197964	12/2020	Sjolund et al.	N/A	N/A
11260169	12/2021	Estes	N/A	N/A
11309089	12/2021	Kahlbaugh	N/A	N/A
D954078	12/2021	Rahate et al.	N/A	N/A
11738144	12/2022	Lee et al.	N/A	N/A
2001/0021803	12/2000	Blank et al.	N/A	N/A
2001/0034023	12/2000	Stanton et al.	N/A	N/A
2001/0034502	12/2000	Moberg et al.	N/A	N/A
2001/0048969	12/2000	Constantino et al.	N/A	N/A
2001/0051377	12/2000	Hammer et al.	N/A	N/A
2001/0053895	12/2000	Vaillancourt	N/A	N/A
2001/0056258	12/2000	Evans	N/A	N/A
2002/0010401	12/2001	Bushmakin et al.	N/A	N/A
2002/0010423	12/2001	Gross et al.	N/A	N/A
2002/0016568	12/2001	Lebel et al.	N/A	N/A
2002/0040208	12/2001	Flaherty et al.	N/A	N/A
2002/0047768	12/2001	Duffy	N/A	N/A
2002/0070983	12/2001	Kozub et al.	N/A	N/A
2002/0123740	12/2001	Flaherty et al.	N/A	N/A
2002/0128543	12/2001	Leonhardt	N/A	N/A
2002/0147423	12/2001	Burbank et al.	N/A	N/A
2002/0155425	12/2001	Han et al.	N/A	N/A
2002/0161288	12/2001	Shin et al.	N/A	N/A
2002/0173769	12/2001	Gray et al.	N/A	N/A
2002/0190818	12/2001	Endou et al.	N/A	N/A
2003/0023148	12/2002	Lorenz et al.	N/A	N/A
2003/0023152	12/2002	Abbink et al.	N/A	N/A
2003/0034124	12/2002	Sugaya et al.	N/A	N/A
2003/0040715	12/2002	D'Antonio et al.	N/A	N/A
2003/0050621	12/2002	Lebel et al.	N/A	N/A
2003/0060692	12/2002	L. Ruchti et al.	N/A	N/A
2003/0060765	12/2002	Campbell et al.	N/A	N/A
2003/0086073	12/2002	Braig et al.	N/A	N/A
2003/0086074	12/2002	Braig et al.	N/A	N/A
2003/0086075	12/2002	Braig et al.	N/A	N/A

2003/0090649	12/2002	Sterling et al.	N/A	N/A
2003/0100040	12/2002	Bonnecaze et al.	N/A	N/A
2003/0114836	12/2002	Estes et al.	N/A	N/A
2003/0122647	12/2002	Ou	N/A	N/A
2003/0130616	12/2002	Steil et al.	N/A	N/A
2003/0135388	12/2002	Martucci et al.	N/A	N/A
2003/0144582	12/2002	Cohen et al.	N/A	N/A
2003/0148024	12/2002	Kodas et al.	N/A	N/A
2003/0163097	12/2002	Fleury et al.	N/A	N/A
2003/0170436	12/2002	Sumi et al.	N/A	N/A
2003/0175806	12/2002	Rule et al.	N/A	N/A
2003/0181852	12/2002	Mann et al.	N/A	N/A
2003/0187525	12/2002	Mann et al.	N/A	N/A
2003/0191431	12/2002	Mann et al.	N/A	N/A
2003/0195404	12/2002	Knobbe et al.	N/A	N/A
2003/0195462	12/2002	Mann et al.	N/A	N/A
2003/0208113	12/2002	Mault et al.	N/A	N/A
2003/0208154	12/2002	Close et al.	N/A	N/A
2003/0212364	12/2002	Mann et al.	N/A	N/A
2003/0212379	12/2002	Bylund et al.	N/A	N/A
2003/0216627	12/2002	Lorenz et al.	N/A	N/A
2003/0220605	12/2002	Bowman et al.	N/A	N/A
2003/0221621	12/2002	Pokharna et al.	N/A	N/A
2004/0001027	12/2003	Killen et al.	N/A	N/A
2004/0010207	12/2003	Flaherty et al.	N/A	N/A
2004/0034295	12/2003	Salganicoff	N/A	N/A
2004/0045879	12/2003	Shults et al.	N/A	N/A
2004/0051368	12/2003	Caputo et al.	N/A	N/A
2004/0064088	12/2003	Gorman et al.	N/A	N/A
2004/0064259	12/2003	Haaland et al.	N/A	N/A
2004/0068224	12/2003	Couvillon et al.	N/A	N/A
2004/0069004	12/2003	Gist et al.	N/A	N/A
2004/0069044	12/2003	Lavi et al.	N/A	N/A
2004/0087904	12/2003	Langley et al.	N/A	N/A
2004/0097796	12/2003	Berman et al.	N/A	N/A
2004/0116847	12/2003	Wall	N/A	N/A
2004/0122353	12/2003	Shahmirian et al.	N/A	N/A
2004/0133166	12/2003	Moberg et al.	N/A	N/A
2004/0147034	12/2003	Gore et al.	N/A	N/A
2004/0171983	12/2003	Sparks et al.	N/A	N/A
2004/0203357	12/2003	Nassimi	N/A	N/A
2004/0204868	12/2003	Maynard et al.	N/A	N/A
2004/0215492	12/2003	Choi	N/A	N/A
2004/0220517	12/2003	Starkweather et al.	N/A	N/A
2004/0241736	12/2003	Hendee et al.	N/A	N/A
2004/0249308	12/2003	Forssell	N/A	N/A
2005/0003470	12/2004	Nelson et al.	N/A	N/A
2005/0020980	12/2004	Inoue et al.	N/A	N/A
2005/0022274	12/2004	Campbell et al.	N/A	N/A
2005/0033148	12/2004	Haueter et al.	N/A	N/A
2005/0043598	12/2004	Goode et al.	N/A	N/A
2005/0049179	12/2004	Davidson et al.	N/A	N/A
2005/0055242	12/2004	Bello et al.	N/A	N/A
2005/0065464	12/2004	Talbot et al.	N/A	N/A
2005/0065465	12/2004	Lebel et al.	N/A	N/A
2005/0075624	12/2004	Miesel	N/A	N/A
2005/0105095	12/2004	Pesach et al.	N/A	N/A
2005/0134609	12/2004	Yu	N/A	N/A
2005/0137573	12/2004	McLaughlin	N/A	N/A
2005/0171503	12/2004	Van et al.	N/A	N/A
2005/0171513	12/2004	Mann et al.	N/A	N/A
2005/0177398	12/2004	Watanabe et al.	N/A	N/A
2005/0182306	12/2004	Sloan	N/A	N/A
2005/0182366	12/2004	Vogt et al.	N/A	N/A
2005/0192494	12/2004	Ginsberg	N/A	N/A
2005/0192557	12/2004	Brauker et al.	N/A	N/A
2005/0197621	12/2004	Poulsen et al.	N/A	N/A
2005/0203360	12/2004	Brauker et al.	N/A	N/A
2005/0203461	12/2004	Flaherty et al.	N/A	N/A
2005/0238507	12/2004	Diianni et al.	N/A	N/A

2005/0261660	12/2004	Choi	N/A	N/A
2005/0262451	12/2004	Remignanti et al.	N/A	N/A
2005/0272640	12/2004	Doyle et al.	N/A	N/A
2005/0277912	12/2004	John	N/A	N/A
2006/0009727	12/2005	O'Mahony et al.	N/A	N/A
2006/0041229	12/2005	Garibotto et al.	N/A	N/A
2006/0064053	12/2005	Bollish et al.	N/A	N/A
2006/0079765	12/2005	Neer et al.	N/A	N/A
2006/0079809	12/2005	Goldberger et al.	N/A	N/A
2006/0086994	12/2005	Mefers et al.	N/A	N/A
2006/0100494	12/2005	Kroll	N/A	N/A
2006/0134323	12/2005	O'Brien	N/A	N/A
2006/0134491	12/2005	Hilchenko et al.	N/A	N/A
2006/0167350	12/2005	Monfre et al.	N/A	N/A
2006/0173406	12/2005	Hayes et al.	N/A	N/A
2006/0178633	12/2005	Garibotto et al.	N/A	N/A
2006/0189925	12/2005	Gable et al.	N/A	N/A
2006/0189926	12/2005	Hall et al.	N/A	N/A
2006/0197015	12/2005	Sterling et al.	N/A	N/A
2006/0200070	12/2005	Calliccoat et al.	N/A	N/A
2006/0204535	12/2005	Johnson	N/A	N/A
2006/0229531	12/2005	Goldberger et al.	N/A	N/A
2006/0253067	12/2005	Staib et al.	N/A	N/A
2006/0253085	12/2005	Geismar et al.	N/A	N/A
2006/0264895	12/2005	Flanders	N/A	N/A
2006/0270983	12/2005	Lord et al.	N/A	N/A
2006/0276771	12/2005	Galley et al.	N/A	N/A
2006/0282290	12/2005	Flaherty et al.	N/A	N/A
2007/0016127	12/2006	Staib et al.	N/A	N/A
2007/0060796	12/2006	Kim	N/A	N/A
2007/0060869	12/2006	Tolle et al.	N/A	N/A
2007/0060872	12/2006	Hall et al.	N/A	N/A
2007/0083160	12/2006	Hall et al.	N/A	N/A
2007/0100635	12/2006	Mahajan et al.	N/A	N/A
2007/0106135	12/2006	Sloan et al.	N/A	N/A
2007/0116601	12/2006	Patton	N/A	N/A
2007/0118405	12/2006	Campbell et al.	N/A	N/A
2007/0129690	12/2006	Rosenblatt et al.	N/A	N/A
2007/0142720	12/2006	Ridder et al.	N/A	N/A
2007/0166453	12/2006	Van et al.	N/A	N/A
2007/0173761	12/2006	Kanderian et al.	N/A	N/A
2007/0173974	12/2006	Lin	N/A	N/A
2007/0179352	12/2006	Randlov et al.	N/A	N/A
2007/0191716	12/2006	Goldberger et al.	N/A	N/A
2007/0197163	12/2006	Robertson	N/A	N/A
2007/0225675	12/2006	Robinson et al.	N/A	N/A
2007/0244381	12/2006	Robinson et al.	N/A	N/A
2007/0249007	12/2006	Rosero	N/A	N/A
2007/0259768	12/2006	Kear et al.	N/A	N/A
2007/0264707	12/2006	Liederman et al.	N/A	N/A
2007/0282269	12/2006	Carter et al.	N/A	N/A
2007/0287985	12/2006	Estes et al.	N/A	N/A
2007/0293843	12/2006	Ireland et al.	N/A	N/A
2008/0033272	12/2007	Gough et al.	N/A	N/A
2008/0033320	12/2007	Racchini et al.	N/A	N/A
2008/0033357	12/2007	Mann et al.	N/A	N/A
2008/0051738	12/2007	Griffin	N/A	N/A
2008/0051764	12/2007	Dent et al.	N/A	N/A
2008/0058625	12/2007	McGarraugh et al.	N/A	N/A
2008/0065050	12/2007	Sparks et al.	N/A	N/A
2008/0071157	12/2007	McGarraugh et al.	N/A	N/A
2008/0071158	12/2007	McGarraugh et al.	N/A	N/A
2008/0078400	12/2007	Martens et al.	N/A	N/A
2008/0097289	12/2007	Steil et al.	N/A	N/A
2008/0114304	12/2007	Nalesso et al.	N/A	N/A
2008/0132880	12/2007	Buchman	N/A	N/A
2008/0147004	12/2007	Mann et al.	N/A	N/A
2008/0147050	12/2007	Mann et al.	N/A	N/A
2008/0160492	12/2007	Campbell et al.	N/A	N/A
2008/0161664	12/2007	Mastrototaro et al.	N/A	N/A

2008/0172026	12/2007	Blomquist	N/A	N/A
2008/0172028	12/2007	Blomquist	N/A	N/A
2008/0177165	12/2007	Blomquist et al.	N/A	N/A
2008/0183060	12/2007	Steil et al.	N/A	N/A
2008/0188796	12/2007	Steil et al.	N/A	N/A
2008/0200838	12/2007	Goldberger et al.	N/A	N/A
2008/0206067	12/2007	De et al.	N/A	N/A
2008/0208113	12/2007	Damiano et al.	N/A	N/A
2008/0214919	12/2007	Harmon et al.	N/A	N/A
2008/0228056	12/2007	Blomquist et al.	N/A	N/A
2008/0249386	12/2007	Besterman et al.	N/A	N/A
2008/0269585	12/2007	Ginsberg	N/A	N/A
2008/0269714	12/2007	Mastrototaro et al.	N/A	N/A
2008/0269723	12/2007	Mastrototaro et al.	N/A	N/A
2008/0287906	12/2007	Burkholz et al.	N/A	N/A
2008/0300572	12/2007	Rankers et al.	N/A	N/A
2008/0319384	12/2007	Yodfat et al.	N/A	N/A
2009/0006061	12/2008	Thukral et al.	N/A	N/A
2009/0018406	12/2008	Yodfat et al.	N/A	N/A
2009/0030398	12/2008	Yodfat et al.	N/A	N/A
2009/0036753	12/2008	King	N/A	N/A
2009/0043240	12/2008	Robinson et al.	N/A	N/A
2009/0054753	12/2008	Robinson et al.	N/A	N/A
2009/0069743	12/2008	Krishnamoorthy et al.	N/A	N/A
2009/0069745	12/2008	Estes et al.	N/A	N/A
2009/0069787	12/2008	Estes et al.	N/A	N/A
2009/0099521	12/2008	Gravesen et al.	N/A	N/A
2009/0105573	12/2008	Malecha	N/A	N/A
2009/0131861	12/2008	Braig et al.	N/A	N/A
2009/0149728	12/2008	Van et al.	N/A	N/A
2009/0156922	12/2008	Goldberger et al.	N/A	N/A
2009/0156924	12/2008	Shariati et al.	N/A	N/A
2009/0163781	12/2008	Say et al.	N/A	N/A
2009/0164239	12/2008	Hayter et al.	N/A	N/A
2009/0164251	12/2008	Hayter	N/A	N/A
2009/0198350	12/2008	Thiele	N/A	N/A
2009/0212966	12/2008	Panduro	N/A	N/A
2009/0221890	12/2008	Saffer et al.	N/A	N/A
2009/0222247	12/2008	Hellwig et al.	N/A	N/A
2009/0228214	12/2008	Say et al.	N/A	N/A
2009/0318791	12/2008	Kaastrup	N/A	N/A
2009/0326343	12/2008	Gable et al.	N/A	N/A
2009/0326472	12/2008	Carter et al.	N/A	N/A
2010/0017141	12/2009	Campbell et al.	N/A	N/A
2010/0036326	12/2009	Matusch	N/A	N/A
2010/0049164	12/2009	Estes	N/A	N/A
2010/0057042	12/2009	Hayter	N/A	N/A
2010/0064243	12/2009	Buck et al.	N/A	N/A
2010/0077198	12/2009	Buck et al.	N/A	N/A
2010/0082167	12/2009	Haueter et al.	N/A	N/A
2010/0114026	12/2009	Karratt et al.	N/A	N/A
2010/0121170	12/2009	Rule	N/A	N/A
2010/0125241	12/2009	Prud et al.	N/A	N/A
2010/0137784	12/2009	Cefai et al.	N/A	N/A
2010/0137788	12/2009	Braithwaite et al.	N/A	N/A
2010/0138197	12/2009	Sher	N/A	N/A
2010/0145272	12/2009	Cefai et al.	N/A	N/A
2010/0152658	12/2009	Hanson et al.	N/A	N/A
2010/0174228	12/2009	Buckingham et al.	N/A	N/A
2010/0185183	12/2009	Alme et al.	N/A	N/A
2010/0211003	12/2009	Sundar et al.	N/A	N/A
2010/0228110	12/2009	Tsoukalis	N/A	N/A
2010/0241066	12/2009	Hansen et al.	N/A	N/A
2010/0256466	12/2009	Shekalim et al.	N/A	N/A
2010/0262117	12/2009	Magni et al.	N/A	N/A
2010/0262434	12/2009	Shaya	N/A	N/A
2010/0292634	12/2009	Kircher et al.	N/A	N/A
2010/0295686	12/2009	Sloan et al.	N/A	N/A
2010/0298765	12/2009	Budiman et al.	N/A	N/A
2011/0015511	12/2010	Bousamra et al.	N/A	N/A

2011/0021584	12/2010	Berggren et al.	N/A	N/A
2011/0028817	12/2010	Jin et al.	N/A	N/A
2011/0049394	12/2010	De Rochemont	N/A	N/A
2011/0054390	12/2010	Searle et al.	N/A	N/A
2011/0054399	12/2010	Chong et al.	N/A	N/A
2011/0065224	12/2010	Bollman et al.	N/A	N/A
2011/0071765	12/2010	Yodfat et al.	N/A	N/A
2011/0098638	12/2010	Chawla et al.	N/A	N/A
2011/0124996	12/2010	Reinke et al.	N/A	N/A
2011/0144586	12/2010	Michaud et al.	N/A	N/A
2011/0160652	12/2010	Yodfat et al.	N/A	N/A
2011/0178472	12/2010	Cabiri	N/A	N/A
2011/0190694	12/2010	Lanier et al.	N/A	N/A
2011/0202005	12/2010	Yodfat et al.	N/A	N/A
2011/0205065	12/2010	Strachan et al.	N/A	N/A
2011/0208156	12/2010	Doyle et al.	N/A	N/A
2011/0218495	12/2010	Remde	N/A	N/A
2011/0230833	12/2010	Landman et al.	N/A	N/A
2011/0251509	12/2010	Beyhan et al.	N/A	N/A
2011/0313680	12/2010	Doyle et al.	N/A	N/A
2011/0316562	12/2010	Cefai et al.	N/A	N/A
2011/0319322	12/2010	Bashan et al.	N/A	N/A
2012/0003935	12/2011	Lydon et al.	N/A	N/A
2012/0010594	12/2011	Holt et al.	N/A	N/A
2012/0030393	12/2011	Ganesh et al.	N/A	N/A
2012/0053556	12/2011	Lee	N/A	N/A
2012/0059351	12/2011	Nordh	N/A	N/A
2012/0059353	12/2011	Kovatchev et al.	N/A	N/A
2012/0078067	12/2011	Kovatchev et al.	N/A	N/A
2012/0078161	12/2011	Masterson et al.	N/A	N/A
2012/0078181	12/2011	Smith et al.	N/A	N/A
2012/0101451	12/2011	Boit et al.	N/A	N/A
2012/0123234	12/2011	Atlas et al.	N/A	N/A
2012/0124521	12/2011	Guo	N/A	N/A
2012/0136336	12/2011	Mastrototaro et al.	N/A	N/A
2012/0150446	12/2011	Chang et al.	N/A	N/A
2012/0172694	12/2011	Desborough et al.	N/A	N/A
2012/0190955	12/2011	Rao et al.	N/A	N/A
2012/0203085	12/2011	Rebec	N/A	N/A
2012/0203178	12/2011	Tverskoy	N/A	N/A
2012/0215087	12/2011	Cobelli et al.	N/A	N/A
2012/0225134	12/2011	Komorowski	N/A	N/A
2012/0226259	12/2011	Yodfat et al.	N/A	N/A
2012/0227737	12/2011	Mastrototaro et al.	N/A	N/A
2012/0232520	12/2011	Sloan et al.	N/A	N/A
2012/0238851	12/2011	Kamen et al.	N/A	N/A
2012/0245556	12/2011	Kovatchev et al.	N/A	N/A
2012/0246106	12/2011	Atlas et al.	N/A	N/A
2012/0246406	12/2011	Bell	711/119	G06F 12/0862
2012/0250449	12/2011	Nakano	N/A	N/A
2012/0271655	12/2011	Knobel et al.	N/A	N/A
2012/0277668	12/2011	Chawla	N/A	N/A
2012/0282111	12/2011	Nip et al.	N/A	N/A
2012/0295550	12/2011	Wilson et al.	N/A	N/A
2013/0030358	12/2012	Yodfat et al.	N/A	N/A
2013/0102867	12/2012	Desborough et al.	N/A	N/A
2013/0158503	12/2012	Kanderian et al.	N/A	N/A
2013/0172695	12/2012	Nielsen et al.	N/A	N/A
2013/0172710	12/2012	Mears et al.	N/A	N/A
2013/0178791	12/2012	Javitt	N/A	N/A
2013/0231642	12/2012	Doyle et al.	N/A	N/A
2013/0245545	12/2012	Arnold et al.	N/A	N/A
2013/0245547	12/2012	El-Khatib et al.	N/A	N/A
2013/0253472	12/2012	Cabiri	N/A	N/A
2013/0261406	12/2012	Rebec et al.	N/A	N/A
2013/0296792	12/2012	Cabiri	N/A	N/A
2013/0296823	12/2012	Melker et al.	N/A	N/A
2013/0298080	12/2012	Griffin et al.	N/A	N/A
2013/0317753	12/2012	Kamen et al.	N/A	N/A
2013/0332874	12/2012	Rosinko et al.	N/A	N/A

2013/0338576	12/2012	O'Connor et al.	N/A	N/A
2013/0338629	12/2012	Agrawal et al.	N/A	N/A
2013/0338630	12/2012	Agrawal et al.	N/A	N/A
2013/0345663	12/2012	Agrawal et al.	N/A	N/A
2013/0346858	12/2012	Neyrinck	N/A	N/A
2014/0005633	12/2013	Finan	N/A	N/A
2014/0018730	12/2013	Mueller-Pathle	N/A	N/A
2014/0032196	12/2013	Albisser et al.	N/A	N/A
2014/0032549	12/2013	McDaniel et al.	N/A	N/A
2014/0066859	12/2013	Ogawa et al.	N/A	N/A
2014/0066884	12/2013	Keenan et al.	N/A	N/A
2014/0066886	12/2013	Roy et al.	N/A	N/A
2014/0066887	12/2013	Mastrototaro et al.	N/A	N/A
2014/0066888	12/2013	Parikh et al.	N/A	N/A
2014/0066889	12/2013	Grosman et al.	N/A	N/A
2014/0074033	12/2013	Sonderegger et al.	N/A	N/A
2014/0088428	12/2013	Yang et al.	N/A	N/A
2014/0108046	12/2013	Echeverria et al.	N/A	N/A
2014/0121635	12/2013	Hayter	N/A	N/A
2014/0127048	12/2013	Diianni et al.	N/A	N/A
2014/0128839	12/2013	Diianni et al.	N/A	N/A
2014/0129951	12/2013	Amin et al.	N/A	N/A
2014/0135880	12/2013	Baumgartner et al.	N/A	N/A
2014/0142508	12/2013	Diianni et al.	N/A	N/A
2014/0146202	12/2013	Boss et al.	N/A	N/A
2014/0171901	12/2013	Langsdorf et al.	N/A	N/A
2014/0180203	12/2013	Budiman et al.	N/A	N/A
2014/0180240	12/2013	Finan et al.	N/A	N/A
2014/0188072	12/2013	Rinehart et al.	N/A	N/A
2014/0200426	12/2013	Taub et al.	N/A	N/A
2014/0200559	12/2013	Doyle et al.	N/A	N/A
2014/0230021	12/2013	Birtwhistle et al.	N/A	N/A
2014/0276553	12/2013	Rosinko et al.	N/A	N/A
2014/0276554	12/2013	Finan et al.	N/A	N/A
2014/0276555	12/2013	Morales	N/A	N/A
2014/0276556	12/2013	Saint et al.	N/A	N/A
2014/0278123	12/2013	Prodhom et al.	N/A	N/A
2014/0309615	12/2013	Mazlish	N/A	N/A
2014/0316379	12/2013	Sonderegger et al.	N/A	N/A
2014/0325065	12/2013	Birtwhistle et al.	N/A	N/A
2014/0350369	12/2013	Budiman	600/365	A61B 5/7275
2015/0018633	12/2014	Kovachev et al.	N/A	N/A
2015/0025329	12/2014	Amarasingham et al.	N/A	N/A
2015/0025495	12/2014	Peyser	N/A	N/A
2015/0025503	12/2014	Searle et al.	N/A	N/A
2015/0041498	12/2014	Kakiuchi et al.	N/A	N/A
2015/0045767	12/2014	Kamen et al.	N/A	N/A
2015/0073337	12/2014	Saint et al.	N/A	N/A
2015/0120317	12/2014	Mayou et al.	N/A	N/A
2015/0134265	12/2014	Kohlbrecher et al.	N/A	N/A
2015/0134353	12/2014	Ferrell et al.	N/A	N/A
2015/0164343	12/2014	Huang et al.	N/A	N/A
2015/0165117	12/2014	Palerm et al.	N/A	N/A
2015/0165119	12/2014	Palerm et al.	N/A	N/A
2015/0173674	12/2014	Hayes et al.	N/A	N/A
2015/0193585	12/2014	Sunna	N/A	N/A
2015/0202386	12/2014	Brady et al.	N/A	N/A
2015/0205509	12/2014	Scriven et al.	N/A	N/A
2015/0205511	12/2014	Mnna et al.	N/A	N/A
2015/0213217	12/2014	Amarasingham et al.	N/A	N/A
2015/0217052	12/2014	Keenan et al.	N/A	N/A
2015/0217053	12/2014	Booth et al.	N/A	N/A
2015/0238694	12/2014	Steil et al.	N/A	N/A
2015/0265767	12/2014	Vazquez et al.	N/A	N/A
2015/0289821	12/2014	Rack-Gomer et al.	N/A	N/A
2015/0289823	12/2014	Rack-Gomer	600/365	A61B 5/4839
2015/0301691	12/2014	Qin	N/A	N/A
2015/0306312	12/2014	Palerm	N/A	N/A
2015/0306314	12/2014	Doyle et al.	N/A	N/A
2015/0314062	12/2014	Blomquist et al.	N/A	N/A

2015/0328402	12/2014	Nogueira et al.	N/A	N/A
2015/0331995	12/2014	Zhao et al.	N/A	N/A
2015/0351671	12/2014	Vanslyke et al.	N/A	N/A
2015/0351672	12/2014	Vanslyke et al.	N/A	N/A
2015/0356250	12/2014	Polimeni	N/A	N/A
2015/0366945	12/2014	Greene	N/A	N/A
2016/0015891	12/2015	Papiorek	N/A	N/A
2016/0019352	12/2015	Cohen et al.	N/A	N/A
2016/0030669	12/2015	Harris et al.	N/A	N/A
2016/0038673	12/2015	Morales	N/A	N/A
2016/0038689	12/2015	Lee et al.	N/A	N/A
2016/0051749	12/2015	Istoc	N/A	N/A
2016/0082187	12/2015	Schaible et al.	N/A	N/A
2016/0082188	12/2015	Blomquist et al.	N/A	N/A
2016/0089494	12/2015	Guerrini	N/A	N/A
2016/0158438	12/2015	Monirabbasi et al.	N/A	N/A
2016/0162662	12/2015	Monirabbasi et al.	N/A	N/A
2016/0175520	12/2015	Palerm et al.	N/A	N/A
2016/0213841	12/2015	Geismar et al.	N/A	N/A
2016/0220181	12/2015	Rigoard et al.	N/A	N/A
2016/0228641	12/2015	Gescheit et al.	N/A	N/A
2016/0243318	12/2015	Despa et al.	N/A	N/A
2016/0256087	12/2015	Doyle et al.	N/A	N/A
2016/0256629	12/2015	Grosman et al.	N/A	N/A
2016/0259889	12/2015	Murtha et al.	N/A	N/A
2016/0287512	12/2015	Cooper et al.	N/A	N/A
2016/0302054	12/2015	Kimura et al.	N/A	N/A
2016/0317743	12/2015	Estes	N/A	N/A
2016/0331310	12/2015	Kovatchev	N/A	N/A
2016/0354543	12/2015	Cinar et al.	N/A	N/A
2017/0007882	12/2016	Werner	N/A	N/A
2017/0021096	12/2016	Cole et al.	N/A	N/A
2017/0049386	12/2016	Abraham et al.	N/A	N/A
2017/0131887	12/2016	Kim et al.	N/A	N/A
2017/0143899	12/2016	Gondhalekar et al.	N/A	N/A
2017/0143900	12/2016	Rioux et al.	N/A	N/A
2017/0156682	12/2016	Doyle et al.	N/A	N/A
2017/0173261	12/2016	O'Connor et al.	N/A	N/A
2017/0182248	12/2016	Rosinko	N/A	N/A
2017/0188943	12/2016	Braig et al.	N/A	N/A
2017/0189625	12/2016	Cirillo et al.	N/A	N/A
2017/0203038	12/2016	Desborough et al.	N/A	N/A
2017/0203039	12/2016	Desborough et al.	N/A	N/A
2017/0216524	12/2016	Haider et al.	N/A	N/A
2017/0232195	12/2016	Desborough et al.	N/A	N/A
2017/0239415	12/2016	Hwang et al.	N/A	N/A
2017/0258987	12/2016	Caspers	N/A	N/A
2017/0281877	12/2016	Marlin et al.	N/A	N/A
2017/0296746	12/2016	Chen et al.	N/A	N/A
2017/0311903	12/2016	Davis et al.	N/A	N/A
2017/0332952	12/2016	Desborough et al.	N/A	N/A
2017/0347971	12/2016	Davis et al.	N/A	N/A
2017/0348482	12/2016	Duke et al.	N/A	N/A
2018/0036495	12/2017	Searle et al.	N/A	N/A
2018/0040255	12/2017	Freeman et al.	N/A	N/A
2018/0075200	12/2017	Davis et al.	N/A	N/A
2018/0075201	12/2017	Davis et al.	N/A	N/A
2018/0075202	12/2017	Davis et al.	N/A	N/A
2018/0092576	12/2017	Afonso	N/A	N/A
2018/0126073	12/2017	Wu et al.	N/A	N/A
2018/0169333	12/2017	Grosman et al.	N/A	N/A
2018/0169334	12/2017	Grosman et al.	N/A	N/A
2018/0174675	12/2017	Roy et al.	N/A	N/A
2018/0200434	12/2017	Mazlish et al.	N/A	N/A
2018/0200436	12/2017	Mazlish et al.	N/A	N/A
2018/0200438	12/2017	Mazlish et al.	N/A	N/A
2018/0200440	12/2017	Mazlish et al.	N/A	N/A
2018/0200441	12/2017	Desborough et al.	N/A	N/A
2018/0204636	12/2017	Edwards et al.	N/A	N/A
2018/0277253	12/2017	Gondhalekar et al.	N/A	N/A

2018/0289891	12/2017	Finan et al.	N/A	N/A
2018/0296757	12/2017	Finan et al.	N/A	N/A
2018/0307515	12/2017	Meller et al.	N/A	N/A
2018/0342317	12/2017	Skirble et al.	N/A	N/A
2018/0369479	12/2017	Hayter et al.	N/A	N/A
2019/0076600	12/2018	Grosman et al.	N/A	N/A
2019/0095052	12/2018	De et al.	N/A	N/A
2019/0132801	12/2018	Kamath et al.	N/A	N/A
2019/0184091	12/2018	Sjolund et al.	N/A	N/A
2019/0240403	12/2018	Palerm et al.	N/A	N/A
2019/0290844	12/2018	Monirabbasi et al.	N/A	N/A
2019/0321545	12/2018	Saint	N/A	N/A
2019/0336683	12/2018	O'Connor et al.	N/A	N/A
2019/0336684	12/2018	O'Connor et al.	N/A	N/A
2019/0348157	12/2018	Booth et al.	N/A	N/A
2019/0374714	12/2018	Rioux et al.	N/A	N/A
2020/0001006	12/2019	Pizzochero et al.	N/A	N/A
2020/0046268	12/2019	Patek et al.	N/A	N/A
2020/0101222	12/2019	Lintereur et al.	N/A	N/A
2020/0101223	12/2019	Lintereur et al.	N/A	N/A
2020/0101225	12/2019	O'Connor et al.	N/A	N/A
2020/0113515	12/2019	O'Connor et al.	N/A	N/A
2020/0219625	12/2019	Kahlbaugh	N/A	N/A
2020/0342974	12/2019	Chen et al.	N/A	N/A
2021/0050085	12/2020	Hayter et al.	N/A	N/A
2021/0098105	12/2020	Lee et al.	N/A	N/A
2022/0023536	12/2021	Graham et al.	N/A	N/A
2022/0105270	12/2021	Doyle et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2015200829	12/2014	AU	N/A
2015200834	12/2014	AU	N/A
2015301146	12/2016	AU	N/A
1040271	12/1977	CA	N/A
3026851	12/2019	CA	N/A
1297140	12/2000	CN	N/A
101010676	12/2006	CN	N/A
101208699	12/2007	CN	N/A
102500013	12/2011	CN	N/A
102596307	12/2011	CN	N/A
103400028	12/2012	CN	N/A
103418053	12/2012	CN	N/A
103907116	12/2013	CN	N/A
104769595	12/2014	CN	N/A
104837517	12/2014	CN	N/A
105452866	12/2015	CN	N/A
4200595	12/1992	DE	N/A
19756872	12/1998	DE	N/A
0026056	12/1980	EP	N/A
0341049	12/1988	EP	N/A
0496305	12/1991	EP	N/A
0549341	12/1992	EP	N/A
0867196	12/1997	EP	N/A
0939451	12/1998	EP	N/A
1376759	12/2003	EP	N/A
1177802	12/2003	EP	N/A
1491144	12/2003	EP	N/A
1498067	12/2004	EP	N/A
1571582	12/2004	EP	N/A
0801578	12/2005	EP	N/A
2139382	12/2009	EP	N/A
2397181	12/2010	EP	N/A
2468338	12/2011	EP	N/A
2666520	12/2012	EP	N/A
2695573	12/2013	EP	N/A
2703024	12/2013	EP	N/A
2830499	12/2014	EP	N/A
2897071	12/2014	EP	N/A
2943149	12/2014	EP	N/A
2967450	12/2015	EP	N/A

3177344	12/2016	EP	N/A
3193979	12/2016	EP	N/A
3314548	12/2017	EP	N/A
3607985	12/2019	EP	N/A
2096275	12/1971	FR	N/A
1125897	12/1967	GB	N/A
2443261	12/2007	GB	N/A
51-125993	12/1975	JP	N/A
02-131777	12/1989	JP	N/A
2004-283378	12/2003	JP	N/A
2005-326943	12/2004	JP	N/A
2007-525276	12/2006	JP	N/A
2008-513142	12/2007	JP	N/A
2008-545454	12/2007	JP	N/A
2010-531678	12/2009	JP	N/A
2012-527981	12/2011	JP	N/A
2017-516548	12/2016	JP	N/A
2017-525451	12/2016	JP	N/A
2018-153569	12/2017	JP	N/A
2019-525276	12/2018	JP	N/A
200740148	12/2006	TW	N/A
M452390	12/2012	TW	N/A
86/06796	12/1985	WO	N/A
98/00193	12/1997	WO	N/A
98/55073	12/1997	WO	N/A
99/10040	12/1998	WO	N/A
99/10049	12/1998	WO	N/A
99/56803	12/1998	WO	N/A
99/62576	12/1998	WO	N/A
00/30705	12/1999	WO	N/A
00/32258	12/1999	WO	N/A
00/48112	12/1999	WO	N/A
01/72354	12/2000	WO	N/A
01/78812	12/2000	WO	N/A
02/15954	12/2001	WO	N/A
02/26282	12/2001	WO	N/A
02/43866	12/2001	WO	N/A
02/76535	12/2001	WO	N/A
02/82990	12/2001	WO	N/A
03/16882	12/2002	WO	N/A
03/39362	12/2002	WO	N/A
03/45233	12/2002	WO	N/A
03/97133	12/2002	WO	N/A
2004/043250	12/2003	WO	N/A
2004/092715	12/2003	WO	N/A
2005/051170	12/2004	WO	N/A
2005/082436	12/2004	WO	N/A
2005/110601	12/2004	WO	N/A
2005/113036	12/2004	WO	N/A
2006/021430	12/2005	WO	N/A
2006/053007	12/2005	WO	N/A
2006/124716	12/2006	WO	N/A
2007/064835	12/2006	WO	N/A
2007/066152	12/2006	WO	N/A
2007/078937	12/2006	WO	N/A
2008/024810	12/2007	WO	N/A
2008/029403	12/2007	WO	N/A
2008/057384	12/2007	WO	N/A
2008/133702	12/2007	WO	N/A
2008/157780	12/2007	WO	N/A
2009/023407	12/2008	WO	N/A
2009/039203	12/2008	WO	N/A
2009/045462	12/2008	WO	N/A
2009/049252	12/2008	WO	N/A
2009/066287	12/2008	WO	N/A
2009/066288	12/2008	WO	N/A
2009/098648	12/2008	WO	N/A
2009/134380	12/2008	WO	N/A
2009/146119	12/2008	WO	N/A
2010/022069	12/2009	WO	N/A

2010/053702	12/2009	WO	N/A
2010/077279	12/2009	WO	N/A
2010/089307	12/2009	WO	N/A
2010/132077	12/2009	WO	N/A
2010/138848	12/2009	WO	N/A
2010/139793	12/2009	WO	N/A
2010/147659	12/2009	WO	N/A
2011/030343	12/2010	WO	N/A
2011/031458	12/2010	WO	N/A
2011/075042	12/2010	WO	N/A
2011/095483	12/2010	WO	N/A
2011/133823	12/2010	WO	N/A
2012/006208	12/2011	WO	N/A
2012/045667	12/2011	WO	N/A
2012/073032	12/2011	WO	N/A
2012/108959	12/2011	WO	N/A
2012/134588	12/2011	WO	N/A
2012/177353	12/2011	WO	N/A
2012/178134	12/2011	WO	N/A
2013/050535	12/2012	WO	N/A
2013/078200	12/2012	WO	N/A
2013/134486	12/2012	WO	N/A
2013/149186	12/2012	WO	N/A
2013/176770	12/2012	WO	N/A
2013/177565	12/2012	WO	N/A
2013/182321	12/2012	WO	N/A
2014/029416	12/2013	WO	N/A
2014/035672	12/2013	WO	N/A
2014/109898	12/2013	WO	N/A
2014/110538	12/2013	WO	N/A
2014/149357	12/2013	WO	N/A
2014/149535	12/2013	WO	N/A
2014/179774	12/2013	WO	N/A
2014/194183	12/2013	WO	N/A
2015/056259	12/2014	WO	N/A
2015/061493	12/2014	WO	N/A
2015/073211	12/2014	WO	N/A
2015/081337	12/2014	WO	N/A
2015/117082	12/2014	WO	N/A
2015/117854	12/2014	WO	N/A
2015/167201	12/2014	WO	N/A
2015/177082	12/2014	WO	N/A
2015/187366	12/2014	WO	N/A
2015/187738	12/2014	WO	N/A
2016/004088	12/2015	WO	N/A
2016/022650	12/2015	WO	N/A
2016/041873	12/2015	WO	N/A
2016/089702	12/2015	WO	N/A
2016/141082	12/2015	WO	N/A
2016/161254	12/2015	WO	N/A
2017/004278	12/2016	WO	N/A
2017/027459	12/2016	WO	N/A
2017/091624	12/2016	WO	N/A
2017/105600	12/2016	WO	N/A
2017/124006	12/2016	WO	N/A
2017/184988	12/2016	WO	N/A
2017/187177	12/2016	WO	N/A
2017/205816	12/2016	WO	N/A
2018/009614	12/2017	WO	N/A
2018/067748	12/2017	WO	N/A
2018/120104	12/2017	WO	N/A
2018/136799	12/2017	WO	N/A
2018/204568	12/2017	WO	N/A
2019/077482	12/2018	WO	N/A
2019/094440	12/2018	WO	N/A
2019/213493	12/2018	WO	N/A
2019/246381	12/2018	WO	N/A
2020/081393	12/2019	WO	N/A
2021/011738	12/2020	WO	N/A

OTHER PUBLICATIONS

US 5,954,699 A, 09/1999, Jost et al. (withdrawn) cited by applicant

Dunn et al. Development of the Likelihood of Low Glucose (LLG) Algorithm for Evaluating Risk of Hypoglycemia: A New Approach for Using Continuous Glucose Data to Guide Therapeutic Decision Making. *Journal of Diabetes and Science Technology*. 2014, vol. 8, No. 4, pp. 720-730 (Year: 2014). cited by examiner

Trevitt, S., Simpson, S. and Wood, A., 2016. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development?. *Journal of diabetes science and technology*, 10(3), pp. 714-723. (Year: 2016). cited by examiner

Patek, S.D., Magni, L., Dassau, E., Karvetski, C., Toffanin, C., De Nicolao, G., Del Favero, S., Breton, M., Dalla Man, C., Renard, E. and Zisser, H., 2012. Modular closed-loop control of diabetes. *IEEE Transactions on Biomedical Engineering*, 59(11), pp. 2986-2999. (Year: 2012). cited by examiner

Parker, R.S., Doyle, F.J. and Peppas, N.A., 2001. The intravenous route to blood glucose control. *IEEE Engineering in Medicine and Biology Magazine*, 20(1), pp. 65-73. (Year: 2001). cited by examiner

European Search Report and Search Opinion Received for EP Application No. 17803425, dated on Nov. 5, 2019, 10 pages. cited by applicant

Search Report received in International Application No. PCT/US17/34012, Aug. 17, 2017. cited by applicant

Written Opinion of the International Searching Authority, as issued in connection with the International Patent Application No. PCT/US17/34012 dated Aug. 17, 2017. cited by applicant

Dassau and Associates, 12-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1C and Hypoglycemia, *Diabetes Care*, Oct. 13, 2017. cited by applicant

Samuel Vozeh and Jean-Louis Steimer, Feedback Control Methods for Drug Dosage Optimisation, Concepts, Classification and Clinical Application, *Clinical Pharmacokinetics*, 10(6), pp. 457-476, Nov.-Dec. 1985. cited by applicant

Guy A. Dumont, Feedback Control for Clinicians, Springer Science+Media, Apr. 12, 2013, New York. cited by applicant

Fischer et al., In Vivo Comparison of Different Algorithms for the Artificial Beta-Cell, *Artificial Organs*, 9(2), International Society for Artificial Organs, May 1985, New York. cited by applicant

David A. Copp, Ravi Gondhalekar, and Joao P. Hespanha, Simultaneous Model Predictive Control and Moving Horizon Estimation for Blood Glucose Regulation in Type 1 Diabetes, *Optimal Control Applications and Methods*, Wiley InterScience, DOI: 10.1002/oca, pp. 1-15, Oct. 2016. cited by applicant

Michele Schiavon, Chiara Dalla Man, Yogish C. Kudva, Ananda Basu, and Claudio Cobelli, Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump, *Diabetes Care*, vol. 37, pp. 1216-1223, May 2014. cited by applicant

E. Salzsieder, G. Albrecht, E. Jutzi, and U. Fischer, Estimation of Individually Adapted Control Parameters for an Artificial Beta Cell, *Biomedica Biochimica Acta*. 43(5) pp. 585-596, May 1984. cited by applicant

Chinese Office Action and Search Report from Chinese Application No. 201780010342, dated Mar. 18, 2021, 18 pages. cited by applicant

Anonymous: "Insulin pump", Wikipedia, Dec. 11, 2011 (Dec. 11, 2011), XP055192359. cited by applicant

Anonymous: "Super Bolus – This is Caleb…", Apr. 21, 2010 (Apr. 21, 2010), XP055689518. cited by applicant

Australian Examination Report from Australian Application No. 2017272095, dated May 19, 2021, 3 pages. cited by applicant

Canadian Examination Report for Canadian Patent Application No. 3,009,351, mailed Jan. 27, 2023, 6 pages. cited by applicant

Canadian Examination Report for Canadian Patent Application No. 3,009,831, dated Aug. 18, 2022, 4 pages. cited by applicant

Chinese Decision of Rejection for Chinese Patent Application No. 202110390474.7, issued May 10, 2023, 10 pages with translation. cited by applicant

European Communication pursuant to Article 94(3) EPC for European Application No. 17803425, dated Feb. 20, 2023, 5 pages. cited by applicant

European Communication pursuant to Article 94(3) EPC for European Application No. 18178056.0, dated Dec. 23, 2022, 5 pages. cited by applicant

European Communication pursuant to Article 94(3) EPC for European Application No. 18178057.8, dated Jan. 24, 2023, 5 pages. cited by applicant

Examination Report for Chinese Application No. 202110390473.7, dated Dec. 27, 2022, 15 pages with translation. cited by applicant

Third Party Observations for European Application No. 18702854.3, dated Jan. 24, 2023, 6 pages. cited by applicant

Wang et al., "Automatic Bolus and Adaptive Basal Algorithm for the Artificial Pancreatic β -Cell," *Diabetes Technology & Therapeutics*, vol. 12, No. 11, (2010), 11 pages. cited by applicant

Canadian Examination Report for Canadian Patent Application No. 3,009,831, dated Jul. 13, 2023, 5 pages. cited by applicant

Japanese Notice of Reasons for Refusal for Japanese Application No. 2022-176176, dated Aug. 15, 2023, 4 pages with English machine translation. cited by applicant

Examination Report of Canadian Patent Application No. 3,009,351, mailed Mar. 6, 2024, 5 pages. cited by applicant

International Search Report received for PCT Patent Application No. PCT/US2018/013643, mailed on May 2, 2018, 3 pages. cited by applicant

Written Opinion of the International Searching Authority of International Application No. PCT/US2018/013659, mailed May 2, 2018, 6 pages. cited by applicant

Written Opinion of the International Searching Authority of International Application No. PCT/US2018/013643, mailed May 2, 2018, 7 pages. cited by applicant

Communication pursuant to Article 94(3) EPC of European Patent Application No. 24196714.0, mailed Nov. 18, 2024, 4 pages. cited by applicant

European Communication pursuant to Article 94(3) EPC for European Application No. 24196714.0, dated Apr. 1, 2025, 4 pages. cited by applicant

Summons to attend oral proceedings pursuant to Rule 115(1) EPC for European Application No. 18702854.3, dated Feb. 21, 2025, 8 pages. cited by applicant

Summons to attend oral proceedings pursuant to Rule 115(1) EPC for European Application No. 18703123.2, dated Mar. 21, 2025, 9 pages. cited by applicant

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATION (1) A claim for benefit of priority to the May 23, 2016 filing date of the U.S. Patent Provisional Application No. 62/340,469, titled INSULIN DELIVERY SYSTEM AND METHODS WITH RISK BASED SET POINTS (the '469 Provisional Application), is hereby made pursuant to 35 U.S.C. § 119 (e). The entire disclosures of the '469 Provisional Application is hereby incorporated by reference.

TECHNICAL FIELD

(1) This document relates to systems and methods for adjusting insulin delivery rates.

BACKGROUND

(2) Diabetes mellitus is a chronic metabolic disorder caused by an inability of a person's pancreas to produce sufficient amounts of the hormone, insulin, such that the person's metabolism is unable to provide for the proper absorption of sugar and starch. This failure leads to hyperglycemia, i.e., the presence of an excessive amount of glucose within the blood plasma. Persistent hyperglycemia has been associated with a variety of serious symptoms and life threatening long-term complications such as dehydration, ketoacidosis, diabetic coma, cardiovascular diseases, chronic renal failure, retinal damage and nerve damages with the risk of amputation of extremities. Because healing is not yet possible, a permanent therapy is necessary that provides constant glycemic control in order to constantly maintain the level of blood glucose within normal limits. Such glycemic control is achieved by regularly supplying external drugs to the body of the patient to thereby reduce the elevated levels of blood glucose.

(3) Historically, diabetes is treated with multiple, daily injections of rapid and long acting insulin via a hypodermic syringe. One or two injections per day of a long acting insulin is administered to provide a basal level of insulin and additional injections of a rapidly acting insulin is administered before or with each meal in an amount proportional to the size of the meal. Insulin therapy can also be administered using an insulin pump that provides periodic or continuous release of the rapidly acting insulin to provide for a basal level of insulin and larger doses of that same insulin at the time of meals. Insulin pumps allow for the delivery of insulin in a manner that bears greater similarity to the naturally occurring physiological processes and can be controlled to follow standard or individually modified protocols to give the patient better glycemic control. In some circumstances, an insulin pump device can store (via input from a clinician or a user) a number of settings (e.g., dosage parameters or other settings) that are customized by the physician for the particular user.

(4) People with diabetes, their caregivers, and their health care providers (HCPs) bear a great deal of cognitive burden in managing intensive medicine therapy. Delivering the correct amount of the medicine at the correct time is an extremely challenging endeavor. Such delivery requires the patient to make dosing determinations multiple times per day and also requires a combination of the patient and the HCP to recalibrate the therapeutic parameters of the therapy on an episodic time frame that varies from individual to individual, and within individuals based on age and/or behavior (e.g., change in exercise, change in diet).

(5) In light of the many deficiencies and problems associated with current systems and methods for maintaining proper glycemic control, enormous resources have been put into finding better solutions. A number of new technologies promise to mitigate some of the cognitive burden that intensive insulin therapy now requires. Developing workable solutions to the problem that are simple, safe, reliable and able to gain regulatory approval has, however, proved to be elusive. For years, researchers have contemplated coupling a continuous glucose monitoring system with an insulin delivery device to provide an "artificial pancreas" to assist people living with diabetes. Their efforts have yet to result in a commercial product. What has been needed is a system and method that provides a level of automatic control of drug delivery devices for improved medicine delivery and glycemic control that is simple, safe, and reliable in a real world setting.

BRIEF SUMMARY

(6) Methods and systems provided herein simplify the delivery of basal insulin, which can reduce the cognitive burden for managing diabetes for a user (e.g., a patient, caretaker, or clinician).

(7) In one or more embodiments, the present disclosure may include a method that includes obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

(8) In accordance with the preceding method of the above paragraph, the method may include determining the variability may include determining a measure of dispersion for blood glucose values for the diurnal period and determining an approximate percentage of blood glucose measurements expected to fall below a threshold blood glucose level.

(9) In accordance with one or more methods of the present disclosure, including the method of the above paragraph, the method may include modifying a target blood glucose level may include incrementally increasing the target blood glucose level if the determined approximate percentage exceeds a threshold percentage.

(10) In accordance with one or more methods of the present disclosure, including the method of the above paragraph, the method may include, the threshold percentage may be determined by a fear of hypoglycemia index (FHI) set by a user.

(11) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding two paragraphs, the method may include the increase in the diurnal target blood glucose level may be determined by determining a diurnal measure of central tendency (such as exponentially weighted geometric mean) and a diurnal measure of dispersion (such as exponentially weighted geometric standard deviation) for blood glucose values and determining a shift to the diurnal target blood glucose level that would approximately achieve the threshold percentage of the blood glucose values being below the threshold blood glucose level. In some cases, blood glucose data can be analyzed using a lognormal distribution.

(12) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding four paragraphs, the target blood glucose level may be capped at a maximum target blood glucose level.

(13) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding five paragraphs, modifying a target blood glucose level may include incrementally decreasing the target blood glucose level if the determined approximate percentage is less than a threshold percentage.

(14) In accordance with one or more methods of the present disclosure, including the methods of the above paragraph, the target blood

glucose level may be limited by a minimum target blood glucose level.

(15) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding two paragraphs, the threshold percentage may be determined by a fear of hypoglycemia index (FHI) set by a user.

(16) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding three paragraphs, the decrease in the diurnal target blood glucose level is determined by determining a diurnal measure of central tendency (such as exponentially weighted geometric mean) and a diurnal measure of dispersion (such as exponentially weighted geometric standard deviation) for blood glucose values and determining a shift to the diurnal target blood glucose level that would approximately achieve the threshold percentage of the blood glucose values being below the threshold blood glucose level. In some cases, blood glucose data can be analyzed using a lognormal distribution.

(17) In accordance with one or more methods of the present disclosure, including the methods of the above paragraph, the target blood glucose value may be decreased by no more than 2 mg/dL per day.

(18) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding eleven paragraphs, modifying the diurnal period may further include modifying an adjacent diurnal period in the same direction to smooth changes in target blood glucose targets between diurnal periods.

(19) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding twelve paragraphs, delivering insulin during the diurnal time period based on the modified target blood glucose level may include generating a first plurality of insulin delivery profiles, where each of the first plurality of insulin delivery profiles includes a first series of insulin delivery actions spanning a first time interval extending over the diurnal period and subsequent diurnal periods. Delivering insulin may also include projecting a first plurality of future blood glucose values for each insulin delivery profile of the first plurality of insulin delivery profiles for a plurality of times spanning the first time interval, where each projected future blood glucose values being projected may use at least one up-to-date blood glucose level for a person with diabetes (PWD). Delivering insulin may additionally include selecting a first profile of the first plurality of insulin delivery profiles based at least in part upon a comparison between the first plurality of future blood glucose values for each insulin delivery profile and a plurality of modified target blood glucose levels for each diurnal period overlapping with the first time interval. Delivering insulin may also include delivering a first dose of insulin using an insulin pump for a second time interval after a previous dose of insulin, the first dose of insulin corresponding to a first action in the first series of insulin delivery actions of the first profile, and the second time interval being equal to or shorter than the diurnal period.

(20) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding thirteen paragraphs, in accordance with one or more methods of the present disclosure, determining an estimated rate of variability in the blood glucose levels over the diurnal period for the plurality of days may include weighting blood glucose levels from more recent days of the plurality of days more heavily than blood glucose levels from older days of the plurality of days.

(21) In accordance with one or more methods of the present disclosure, including the methods of one or more of the preceding fourteen paragraphs, determining an estimated rate of variability in the blood glucose levels over the diurnal period for the plurality of days may include excluding from the plurality of days blood glucose levels from days older than a cutoff date.

(22) In one or more embodiments, the present disclosure may include a system that includes a glucose sensor configured to generate blood glucose level readings, an insulin pump configured to deliver insulin based on a message, and a control device. The control device may be configured to obtain blood glucose level readings over a diurnal period for each of a plurality of days, and determine an estimated variability in the blood glucose levels over the diurnal period for the plurality of days. The control device may additionally be configured to modify, based on the estimated variability in the blood glucose level, a target blood glucose level to a modified target blood glucose level, and generate a message to deliver insulin during the diurnal period based on the modified target blood glucose level.

(23) In accordance with one or more systems of the present disclosure, including the system of the above paragraph, the control device may be one of a mobile computing device, a remote server, and control circuitry.

(24) In accordance with one or more systems of the present disclosure, including the systems of one or more of the preceding two paragraphs, the message may include instructions to control circuitry to utilize the modified target blood glucose level in controlling delivery of insulin.

(25) In accordance with one or more systems of the present disclosure, including the systems of one or more of the preceding three paragraphs, the glucose sensor may include a continuous glucose monitor (CGM).

(26) In one or more embodiments, the present disclosure may include a non-transitory computer-readable medium that may contain instructions that, when executed by a processor, are configured to perform operations. The operations may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days, and determining an estimated variability in the blood glucose levels over the diurnal period for the plurality of days. The operations may additionally include modifying, based on the estimated variability in the blood glucose level, a target blood glucose level to a modified target blood glucose level, and generating a message to deliver insulin during the diurnal period based on the modified target blood glucose level.

(27) The details of one or more implementations of various embodiments are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the various embodiments will be apparent from the description and drawings, and from the claims.

(28) It is to be understood that both the foregoing general description and the following detailed description are merely examples and explanatory and are not restrictive of the claims.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) Example embodiments will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:

(2) FIG. 1 is an example diabetes management system (DMS);

(3) FIG. 2 is a flowchart of an example technique for adjusting basal insulin delivery rates;

(4) FIG. 3 illustrates multiple example insulin delivery profiles, projected blood glucose levels for the profiles, and a “loss” calculation for each profile;

(5) FIG. 4 illustrates an example model for calculating future blood glucose values;

(6) FIG. 5 illustrates an example chart of blood glucose level distributions;

(7) FIG. 6 illustrates data recorded for a simulated person with diabetes using methods and systems provided herein;

- (8) FIGS. 7A and 7B depict additional details of the example DMS of FIG. 1;
(9) FIG. 8 illustrates a flowchart of an example method of using insulin delivery profiles;
(10) FIG. 9 illustrates a flowchart of an example method of adjusting insulin delivery rates;
(11) FIG. 10 illustrates a flowchart of an example method of utilizing a fear of hypoglycemia index;
(12) FIG. 11 illustrates a flowchart of an example method of utilizing a temporary override; and
(13) FIG. 12 illustrates a flowchart of an example method of modifying target blood glucose levels.

DETAILED DESCRIPTION

- (14) Medicine delivery systems and methods provided herein may be used and performed, respectively, by a user, for example, a person with diabetes (PWD). The PWD may live with type 1, type 2, or gestational diabetes. In some cases, a user can be a healthcare professional or caregiver for a PWD.
- (15) Methods and systems provided herein can use information from a glucose measurement device (e.g., a continuous glucose monitor) to have up-to-date blood glucose data (e.g., a plurality of blood glucose data points each hour) for the PWD in order to determine how to adjust basal insulin delivery rates. In some cases, methods and systems provided herein can use blood glucose data from both one or more continuous glucose monitors and one or more blood glucose meters. Methods and systems provided herein can be part of a hybrid closed-loop system (for example, where basal rates can be adjusted automatically and the PWD can manually enter or deliver a bolus). In some cases, methods and systems provided herein can be part of a fully closed-loop system (for example, where basal rates can be adjusted automatically and boluses can be delivered automatically). In some cases, “up-to-date” may mean less than 1 hour old, less than 30 minutes old, or less than 15 minutes old.
- (16) Methods and systems provided herein can use a model to predict multiple future blood glucose levels for multiple different basal insulin delivery profiles or basal insulin delivery rates, and select one of the basal insulin delivery profiles or basal insulin delivery rates based on prediction of which profile or rate will approximate a target blood glucose level, or more specifically, select the profile that minimizes the differences between the predicted future blood glucose values and one or more target blood glucose values. In some cases, the profile that minimizes, lessens, or lowers variations from one or more target blood glucose levels in the future may be selected. The selected basal profile can then be delivered to the PWD at least until a process of evaluating different basal insulin delivery profiles or rates is repeated. In some cases, methods and systems provided herein can repeat a process of evaluating multiple different basal insulin delivery profiles or basal insulin delivery rates at a time interval that is less than the time interval for the plurality of future predicted blood glucose values. For example, in some cases, the time interval between evaluating and selecting from multiple different basal insulin delivery profiles or basal insulin delivery rates can be less than one hour while the plurality of future predicted blood glucose values can extend over a time interval of at least two hours into the future. In some cases of methods and systems provided herein, each of the evaluated basal insulin delivery profiles or rates can extend for a time interval greater than the time interval between evaluation processes. In some cases, methods and systems provided herein can evaluate insulin delivery profiles and rates that extend at least two hours into the future and predicted blood glucose values can also be predicted over a time interval that extends at least two hours into the future. In some cases, the profiles/rates and time interval of predicted future blood glucose values extends at least three hours into the future. In some cases, the profiles/rates and time interval of predicted future blood glucose values extends a period of time (e.g., at least four hours) into the future. In some cases, the profiles/rates and time interval of predicted future blood glucose values extends at least five hours into the future.
- (17) The different basal insulin delivery profiles or rates for each evaluation process can be generated using any suitable techniques. In some cases, multiple profiles or delivery rates are generated using one or more user-specific dosage parameters. In some cases, one or more user-specific dosage parameters can be entered by a user, calculated by information entered by a user, and/or calculated by monitoring data generated from the PWD (e.g., monitoring insulin delivery rates and blood glucose data while the PWD is using a pump in an open-loop mode). In some cases, methods and systems provided herein can modify user-specific dosage parameters over time based on one or more selected basal insulin delivery profiles or rates and/or other data obtained from the PWD. In some cases, the user-specific dosage parameters can be dosage parameters that are commonly used in the treatment of diabetes, such as average total daily insulin, total daily basal (TDB) insulin, average basal rate, insulin sensitivity factor (ISF), and carbohydrate-to-insulin ratio (CR). For example, in some cases, a PWD's average basal rate can be used to calculate multiple different basal insulin delivery profiles based on multiples or fractions of the average basal rate used over different intervals of time. In some cases, methods and systems provided herein can use time-interval-specific user-specific dosage parameters (e.g., a time-interval-specific baseline basal rate). In some cases, methods and systems provided herein can make adjustments to time-interval-specific user-specific dosage parameters for each time interval for where a delivered basal rate varies from a baseline basal rate for that time interval. In some cases, user-specific dosage parameters are specific for time intervals of two hours or less, one hour or less, thirty minutes or less, or fifteen minutes or less. For example, in some cases methods and systems provided herein can store a baseline basal rate for the hour between 1 PM and 2 PM, and can adjust the baseline basal rate for that hour up if the method or system delivers more basal insulin during that time period and adjust the baseline basal rate down if the method or system delivers less basal insulin during that time period. In some cases, adjustments to user-specific dosage parameters can be based on a threshold variation and/or can be limited to prevent excessive adjustments to user-specific dosage parameters. For example, in some cases, a daily adjustment to a user-specific dosage parameter can be limited to less than 10%, less than 5%, less than 3%, less than 2%, or to about 1%. In some cases, an adjustment to a baseline basal rate is less than a difference between the amount of basal insulin actually delivered and the baseline basal for a specific period of time (e.g., if a baseline basal rate is 1 U/hour and systems or methods provided herein actually delivered 2U for the previous hour, the adjustment to any baseline basal rate based on that difference would be less than 1 U/hour).
- (18) Methods and systems provided herein can use any appropriate model to predict multiple future blood glucose values. In some cases, predictive models can use one or more current or recent blood glucose measurements (e.g., from a blood glucose meter and/or a continuous glucose monitor), estimates of rates of change of blood glucose levels, an estimation of unacted carbohydrates, and/or an estimation of unacted insulin. In some cases, predictive models can use one or more user-specific dosage parameters in predicting multiple blood glucose values over a future time interval for multiple different basal insulin delivery profiles or rates over that same future time interval. As discussed above, that future time interval can be at least two hours, at least three hours, or at least four hours, at least five hours, etc. User-specific dosage parameters, which can be time-interval-specific, can also be used in determining an estimation of unacted carbohydrates and/or an estimation of unacted insulin. In some cases, an estimation of unacted insulin can be determined using an Insulin On Board (IOB) calculation, which is common in the art of treating diabetes. In some cases, an IOB calculation used in a predictive model used in methods and systems provided herein can consider insulin delivered to the PWD during the delivery of a bolus. In some cases, the IOB calculation can additionally add or subtract to the IOB based on changes to the basal insulin delivery rate from a baseline basal rate. In some cases, an estimate of unacted carbohydrates can be determined using a Carbohydrates On Board (COB) calculation, which can be based on a decay

function and announced meals. In some cases, predictive models used in methods and systems provided herein can also consider the non-carbohydrate components of a meal. In some cases, methods and systems provided herein can infer an amount of carbohydrates from an unannounced meal due to a spike in up-to-date blood glucose data. In some cases, predictive models used in methods and systems provided herein can additionally consider additional health data or inputs, which may indicate that the PWD is sick, exercising, experiencing menses, or some other condition that may alter the PWD's reaction to insulin and/or carbohydrates. In some cases, at least an IOB, a COB, an insulin sensitivity factor (ISF), and a carbohydrate-to-insulin ratio (CR) are used to predict future blood glucose values for each evaluated basal insulin delivery profile or rate.

(19) Methods and systems provided herein can set one or more blood glucose targets using any suitable technique. In some cases, a blood glucose target can be fixed, either by a user or pre-programmed into the system. In some cases, the target blood glucose level can be time interval specific (e.g., based on diurnal time segments). In some cases, a user can temporarily or permanently adjust the target blood glucose level. In some cases, methods and systems provided herein can make adjustments to target blood glucose levels in order to minimize, lessen, or lower a risk of the PWD having a hypoglycemic event. In some cases, methods and systems provided herein can make adjustments to target blood glucose levels in order to minimize, lessen, or lower a risk of the PWD having a hyperglycemic event. For example, in some cases, methods and systems provided herein can analyze a variability of blood glucose data for the PWD and select a blood glucose target based on that variability. In some cases, methods and systems provided herein can analyze the variability of blood glucose data for diurnal time segments and adjust the blood glucose target individual for each diurnal time segment. For example, some PWDs may have a lower blood glucose variability at night, thus systems and methods provided herein can reduce blood glucose targets for nighttime diurnal time segments because of the lower probability that a lower blood glucose target would result in a hypoglycemic event during those lower variability time segments. Reducing the blood glucose target for diurnal time segments having a lower variability can reduce the amount of hyperglycemic events for the PWD. In some cases, PWDs may have a larger variability around the times of day when they typically have meals (e.g., due to mismatches in timing and amounts of insulin boluses and carbohydrate ingestion), thus methods and systems provided herein can detect diurnal time segments having a wider range of variability and increase the blood glucose target for those time periods to reduce the probability of a hypoglycemic event during those time periods. In some cases, methods and systems provided herein can analyze the variability of blood glucose data for specific days of the week and/or based on other physiological patterns and adjust the blood glucose targets for that individual based on the specific day of the week or based on other physiological patterns. For example, a PWD may have certain days of the week when they exercise and/or PWD may have different insulin needs based on a menses cycle.

(20) Methods and systems provided herein can evaluate each basal insulin delivery profile or rate to select the profile or rate that minimizes a variation from the one or more blood glucose targets using any appropriate method. In some cases, methods and systems provided herein can use a cost function to evaluate differences between the predicted blood glucose values for each basal insulin delivery profile or rate and blood glucose targets, potentially specified for a diurnal time segment. Methods and systems provided herein can then select a basal profile or rate that produces the lowest cost function value. Methods and systems provided herein can use any suitable cost function. In some cases, cost functions can sum the absolute value of the difference between each predicted blood glucose value and each blood glucose target. In some cases, cost functions used in methods and systems provided herein can use a square of the difference. In some cases, cost functions used in methods and systems provided herein can assign a higher cost to blood glucose values below the blood glucose target in order to reduce the risk of a hypoglycemic event. In some cases, the cost function can include a summation of the absolute values of a plurality of predicted deviations, squared deviations, log squared deviations, or a combination thereof. In some cases, a cost function can include variables unrelated to the predicted blood glucose values. For example, a cost function can include a penalty for profiles that do not deliver 100% of the BBR, thus adding a slight preference to use 100% of BBR. In some cases, methods and systems provided herein can include a cost function that provides a slight preference to keep the existing basal modification for every other interval (e.g., a second 15-minute segment), which could reduce the variability in basal insulin delivery rates in typical situations, but allow for more critical adjustments.

(21) Methods and systems provided herein can receive various inputs from a user related to the delivery of basal insulin. In some cases, a user may input a fear of hypoglycemia (FHI) index. The FHI may indicate the preference for or reticence to experience certain blood glucose levels by the PWD. For example, the FHI may indicate that the PWD prefers "high" blood glucose levels (e.g., blood glucose levels above a threshold); or as another example, the FHI may indicate that the PWD is concerned about "going low" (e.g., blood glucose levels below a threshold). In some cases, the FHI may correspond to a threshold and an acceptable probability of crossing the threshold, including using the threshold to signify going high or using the threshold to signify going low, or both. In some cases, a probability of the PWD crossing the threshold may be determined and a baseline basal insulin rate may be modified to more closely align the acceptable probability of crossing the threshold with the actual probability of crossing the threshold. Additionally or alternatively, the FHI may be used in other ways in methods and systems of the present disclosure. For example, modification of the baseline basal insulin rate for a diurnal period may be modified one way for a high FHI and another way for a low FHI. As another example, multiple profiles of insulin delivery steps may use one set of possible steps for a high FHI, and another set of possible steps for a low FHI.

(22) Methods and systems provided herein can modify or alter an insulin delivery profile or rate in any number of ways. In some cases, a user may select a temporary override to indicate a user preference for a particular blood glucose level. For example, the PWD may indicate that they are going for a long drive and do not want to have their blood glucose levels drop below a certain level, and so may designate a target blood glucose level higher than their normal target blood glucose level, which may be set for a particular or indefinite length of time. In some cases, methods and systems provided herein may modify or otherwise select a new profile or rate from multiple profiles that corresponds to the blood glucose level from the temporary override. In some cases, methods and systems provided herein can permit a user to merely indicate a reduced tolerance for the risk of going low and can determine a temporary blood glucose level based on the variability of blood glucose data for that PWD for previous days (optionally for a particular diurnal time segment).

(23) Methods and systems provided herein can store a plurality of user-specific dosage parameters (e.g., BBR, CR, and ISF) as different values for a plurality of different diurnal time segments. As used herein, the term "diurnal time segments" may refer to periods of time during each day, such that the methods and systems will repeat use of each diurnal-specific user-specific dosage parameter during the same time on subsequent days if a stored diurnal-specific user-specific dosage parameter is not modified or change, thus the use of the stored diurnal-specific user-specific dosage parameter will wrap each day. Methods and systems provided herein, however, can be adapted to make daily (or more or less frequent) adjustments to each diurnal-specific user-specific dosage parameter based on the operation of the system. Methods and systems provided herein may additionally store settings or adjustments for specific days of the week or for other repeating cycles.

(24) After a basal insulin delivery profile or rate is selected, methods and systems provided herein can include the delivery of basal insulin to the PWD according to the selected basal insulin profile or rate for any suitable period of time. In some cases, methods and systems provided herein may supply basal insulin according to the selected basal insulin delivery profile or rate for a predetermined amount of time

that may be less than the time interval of the evaluated basal insulin delivery profiles or rates. For example, methods and systems provided herein may analyze projected blood glucose values for basal insulin delivery profiles or rates that last over the next four hours but repeat the process of selecting a new basal insulin delivery profile or rate every fifteen minutes. In some cases, methods and systems provided herein can delay or suspend basal insulin delivery during the delivery of a bolus, which can be triggered by a user requesting a bolus.

(25) As used herein, “basal insulin delivery” has its normal and customary meaning within the art of the treatment of diabetes. Although basal rates are expressed as a continuous supply of insulin over time, basal insulin delivery may constitute multiple discrete deliveries of insulin at regular or irregular intervals. In some cases, methods and systems provided herein may only be able to deliver insulin in discrete fractions of a unit. For example, some insulin delivery devices can only deliver insulin in a dose that are an integer multiple of 0.05 unit or 0.1 unit. In some cases, a delivery of basal insulin can include a delivery of insulin at predetermined time intervals less than or equal to fifteen minutes apart or less, ten minutes apart or less, or five minutes apart or less. In some cases, the time interval between discrete basal insulin deliveries can be determined based on the basal insulin delivery rate (e.g., a basal rate of 1.0 unit/hour might result in the delivery of 0.1 unit every six minutes). As used herein, the term “bolus” has its normal and customary meaning with the art of the treatment of diabetes, and can refer to a bolus delivered in order to counteract a meal (i.e., a meal-time bolus) and/or to correct for elevated blood glucose levels (i.e., a correction bolus).

(26) Methods and systems provided herein can in some cases include multiple delivery modes. In some cases, methods and systems provided herein can monitor the presence of blood glucose using one or more blood glucose measuring devices or methods, control or monitor the dispensation of medicine, and determine and/or update the user-specific dosage parameters regardless of the operating mode. For example, possible operating modes could include closed-loop or hybrid closed-loop modes that automatically adjust basal rates based on continuous glucose monitoring data (CGM) and other user-specific dosage parameters (e.g., baseline basal rate (BBR), insulin sensitivity factor (ISF), and carbohydrate-to-insulin ratio (CR)), modes that can use blood glucose monitor (BGM) data to update user-specific dosage parameters (e.g., BBRs, ISFs, and CRs) for different time blocks over longer periods of time, manual modes that require a patient to manually control the therapy program using an insulin pump, and advisory modes that recommend dosages for a PWD to inject using an insulin pen or syringe. By determining optimized control parameters that work-across-delivery modes, systems and methods provided herein can provide superior analyte control even when a PWD switches to a different delivery mode. For example, methods and systems provided herein may be forced to switch away from a hybrid closed-loop delivery mode that adjusts basal insulin delivery away from a BBR if a continuous glucose monitor malfunctions or the system otherwise loses access to continuous data. In some cases, data can be collected when the system is in an advisory or manual mode to optimize control parameters in preparation for a PWD to switch to a hybrid closed-loop system (e.g., in preparation for a PWD to start use of a continuous glucose monitor (CGM) and/or an insulin pump).

(27) Methods and systems provided herein can include an insulin pump and at least one blood glucose measurement device in communication with the insulin pump. In some cases, the blood glucose measurement device can be a CGM adapted to provide blood glucose measurements at least every fifteen minutes. In some cases, methods and systems provided herein include a CGM adapted to provide blood glucose measurements at least every ten minutes. In some cases, methods and systems provided herein include a CGM adapted to provide blood glucose measurements every five minutes. Methods and systems provided herein additionally include a controller adapted to determine an amount of basal insulin for delivery to a PWD and memory to store multiple user-specific dosage parameters. In some cases, the controller can be part of an insulin pump. In some cases, a controller can be part of a remote device, which can communicate wirelessly with an insulin pump. In some cases, the controller can communicate wirelessly with a CGM. In some cases, methods and systems provided herein can additionally include a user interface for displaying data and/or receiving user commands, which can be included on any component of a system provided herein. In some cases, the user interface can be part of smartphone. In some cases, a user can input information on the user interface to trigger methods and systems provided herein to deliver a bolus of insulin. In some cases, methods and systems provided herein can use a blood glucose meter adapted to use a test strip as a blood glucose measurement device. In some cases, methods and systems provided herein can additionally include an insulin pen, which can optionally communicate wirelessly with a controller.

(28) Example Diabetes Management System

(29) FIG. 1 depicts an example diabetes management system 10 including an insulin pump assembly 15 and a continuous glucose monitor 50. As shown, the continuous glucose monitor 50 is in wireless communication with insulin pump assembly 15. In some cases, a continuous glucose monitor can be in wired communication with insulin pump assembly 15. In some cases not shown, a continuous glucose monitor can be incorporated into an insulin pump assembly. As shown, insulin pump assembly can include a reusable pump controller 200 that forms part of the pump assembly. In some cases, reusable pump controller 200 is adapted to determine one or more basal delivery rates. In some cases, continuous glucose monitor 50 can act as a controller adapted to communicate basal delivery rates to insulin pump assembly 15.

(30) Insulin pump assembly 15, as shown, can include reusable pump controller 200 and a disposable pump 100, which can contain a reservoir for retaining insulin. A drive system for pushing insulin out of the reservoir can be included in either the disposable pump 100 or the reusable pump controller 200 in a controller housing 210. Reusable pump controller 200 can include a wireless communication device 247, which can be adapted to communicate with a wireless communication device 54 of continuous glucose monitor 50 and other diabetes devices in the system, such as those discussed below. In some cases, insulin pump assembly 15 can be sized to fit within a palm of a hand 5. Insulin pump assembly 15 can include an infusion set 146. Infusion set 146 can include a flexible tube 147 that extends from the disposable pump 100 to a subcutaneous cannula 149 that may be retained by a skin adhesive patch (not shown) that secures the subcutaneous cannula 149 to the infusion site. The skin adhesive patch can retain the cannula 149 in fluid communication with the tissue or vasculature of the PWD so that the medicine dispensed through tube 147 passes through the cannula 149 and into the PWD's body. The cap device 130 can provide fluid communication between an output end of an insulin cartridge (not shown) and tube 147 of infusion set 146. Although insulin pump assembly 15 is depicted as a two-part insulin pump, one piece insulin pumps are also contemplated. Additionally, an insulin pump assemblies used in methods and systems provided herein can alternatively be a patch pump.

(31) Continuous glucose monitor 50 (e.g., a glucose sensor) can include a housing 52, a wireless communication device 54, and a sensor shaft 56. The wireless communication device 54 can be contained within the housing 52 and the sensor shaft 56 can extend outward from the housing 52. In use, the sensor shaft 56 can penetrate the skin 20 of a user to make measurements indicative of the PWD's blood glucose level or the like. In some cases, the sensor shaft 56 can measure glucose or another analyte in interstitial fluid or in another fluid and correlate that to blood glucose levels. In response to the measurements made by the sensor shaft 56, the continuous glucose monitor 50 can employ the wireless communication device 54 to transmit data to a corresponding wireless communication device 247 housed in the pump assembly 15. In some cases, the continuous glucose monitor 50 may include a circuit that permits sensor signals (e.g., data from the sensor shaft 56) to be communicated to the communication device 54. The communication device 54 can transfer the collected data to reusable pump controller 200 (e.g., by wireless communication to the communication device 247). Additionally or alternatively, the system 10 may

include another glucose monitoring device that may utilize any of a variety of methods of obtaining information indicative of a PWD's blood glucose levels and transferring that information to reusable pump controller **200**. For example, an alternative monitoring device may employ a micropore system in which a laser porator creates tiny holes in the uppermost layer of a PWD's skin, through which interstitial glucose is measured using a patch. In the alternative, the monitoring device can use iontophoretic methods to non-invasively extract interstitial glucose for measurement. In other examples, the monitoring device can include non-invasive detection systems that employ near IR, ultrasound or spectroscopy, and particular implementations of glucose-sensing contact lenses. In other examples, the monitoring device can detect glucose levels using equilibrium fluorescence detectors (e.g., sensors including a diboronic acid receptor attached to a fluorophore). Furthermore, it should be understood that in some alternative implementations, continuous glucose monitor **50** can be in communication with reusable pump controller **200** or another computing device via a wired connection. In some cases, continuous glucose monitor **50** can be adapted to provide blood glucose measurements for a PWD when in use for the PWD at regular or irregular time intervals. In some cases, continuous glucose monitor **50** can detect blood glucose measurements at least every thirty minutes, at least every fifteen minutes, at least every ten minutes, at least every five minutes, or about every minute. In some cases, continuous glucose monitor **50** can itself determine a basal delivery rate using methods provided herein and communicate that basal rate to the insulin pump assembly **15**. In some cases, continuous glucose monitor **50** can transmit blood glucose measurement data to reusable pump controller **200** and reusable pump controller **200** can use methods provided herein to determine a basal delivery rate. In some cases, a remote controller can receive glucose data from continuous glucose monitor **50**, determine a basal delivery rate using methods provided herein, and communicate the basal rate to insulin pump assembly **15**.

(32) Diabetes management system **10** may optionally include a blood glucose meter **70** (e.g., a glucose sensor). In some cases, blood glucose meter **70** can be in wireless communication with reusable pump controller **200**. Blood glucose meter **70** can take a blood glucose measurement using one or more test strips (e.g., blood test strips). A test strip can be inserted into a strip reader portion of the blood glucose meter **70** and then receive the PWD's blood to determine a blood glucose level for the PWD. In some cases, the glucose meter device **70** is configured to analyze the characteristics of the PWD's blood and communicate (e.g., via a BLUETOOTH® wireless communication connection) the information to reusable pump controller **200**. In some cases, a user can manually input a glucose meter reading. The blood glucose meter **70** can be manually operated by a user and may include an output subsystem (e.g., display, speaker) that can provide the user with blood glucose readings that can be subsequently entered into the controller or user interface to collect the data from an unconnected BGM into the system. The blood glucose meter **70** may be configured to communicate data (e.g., blood glucose readings) obtained to reusable pump controller **200** and/or other devices, such as the mobile computing device **60** (e.g., a control device). Such communication can be over a wired and/or wireless connection, and the data can be used by system **10** for a number of functions (e.g., calibrating the continuous glucose monitor **50**, confirming a reading from the continuous glucose monitor **50**, determining a more accurate blood glucose reading for a bolus calculation, detecting a blood glucose level when the continuous glucose monitor **50** is malfunctioning).

(33) In some cases, the system **10** can further include a mobile computing device **60** that can communicate with the reusable pump controller **200** through a wireless and/or wired connection with the reusable pump controller **200** (e.g., via a BLUETOOTH® wireless communication connection or a near-field communication connection). In some cases, the mobile computing device **60** communicate wirelessly with other diabetes devices of system **10**. The mobile computing device **60** can be any of a variety of appropriate computing devices, such as a smartphone, a tablet computing device, a wearable computing device, a smartwatch, a fitness tracker, a laptop computer, a desktop computer, and/or other appropriate computing devices. In some cases (for example, where the reusable pump controller **200** does not determine a basal delivery rate), the mobile computing device **60** can receive and log data from other elements of the system **10** and determine basal delivery rates using methods provided herein. In some cases, a user can input relevant data into the mobile computing device **60**. In some cases, the mobile computing device **60** can be used to transfer data from the controller device **200** to another computing device (e.g., a back-end server or cloud-based device). In some cases, one or more methods provided herein can be performed or partially performed by the other computing device. In some cases, the mobile computing device **60** provides a user interface (e.g., graphical user interface (GUI), speech-based user interface, motion-controlled user interface) through which users can provide information to control operation of the reusable pump controller **200** and the system **10**. For example, the mobile computing device **60** can be a mobile computing device running a mobile app that communicates with reusable pump controller **200** over short-range wireless connections (e.g., BLUETOOTH® connection, Wi-Fi Direct connection, near-field communication connection, etc.) to provide status information for the system **10** and allow a user to control operation of the system **10** (e.g., toggle between delivery modes, adjust settings, log food intake, change a fear of hypoglycemia index (FHI), confirm/modify/cancel bolus dosages, and the like).

(34) Optionally, system **10** may include a bolus administering device **80** (e.g., a syringe, an insulin pen, a smart syringe with device communication capabilities, or the like) through which bolus dosages can be manually administered to a PWD. In some cases, a suggested dosage for a bolus to be administered using the bolus administering device **80** can be output to a user via the user interface of reusable pump controller **200** and/or the user interface of the mobile computing device **60**. In some cases, the bolus administering device **80** can communicate through a wired and/or wireless connection with reusable pump controller **200** and/or the mobile computing device **60**. In some cases, system **10** can allow users to input insulin deliveries made using a syringe or insulin pen.

(35) Operation of a Diabetes Management System

(36) FIG. 2 depicts an example method **200** for operation of a diabetes management system, such as system **10** depicted in FIG. 1. As shown in FIG. 2, a system can receive user inputs, such as user inputs at blocks **251** and **252**, which can be used to provide initial settings, such as one or more target blood glucose values that may be used or determined at block **261** and/or one or more user-specific dosage parameters that may be used or determined at block **262**. In some cases, user inputs at blocks **251** and **252** can be entered by a PWD, a caregiver for the PWD, or a healthcare professional. In some cases, user inputs at blocks **251** and **252** can be entered on a mobile computing device **60**, such as a smartphone. Based on the user-specific dosage parameters, the method **200** can generate multiple basal insulin delivery profiles and/or rates at block **263**. In some cases, the plurality of basal insulin delivery profiles and/or rates can be based upon one or more baseline basal rates. At block **264**, the method **200** can analyze each basal delivery profile or rate generated at block **263** based on variations of predicted future blood glucose values from one or more target blood glucose values (such as the target blood glucose values from block **261**) using blood glucose data from a continuous glucose monitor (CGM) or blood glucose meter (BGM), such as generated in block **271**. In some cases, the blood glucose data can be from the continuous glucose monitor **50** from the system **10** of FIG. 1. As will be discussed below, predicted blood glucose values for each generated basal delivery profile or rate can use user-specific dosage parameters (for example, those determined or otherwise adjusted at block **262**). Additionally, predicted blood glucose values can include inputs regarding previous dosages of insulin and/or food consumption (e.g., estimates of carbohydrates consumed). In some cases, predicted blood glucose values used at block **264** can consider data indicative of exercise, sickness, or any other physical state that might impact blood glucose levels in a PWD. Based on an analysis of a variation of predicted blood glucose levels performed at block **264**, a basal delivery profile or rate generated at

block 263 can be selected at block 265 and the system can deliver basal insulin according to that selected basal delivery profile or rate to the PWD for a select period of time at block 272. In some cases, the insulin pump assembly 15 of system 10 of FIG. 1 can be used to deliver the insulin. In some cases, the blocks 263, 264, 265, and 272 can each be conducted by reusable pump controller 200 of system 10. In some cases, the blocks 271, 263, 264, and 265 can all be conducted by continuous glucose monitor 50 of system 10, with data regarding the selected delivery rate being sent to reusable pump controller 200. In some cases, the blocks 251, 252, 261, 262, 263, 264, and 265 can all be conducted on mobile computing device 60 of system 10 of FIG. 1, with data regarding the selected delivery rate being sent to reusable pump controller 200 from the mobile computing device 60.

(37) Methods and systems provided herein can additionally update or adjust user-specific dosage parameters at block 262 and can update or adjust the blood glucose targets at block 261 based on the selected basal delivery profiles and/or rates selected at block 265 or based on blood glucose data obtained at block 271. In some cases, at block 281, periods of time when a selected basal delivery was different from a baseline basal rate for that period of time can be detected. For these select periods of time (e.g., diurnal time segments), at block 262 the user-specific dosage parameters can be adjusted for that period of time. For example, if the selected basal delivery for a time block exceeds the baseline basal rate for that time block, at block 262 the system 10 can increase the baseline basal rate for that time block (e.g., a diurnal period) or some other related time block (such as the preceding diurnal period). For example, if the selected basal delivery from 2 PM to 3 PM exceeded the baseline basal rate for that time, the system 10 may increase the baseline basal rate for 2 PM to 3 PM or may adjust the baseline basal rate for 1 PM to 2 PM, 12 PM to 1 PM and/or 11 AM to 12 PM. In some cases, each adjustment to a baseline basal rate is less than the difference between the baseline basal rate and the selected basal delivery. In some cases, each adjustment can be a predetermined amount (e.g., baseline basal rate adjusted up or down by 0.5 unit/hour, 0.3 unit/hour, 0.1 unit per hour) or percentage (e.g., 5%, 3%, 1%), which can limit the change to the user-specific dosage parameters due to an irregular event. At block 283, the variability of blood glucose data can be analyzed to make adjustments to the blood glucose target(s) at block 261. For example, at block 283, a blood glucose data distribution can be determined for a diurnal period (e.g., between 1 AM and 2 AM) to determine a measure of dispersion of blood glucose values for the PWD during that diurnal period, and at block 261 adjustments can be made to the blood glucose target for that diurnal period, and/or adjacent periods, based on the measure of dispersion.

(38) Each of the processes discussed in regards to FIG. 2 are discussed at further length below.

(39) Setting Initial User-Specific Dosage Parameters

(40) Systems and methods provided herein can use multiple user-specific dosage parameters for a PWD in order to determine rates of basal insulin delivery and optionally amounts of bolus insulin delivery. In some cases, initial user-specific dosage parameters can be set by a healthcare professional. In some cases, data entered by a user (e.g., the PWD, the PWD's caregiver, or a health care professional) can be used to estimate one or more user-specific dosage parameters. For example, FIG. 2 depicts a method where a user enters at least one dosage parameter at block 252.

(41) In some cases, multiple user-specific dosage parameters can be set for multiple diurnal time segments. In some cases, different user-specific dosage parameters can have diurnal time segments of the same length of time or different lengths of time. In some cases, an initial setting for each user-specific dosage parameter can be set at the same value for each diurnal time segment, but the user-specific dosage parameter for each diurnal time segment can be independently adjusted in the methods and systems provided herein. In some cases, users (e.g., health care professionals) can input different user-specific dosage parameter values for different diurnal time segments.

(42) Methods and systems provided herein can, in some cases, use user-specific dosage parameters that are commonly used in the treatment of diabetes. For example, methods and systems provided herein can ask a user to input one or more of an average Total Daily Dose (TDD) of insulin, a total daily basal (TDB) dose of insulin, an average basal rate (ABR) (which can be used as an initial baseline basal rate (BBR) in methods and systems provided herein), an insulin sensitivity factor (ISF), and/or a carbohydrate-to-insulin ratio (CR). In some cases, methods and systems provided herein can ask for a weight, age, or combination thereof of a PWD to estimate one or more user-specific dosage parameters. In some cases, methods and systems will store a BBR, an ISF, and a CR, which can each be set for multiple different time blocks over a repeating period of time (e.g., fifteen, thirty, sixty, or one hundred twenty minute diurnal periods). As will be discussed in further detail below, methods and systems provided herein can adjust user-specific dosage parameters for each of the diurnal periods in order to personalize the delivery of insulin for the PWD in order to minimize risks for the PWD.

(43) Methods and systems provided herein can ask for or permit a user to input a variety of different user-specific dosage parameters or dosage proxies to determine values for the initial settings of one or more user-specific dosage parameters and/or blood glucose targets. In some cases, the inputs can be limited to a Total Daily Basal (TDB) amount of insulin and a Fear of Hypoglycemia Index (FHI). In some cases, the inputs can be limited to a Total Daily Dose (TDD) amount of insulin and a FHI. In some cases, the TDB or TDD can be used to determine the initial baseline basal rate (BBR), the initial carbohydrate-to-insulin ratio (CR), and the initial insulin sensitivity factor (ISF) based on mathematical relationships among and between for BBR, CR, ISF, TDB, and TDD. In some cases, a user can also set an initial ISF and CR. In some cases, a user (e.g., a health care professional) can optionally input any combination of BBR, CR, ISF, TDB, and TDD, and at least the initial BBR, initial CR, and initial ISF can be based on the values entered. For example, in some cases, a relationship between initial TDD, TDD, BBR, CR, and ISF can be expressed as follows: $TDD [u/day] = 2 \times TDB [u/day] = 1800 / ISF [mg/dL/u \text{ or } [mmol/u]] = 400 / CR [g/u] = 48 \text{ hours/day} \times BBR [u/hour]$. In some cases, the mathematical equation used to estimate ISF, CR, and BBR can use non-linear relationships between BBR, ISF, and CR.

(44) Methods and systems provided herein can also make adjustments to user-entered user-specific dosage parameters prior to initial use. In some cases, methods and systems provided herein adjust user entered initial BBR, CR, and/or ISF values based on mathematical relationships among and between the initial BBR, CR, and ISF values. In some cases, if an entered ISF and an entered CR are outside of a predefined relationship between BBR, CR, and ISF, methods and systems provided herein will calculate a CR and an ISF that meets a predetermined relationship between BBR, CR, and ISF while minimizing a total change from the entered values for ISF and CR. In some cases, the predetermined relationship permits a range of CR values for each ISF value, permits a range of ISF values for each CR value, and permits a range of ISF and CR values for each BBR value. In some cases, the predetermined relationship represents a confidence interval for empirical data regarding relationships between basal rates, ISF, and CR values for a population of PWDs. In some cases, if an entered ISF, BBR, and/or CR are outside of a predefined relationship between BBR, CR, and ISF, methods and systems of the present disclosure may notify the user of the deviation from the predefined relationship. Additionally or alternatively, a healthcare provider override may be required to include ISF, BBR, and/or CR values outside of the predefined relationship as the initial user-specific dosage parameters.

(45) Setting Initial Blood Glucose Targets

(46) Initial blood glucose targets can be set or determined using any suitable technique. In some cases, blood glucose targets can be preprogrammed on memory within a system or device provided herein. In some cases, there can be a single blood glucose target preprogrammed into the system that does not change. In some cases, the diurnal time segments can each have a preprogrammed blood

glucose target. In some cases, a user can program one or more blood glucose targets, which can be set differently for different periods of time. In some cases, a user can program the typical sleeping schedule, exercise schedule, and/or meal schedule for a PWD, and methods and systems provided herein can select lower blood glucose targets for sleep times and higher blood glucose targets around meal times and/or exercise times. In some cases, historical continuous glucose monitor data for the PWD prior to the PWD using the system can be used to set initial blood glucose targets (either for specific diurnal periods or for an entire day). For example, the historical variability in CGM data can be used to set higher initial blood glucose targets for times of greater variability and lower initial blood glucose targets for times of lower variability. In some cases, methods provided herein can have a PWD wear a CGM for a preliminary period of time (e.g., at least twenty-four hours, at least forty-eight hours, at least five days, or at least ten days) prior to allowing the methods and systems provided herein from delivering insulin at rates other than the BBR to detect blood glucose variability data for the PWD to set one or more initial blood glucose targets.

(47) In some cases, such as shown in FIG. 2 at block 251, a user can enter a fear of hypoglycemia index (FHI), which can be used to determine and/or adjust blood glucose targets. An FHI can be represented to the user in a number of ways. In some cases, the FHI can be represented to the user as an aggressiveness index, which could be set at “prefer high,” “prefer low,” or “prefer moderate.” In some cases, the FHI can be represented to the user as a target blood glucose level or target average blood glucose level (e.g., 100 mg/dl, 120 mg/dl, or 140 mg/dl). In some cases, the FHI can be represented to the user as a target A1C level. In some cases, the FHI can be represented to the user as a probability of going above or below a certain threshold (e.g., a five percent chance of going below 80 mg/dl, or a three percent chance of going above 200 mg/dl). In these and other cases, a user interface may be generated with an interactive feature (e.g., radio buttons, check boxes, hyperlinked images/text, drop-down list, etc.) that a user can interact with to make a selection of the FHI. In some cases, the PWD may interact with the interface to select the FHI, and in some cases, the user can be a health care professional that selects the FHI.

(48) In some cases, the FHI can be used to set and/or adjust therapy parameters to adjust a propensity for having blood glucose above or below certain threshold levels. For example, the FHI can be used to set a limit or target percentage (e.g., a 5% probability) of real glucose values to fall below or exceed certain threshold levels. In some cases, the FHI can be used to set one or more initial target blood glucose levels in a closed-loop control algorithm, and patterns of glucose values used to adjust the one or more target glucose levels based on a measure of a hypoglycemia propensity. In some cases, each possible FHI value can correspond to a preprogrammed initial blood glucose target. For example, an FHI of “prefer high” might correspond to a preprogrammed initial blood glucose target of 140 mg/dl, an FHI of “prefer moderate” might correspond to a preprogrammed initial blood glucose target of 120 mg/dl, and an FHI of “prefer low” might correspond to a preprogrammed initial blood glucose target of 100 mg/dl. As will be discussed below, initial blood glucose targets can be adjusted over time based on data collected in methods and systems provided herein.

Modes of Operation

(49) Methods and systems provided herein can in some cases include multiple delivery modes. In some cases, methods and systems provided herein can monitor the presence of blood glucose using one or more blood glucose measuring devices or methods, control or monitor the dispensation of insulin, and determine and/or update the user-specific dosage parameters regardless of the operating mode. For example, possible operating modes could include closed-loop or hybrid closed-loop modes that automatically adjust basal rates based on continuous glucose monitoring data (CGM) and other user-specific dosage parameters (e.g., BBR, ISF, and CR), modes that can use blood glucose monitor (BGM) data to update user-specific dosage parameters (e.g., BBRs, ISFs, and CRs) for different time blocks over longer periods of time, manual modes that require a patient to manually control the therapy program using an insulin pump, and advisory modes that recommend dosages for a user to inject using an insulin pen or syringe. By determining optimized control parameters that work across delivery modes, systems and methods provided herein can provide superior blood glucose control even when a PWD switches to a different delivery mode. For example, methods and systems provided herein may be forced to switch away from a hybrid closed-loop delivery mode that adjusts basal insulin delivery away from a BBR if a continuous glucose monitor malfunctions or the system otherwise loses access to continuous data, yet still use a personalized ISF and CR for calculating correction and/or mealtime bolus amounts. In some cases, data can be collected when the system is in an advisory or manual mode to optimize control parameters in preparation for a PWD to switch to a hybrid closed-loop system (e.g., in preparation for a PWD to start use of a continuous glucose monitor (CGM) and/or an insulin pump). In some cases, the use of a closed-loop delivery mode that adjusts basal insulin delivery away from a BBR may be prevented until a sufficient amount of current blood glucose data is available (e.g., the insulin delivery according to multiple profiles that can occur at blocks 263, 264, 265, and 272 of FIG. 2 may not occur until sufficient CGM and/or BGM data is collected at the block 271 of FIG. 2). In some cases, systems and methods provided herein can deliver insulin at the BBR rate for each diurnal period when insufficient blood glucose data is available. In some cases, methods and systems provided herein can switch between open-loop and closed-loop modes based on whether there are a predetermined number of authenticated blood glucose measurements from a continuous glucose monitor within a predetermined period of time (e.g., at least two authenticated blood glucose data points within the last twenty minutes).

(50) Automating Basal-Insulin Delivery

(51) Systems and methods provided herein can automate basal insulin delivery based on one or more stored user-specific dosage parameters (e.g., BBR, ISF, CR), one or more blood glucose targets, and/or blood glucose data. The example method depicted in FIG. 2 depicts an example process of automating basal insulin delivery as blocks 263, 264, 265, and 272. Methods and systems provided herein can use a model predictive control system that projects multiple future blood glucose levels for a future time period for multiple possible basal insulin delivery profiles and/or rates over that future time period and determines which of the multiple possible basal insulin delivery profiles and/or rates will produce future blood glucose values that approximate one or more blood glucose targets. Methods and systems provided herein can produce improved control as compared to control algorithms that merely make adjustments to basal insulin delivery without evaluating multiple possible basal insulin delivery profiles or rates. In some cases, methods and systems provided herein can predict future blood glucose values at least two hours, or at least three hours, or at least four hours, or at least five hours into the future, which can adequately consider the long term impact of increasing or decreasing the basal insulin delivery relative to the BBR. After a rate or profile is selected, the rate or profile can be delivered for a predetermined delivery period of time (for example, the block 272 of FIG. 2) prior to repeating one or more of the steps in the process of selecting a new basal insulin delivery profile or rate. In some cases, this predetermined delivery period of time can be less than the length of time for the generated basal insulin delivery profiles and/or rates and less than the time period for which future blood glucose values were estimated, thus methods and systems provided herein can dynamically make changes to basal insulin delivery based on recent blood glucose data. For example, generating basal delivery profiles at block 263 may be repeated every fifteen minutes, and the period of time evaluated at block 264 may be a four-hour window such that every fifteen minutes, a new four-hour window of analysis for the basal delivery profiles is generated. In this way, each delivery action is based on a prediction not only of that action, but on how the prior delivery action is determined to impact blood glucose levels for four hours into the future.

(52) Generating Possible Basal Delivery Profiles and/or Rates for Evaluation

(53) FIG. 3 illustrates an example chart **300** of delivery profiles **310a-310q** over a four hour time horizon. FIG. 3 also includes a graph **320** illustrating the projected effect of the profiles **310a-310q** on blood glucose levels, and a graph **330** illustrating an accumulation of variations from a target blood glucose level (e.g., loss) using a cost function.

(54) Possible basal insulin delivery profiles and/or rates can be generated using any suitable technique. In some cases, each generated profile or rate can be based on user-specific dosage parameters. In some cases, each generated profile or rate can be based on one or more user-specific dosage parameters that are specific to a particular diurnal period. In some cases, each generated profile or rate is based on a predetermined relationship to a stored baseline basal rate (BBR), such as indicated at block **263** in FIG. 2. In some cases, generated profiles and/or rates for analysis extend for at least two hours, at least three hours, or for at least four hours. In some cases, the generated profiles may extend for a day (e.g., twenty-four hours) or less. In some cases, each generated profile or rate includes basal insulin delivery rates based on predetermined multiples or fractions of one or more stored BBRs. In some cases, multiple insulin delivery profiles and/or rates are based on multiple diurnal-time-block-specific BBRs. In some cases, generated basal insulin delivery profiles each deliver insulin at a ratio of a BBR, such as an integer multiple of one or more stored BBRs (e.g., $0 \times \text{BBR}$, $1 \times \text{BBR}$, $2 \times \text{BBR}$, and $3 \times \text{BBR}$). In some cases, insulin delivery profiles can deliver insulin at ratios that may include both fractions and multiples of one or more stored BBRs (e.g., $0 \times \text{BBR}$, $0.5 \times \text{BBR}$, $1 \times \text{BBR}$, $1.5 \times \text{BBR}$, and $2 \times \text{BBR}$). In some cases, generated basal insulin delivery profiles each deliver insulin at only multiples or fractions of between 0 and 3. In some cases, generated basal insulin delivery profiles each deliver insulin at only multiples or fractions of between 0 and 2. In some cases, such as shown in FIG. 3, multiple generated basal delivery profiles can include only deliveries of basal insulin at 0% of BBR, 100% of BBR, or 200% of BBR. As shown, each generated basal delivery profile permutation has fixed future time periods. In some cases, different future time periods for permutations can have different lengths. In some cases, the number of generated basal delivery profiles or rates for evaluation is less than 100, less than 50, less than 30, less than 25, or less than 20. By limiting the number of evaluated preset permutations based on stored BBRs, methods and systems provided herein can limit an energy expenditure used to run a controller determining a basal delivery rate.

(55) In some cases, one or more of the profiles **310a-310q** may include an inflection point between a first insulin delivery amount for a first portion of delivery actions and a second delivery amount for a second portion of delivery actions. For example, the profile **310b** may include an inflection point between 0% and 100% between 3.5 hours and 4 hours (e.g., for the portion before the inflection point, 0% of the BBR is delivered as the delivery action and for the portion after the inflection point, 100% of the BBR is delivered as the delivery action).

Additionally, the profile **310k** may include an inflection point between 100% and 200% between 1 hour and 1.5 hours (e.g., before the inflection point, 100% of the BBR is delivered as the delivery action and after the inflection point, 200% of the BBR is delivered as the delivery action). In some cases, such as illustrated in FIG. 3, each profile may be a permutation of including a single inflection point (or no inflection point) between three possible delivery actions (e.g., 0%, 100%, 200%), yielding seventeen profiles for a four hour window of projection. In some cases, more than one inflection point may be used, yielding additional profiles. In some cases, the number of profiles may be fewer than seventeen. In some cases, only three profiles are analyzed (e.g., profiles **8**, **9**, and **10** of FIG. 3, **310h-310j**) in order to select between whether to deliver 0%, 100%, or 200%, but additional profiles assuming no basal insulin (e.g., profile **1**, **310a**) or continuing supply of maximum basal insulin (e.g., **17**, **310q**) can allow the system to detect an approaching predicted hypoglycemic event or an approaching predicted hyperglycemic event, and additional profile (e.g., **2-7** & **11-16**) can be selected and recorded to detect situations where future decisions are not conforming to an expected profile. In some cases, methods and systems provided herein can continue to deliver insulin according to a selected profile after the select period of time in block **272**, including changes in basal delivery rates, if reliable up-to-date blood glucose data is lost. In other cases, methods and systems provided herein will revert to another mode or alarm and stop insulin delivery if reliable up-to-date blood glucose data is lost.

(56) In some cases, the range of possible values of the BBR for a given profile can be adjusted or modified depending on the FHI. For example, in some cases, if the FHI is “prefer low” (e.g., indicating a preference for the system to aggressively keep the PWD within range and not go high), the target blood glucose might be set around 100 mg/dl and the range for delivery may include 0%, 50%, 100%, 200%, and 300% BBR. As another example, if the FHI is “prefer high” (e.g., indicating that the PWD prefers to avoid hypoglycemic events even with a higher risk of hyperglycemic events), the target blood glucose might be set around 140 mg/dl and the range for delivery may include 0%, 100%, and 200% of BBR.

(57) Evaluating Generated Basal Delivery Profiles and/or Rates

(58) Referring again to FIG. 2 and FIG. 3, the evaluation of multiple generated basal insulin delivery profiles and/or rates includes projecting future blood glucose levels and comparing those to blood glucose targets. FIG. 3 depicts possible projections for each permutation of insulin delivery depicted in FIG. 3.

(59) Predicting Future Blood Glucose Values

(60) Systems and methods provided herein can use any suitable physiology model to predict future blood glucose values. In some cases, methods and systems provided herein can predict future blood glucose values using past and current carbohydrate, insulin, and blood glucose values.

(61) Systems and methods provided herein can in some cases estimate a first future blood glucose a model as depicted in FIG. 4. In some cases, blood glucose can be approximated using two determinist integrating first order plus dead time (FOPDT) models for the effect of carbohydrates and insulin, combined with an autoregressive (AR2) disturbance model. Accordingly, blood glucose (BG) at time (t) can be estimated using the following equation:

$$BG_{\text{sub.t}} = y_{\text{sub.t}} + BG_{\text{sub.t}} + BG_{\text{sub.it}} + BG_{\text{sub.t}} = G_{\text{sub.cc.sub.t}} + G_{\text{sub.ii.sub.t}} + G_{\text{sub.de.sup.a.sub.t}}$$

From the equation above, the first element may represent the effect on blood glucose due to carbohydrates:

$$(62) G_c = \frac{k_c(1 - c)B^{c_a}}{(1 - c)B(1 - B)}$$

where: B is the backward shift operator such that $BY_{\text{sub.t}} = Y_{\text{sub.t-1}}$, $B^2 Y_{\text{sub.t}} = Y_{\text{sub.t-2}}$, $B^k Y_{\text{sub.t}} = Y_{\text{sub.t-k}}$

$$(63) k_c = \frac{ISF}{CR}$$

is the carb gain (in units of mg/dl/g)

$$(64) c = e^{-\frac{dc}{\tau_c}}$$

where $\tau_{\text{sub.c}}$ is the carb time constant (for example, approximately 30 min), and where t_s is the sampling time (for example, a CGM may use a sampling time interval of every 5 min) $c_{\text{sub.dt}} = \text{floor}(\tau_{\text{sub.dc}}/t_s)$, where $\tau_{\text{sub.dc}}$ is the carb deadtime (for example, approximately 15 min)

From the equation above, the second element may represent the effect on blood glucose due to insulin:

$$(65) G_i = \frac{k_i(1 - i)B^{i_a}}{(1 - i)B(1 - B)}$$

where: $k_{\text{sub.i}} = \text{ISF}$ is the insulin gain (in units of mg/dl/unit)

(66) $i_t = e^{-\frac{t}{\tau_{\text{sub}}}}$, where $\tau_{\text{sub}}.i$ is the insulin time constant (for example, approximately 120 min) $i_{\text{sub}}.dt = \text{floor}(\tau_{\text{sub}}.di/ts)$, where $\tau_{\text{sub}}.di$ is the insulin deadtime (for example, approximately 30 min)

From the equation above, the third element may represent the effect on blood glucose due to disturbances (e.g., the AR2 disturbance model): $G_{\text{sub}}.de.sup.a.sup.t$

and may be based on the following log-transformed AR2 model:

$$(67) \ln\left(\frac{BG_{dt}}{BG_{dt-1}}\right) = \alpha_1 \ln\left(\frac{BG_{dt}}{BG_{dt-1}}\right) + \alpha_2 \ln\left(\frac{BG_{dt-2}}{BG_{dt-1}}\right) + a_t \text{ which when rearranged, yields:}$$

$$BG_{dt}.sub.t = BG_{dt}.sub.t-1.sup.\alpha_1.sup.1.BG_{dt}.sub.t-2.sup.\alpha_2.sup.2.\mu^*.sup.(1-\alpha_1.sup.1-\alpha_2.sup.2).e.sup.a.sup.t \text{ where, in some examples,}$$

$$(68) a_t \sim \text{Normal}(0, \sigma_a) \text{ and } \sigma_a \approx 50\% \ln\left(\frac{1}{1-\alpha_1^2}\right) \sqrt{\frac{1+\alpha_2^2}{1-\alpha_1^2} - \frac{\alpha_2^2}{1-\alpha_1^2}} \text{ with } \sigma_a \sim 10^{\text{Normal}(2.09, 0.08)} \text{ and } \sigma_a \sim 10^{\text{Normal}(0.15, 0.028)} \text{ such that } \alpha_1 \approx 1.6442, \alpha_2 \approx -0.6493.$$

Using the above notation, expansion of the initial equation for $BG_{\text{sub}}.t$ may be represented by the equation:

$$(69) BG_t = \frac{k_c(1-c)}{(1-c)B(1-B)} C_{t-dt_c} + \frac{k_i(1-i)}{(1-i)B(1-B)} i_{t-dt_i} + BG_{dt-1} BG_{dt-2}^{*(1-i-1-2)}$$

(70) Systems and methods provided herein can in some cases calculate an amount of insulin on board (IOB) and/or an amount of carbohydrates on board (COB) in order to predict future blood glucose values. IOB and COB represent the amount of insulin and carbohydrates, respectively, which have been infused and/or consumed but not yet metabolized. Knowledge of IOB and COB can be useful for a user of a method or system provided herein when it comes to bolus decisions to prevent insulin stacking, but knowledge of IOB and COB can also be used in methods and systems provided herein to predict future blood glucose values.

(71) IOB and COB represent the amount of insulin and carbohydrates, respectively, which have been infused and/or consumed but not yet metabolized. Knowledge of IOB can be useful in correcting bolus decisions to prevent insulin stacking. Knowledge of IOB and COB can be useful for predicting and controlling blood glucose. Both insulin infusion and carbohydrate consumption can involve deadtime or transportation delay (e.g., it can take ten to forty minutes for insulin and/or carbohydrates to begin to affect blood glucose). During the period immediately after entering the body (e.g., during the deadtime period), it can be beneficial to account for IOB and COB in any decisions such as bolusing. This can be called “Decision” IOB/COB. “Action” IOB/COB, on the other hand, can represent the insulin and/or carbohydrates available for action on blood glucose. In some cases, Decision IOB can be a displayed IOB, while Action IOB can be an IOB determined for use in selecting a basal delivery rate or profile in methods and systems provided herein.

(72) From the equations above,

$$(73) BG_{it} = \frac{-ISF(1-i)B^{i_{dt}}}{(1-i)B(1-B)} i_{t-i_{dt}}$$

where

$$BY_{\text{sub}}.t = Y_{\text{sub}}.t-1, B_{\text{sup}}.2Y_{\text{sub}}.t = Y_{\text{sub}}.t-2, B_{\text{sup}}.kY_{\text{sub}}.t = Y_{\text{sub}}.t-k$$

$$(74) 0_i = e^{-\frac{t}{\tau_{\text{sub}}}}$$

where $\tau_{\text{sub}}.i$ is the insulin time constant (for example, approximately 120 min) $i_{\text{sub}}.dt = \text{floor}(\tau_{\text{sub}}.di/ts)$, where $\tau_{\text{sub}}.di$ is the insulin deadtime (for example, approximately 30 min) and where ts is the sampling time (for example, a CGM may use a sampling time interval of every 5 min)

“Decision” IOB

(75) In some embodiments, Decision IOB at time (t) ($IOB_D_{\text{sub}}.t$) may be calculated according to the following mathematical process:

$$(76) IOB_D_t = IOB_D_{t-1} - \frac{BG_{it} - BG_{it-1}}{-ISF} + i_t \text{ or, alternatively, } \nabla IOB_D_t = \frac{-\nabla BG_{it}}{-ISF} + i_t$$

substituting the equation above for $BG_{\text{sub}}.it$ into the equation for $IOB_D_{\text{sub}}.t$ or $\nabla IOB_D_{\text{sub}}.t$ yields

$$(77) IOB_{D_t} = \frac{1-i}{1-(i+1)B} \frac{B^{i_{dt}}}{B^2} i_t \text{ or, alternatively, } \nabla IOB_D_t = -\frac{1-i}{1-i} \frac{1}{B} i_{t-i_{dt}} + i_t \text{ “Action” IOB}$$

(78) In some embodiments, Action IOB at time (t) ($IOB_A_{\text{sub}}.t$) may be calculated according to the following mathematical process:

$$(79) IOB_A_t = \frac{1}{1-i} \frac{1}{B} i_{t-1_{dt}}$$

(80) For an arbitrary series of insulin infusions, using an infinite series of expansions of

$$(81) \frac{1}{1-i} \frac{1}{B},$$

$IOB_A_{\text{sub}}.t$ may be represented by

$$(82) IOB_A_t = \sum_{k=0}^n \text{Math.} \frac{k}{i} i_{t-k-i_{dt}}$$

(83) Stated another way,

$$(84) BG_{it} = \frac{-ISF(1-i)}{1-B} IOB_A_t$$

(85) The formulas for COB, including Action COB and Decision COB, may be developed in a similar fashion, using the equation above related to

$$(86) G_{ct} = \frac{k_c(1-c)B^{c_{dt}}}{(1-c)B(1-B)}$$

(87) Accordingly, future blood glucose data can be estimated using current or recent blood glucose data, data about when carbohydrates were consumed, and/or data regarding when insulin was and/or will be administered. Moreover, because evaluated insulin delivery profiles and/or rates include basal insulin delivery rates above and below the BBR, those insulin delivery rates above BBR can be added to the IOB calculation and insulin delivery rates below the BBR can be subtracted from the IOB. In some cases, a variation in a Decision IOB due to actual variations from BBR can be limited to positive deviations in order to prevent a user from entering an excessive bolus.

(88) Estimating Glucose Levels from Blood Glucose Data

(89) Referring back to FIG. 1, continuous glucose monitor 50 and blood glucose meter 70 can both provide blood glucose data to system 10.

The blood glucose data, however, can be inaccurate. In some cases, continuous glucose monitor 50 can be replaced (or have sensor shaft 56 replaced) at regular or irregular intervals (e.g., every three days, every five days, every seven days, or every ten days). In some cases, data from blood glucose meter 70 can be used to calibrate the continuous glucose monitor 50 at regular or irregular intervals (e.g., every three hours, every six hours, every twelve hours, every day, etc.). In some cases, systems and methods provided herein can remind a user to change the continuous glucose monitor 50 or calibrate continuous glucose monitor 50 using blood glucose meter 70 based on data from continuous glucose monitor 50 and/or at regular intervals. For example, if the pattern of insulin delivery varies greatly from an earlier predicted pattern of insulin deliveries (e.g., the system continues to deliver no insulin for multiple hours despite the system continually selecting profiles 6, 7, or 8, 310f-h) it may indicate that the continuous glucose monitor 50 requires maintenance and/or replacement.

(90) In some cases, methods and systems can determine an accuracy factor for blood glucose data from the continuous glucose monitor 50 based upon when the particular continuous glucose monitor sensor shaft 56 was first applied to the PWD and/or when the particular continuous glucose monitor 50 was last calibrated using blood glucose data from blood glucose meter 70. In some cases, methods and

systems provided herein make adjustments to future blood glucose targets based on a calculated accuracy factor for data from the continuous glucose monitor **50** in order to reduce a risk of hypoglycemia. In some cases, methods and systems provided herein can estimate the current blood glucose level as being a predetermined number of standard deviations (e.g., 0.5 standard deviation, one standard deviation, two standard deviations) below data received from continuous glucose monitor **50** based on the accuracy factor in order to reduce a risk of hypoglycemia.

(91) After continuous glucose monitor **50** is calibrated or replaced with a new continuous glucose monitor or has a new sensor shaft **56** installed, however, a discontinuity of reported glucose data from the continuous glucose monitor **50** can occur. In some cases, methods and systems provided herein, however, can use and report historical blood glucose values in selecting insulin basal rates and/or profiles. In some cases, methods and systems provided herein can revise stored and/or reported blood glucose levels based on data from one or more continuous glucose monitors in order to transition between different continuous glucose monitor sensors and/or to data produced after a calibration. In some cases, a continuous glucose monitor **50** can provide each blood glucose value with an estimated rate of change, and the rate of change information can be used to retrospectively adjust one or more historical estimated blood glucose values from data from a continuous glucose monitor **50**. For example, the rate of change of the pre-calibration reported blood glucose value to determine an estimated post-calibration value assuming the same rate of change. A ratio of the post-calibration reported blood glucose value to the estimated post-calibration value can then be used to linearly interpolate multiple historical blood glucose values based on that ratio. In some cases, all readings between calibrations can be linearly interpolated. In some cases, data from a predetermined amount of time prior to a calibration can be linearly interpolated (e.g., fifteen minutes, thirty minutes, one hour, two hours, three hours, or six hours).

(92) Analyzing Variations from Targets

(93) Methods and systems provided herein can evaluate each future basal delivery profile by predicting blood glucose for the basal delivery profiles (e.g., as illustrated in the graph **320** of FIG. **3**) and calculating a variation index of the predicted blood glucose values from the target blood glucose values. Methods and systems provided herein can then select the profile of basal rate delivery actions that corresponds to the lowest variation index (e.g., the lowest value **340** of the graph **330** of FIG. **3**). The variation index can use a variety of different mathematical formulas to weight different types of variations. The variation index can be a cost function. In some cases, methods and systems provided herein can use a cost function that sums up squares of differences for the projected blood glucose values from target blood glucose values for multiple diurnal time segments. Methods and systems provided herein can use any suitable cost function. In some cases, cost functions can sum the absolute value of the difference between each predicted blood glucose value and each blood glucose target. In some cases, cost functions used in methods and systems provided herein can use a square of the difference. In some cases, cost functions used in methods and systems provided herein can use a square of the difference between the logs of each predicted blood glucose level and each corresponding blood glucose target. In some cases, cost functions used in methods and systems provided herein can assign a higher cost to blood glucose values below the blood glucose target in order to reduce the risk of a hypoglycemic event. FIG. **3** depicts the “loss” (i.e., the resulting value for a cost function) for the plurality of basal delivery profiles. As shown in FIG. **3**, the basal delivery profile **11**, **301k** corresponds to the lowest value **340**. In some cases, cost functions provided herein can include elements that additional bias the selected profile toward a profile that maintains the previously administered basal rate and/or that delivers the baseline basal rate, which may prevent the system from changing delivery rates every time a basal delivery profile or rate is selected in block **265**. In some cases, the cost function can square the difference between the log of the values in order to provide a higher cost for projected lows than projected highs.

(94) Selecting a Basal Insulin Delivery Profile or Rate

(95) Methods and systems provided herein can then select a basal profile or rate that produces the lowest cost function value. As shown in FIG. **3**, the delivery profile **11**, **301k** has the lowest loss, and is thus the selected profile for delivery. With reference to FIG. **2**, at block **272** insulin can then be delivered according to the selected profile for an amount of time. In some cases, the amount of time is a predetermined amount of time. In some cases, the predetermined amount of time is less than the time horizon for the estimated future blood glucose values and the length of time for the selected basal delivery profile. In some cases, the predetermined amount of time is ninety minutes or less, sixty minutes or less, forty-five minutes or less, thirty minutes or less, twenty minutes or less, fifteen minutes or less, ten minutes or less, or five minutes or less. After the period of time, the system can again repeat the operations at blocks **263**, **264**, **265**, and **272** to select and deliver a basal insulin for a subsequent period of time.

(96) Adjusting User-Specific Dosage Parameters

(97) Methods and systems provided herein can make adjustments to the user-specific dosage parameters. For example, FIG. **2** includes the block **281** for detecting time periods when an amount of delivered basal insulin is different from a BBR, which can then be used to adjust user-specific dosage parameters at block **262**. These updated user-specific dosage parameters can then be used to generate new basal delivery profiles at block **263** and used at block **264** to evaluate different basal delivery profiles. For example, for a BBR of 1.46 U/hour (associated with a TDB of 35 U/day), if a diurnal period under consideration is one hour and for the first forty-five minutes, insulin was delivered at a rate of 2.92 U/hour (e.g., 2× the BBR) and only the last fifteen minutes was delivered at a rate of 1.46 U/hour (e.g., 1× the BBR), user-specific dosage parameters for a related diurnal time period (e.g., that same hour on another day in the future, or a preceding diurnal time period on a day in the future) may be adjusted.

(98) In some cases, methods and systems provided herein can make adjustments for BBR, ISF, and/or CR for multiple diurnal periods based on variations in the insulin amounts actually delivered for that diurnal period compared to the baseline basal insulin rate for that diurnal period. In some cases, diurnal periods can have a same length of time as a predetermined length of time for the delivery of a selected insulin delivery. In some cases, a diurnal period can be greater than a predetermined length of time for the delivery of a selected insulin delivery, for example, multiple doses of insulin may be delivered during a single diurnal period. In some cases, a diurnal period can be fifteen minutes, thirty minutes, one hour, two hours, etc. In some cases, an actual delivery of insulin for a diurnal period must surpass a predetermined threshold above or below the BBR for that diurnal period in order for user-specific dosage parameters (e.g., BBR, ISF, CR) to be adjusted for that diurnal period. For example, diurnal periods can be one hour long, but each basal delivery profile can be delivered for fifteen minute time periods before methods and systems provided herein determine a new basal insulin delivery profile, and methods and systems provided herein can require that the total basal insulin delivery for the diurnal period be at least greater than 50% of the BBR to increase the BBR for that diurnal period or at 50% or less than the BBR to decrease the BBR for that diurnal period. Using the example from above, for a BBR of 1.46 U/hour, if a diurnal period under consideration is one hour and for the first forty-five minutes (e.g., three iterations of profile generation and delivery actions), insulin was delivered at a rate of 2.92 U/hour (e.g., 2× the BBR) and only the last fifteen minutes (e.g., one iteration of profile generation and delivery action) was delivered at a rate of 1.46 U/hour (e.g., 1× the BBR), the total amount delivered would be at 175% of the BBR for the one hour diurnal period, or an average ratio of 1.75× the BBR. In some cases, because the 175% exceeded 150% of the BBR, methods and systems of the present disclosure may adjust user-specific dosage parameters. As another example using the same 1.46 U/hour BBR and a two hour diurnal time period and delivery profiles reformulated every fifteen minutes, if the first forty-five minutes

delivered no insulin (Ox the BBR) and the last hour and fifteen minutes delivered 1.46 U/hour, the total amount delivered may be 62.5% of the BBR, or 0.625× of the BBR. In some cases, because the 62.5% did not drop below 50% of the BBR, methods and systems of the present disclosure may not adjust the user-specific dosage parameters and may maintain the user-specific dosage parameters for the particular diurnal period.

(99) An adjustment to the CR, ISF, and BBR can be any suitable amount. In some cases, the adjustment to the BBR is less than the difference between the delivered basal insulin and the previously programmed BBR. In some cases, a change to each user-specific dosage parameter (e.g., BBR, ISF, and CR) is at a predetermined percentage or value. For example, in some cases, each of BBR and ISF can be increased by 5%, 3%, or 1% and CR decreased by the same percent for every period where the amount of delivered basal insulin exceeds the BBR by at least 25%. In some cases, BBR and ISF can be decreased by 5%, 3%, or 1% and CR increased by the same percent for every period where the amount of delivered basal insulin exceeds the BBR by at least 25%. By setting each adjustment at a low level, methods and systems provided herein can eventually be personalized for the PWD without over adjusting the system based on an unusual day (e.g., to mitigate the risk of short term disturbances being mistaken for changes in physiological parameters). In some cases, the adjustment to CR, ISF, and BBR may be based on a relationship between CR, ISF, and BBR, rather than a fixed amount or percentage. In some cases, CR, ISF, and BBR can be adjusted based on a predetermined relationship between their log-transformed values. In some cases, the adjustments to CR, ISF, and BBR may be performed independently. In these and other cases, systems and methods provided herein can monitor for variations in adjustments to CR, ISF, and/or BBR away from a relationship between CR, ISF, and BBR. In such cases, a notification may be provided to a user (e.g., the PWD or a health care provider) that the systems and methods of the present disclosure had adjusted one or more user-specific dosage guidelines outside of or away from a relationship between CR, ISF, and BBR.

(100) In some cases, systems and methods provided herein can update or adjust user-specific operating parameters for select time blocks every twenty-four hours. In some cases, diurnal periods can be updated dynamically (e.g., immediately after a basal delivery profile or rate is selected). In some cases, diurnal periods can be updated by controller **200**, by mobile computing device **60**, or using a remote server in the cloud. In some cases, the length of diurnal periods can vary depending on the time of day (e.g., nighttime diurnal periods could be longer) or depending on the user-specific dosage parameter (e.g., BBRs might have fifteen minute diurnal periods while the CR and ISF might have one hour diurnal periods).

(101) In some cases, when performing an adjustment, a related diurnal period may be adjusted based on variation from the BBR for a given diurnal period. For example, if an adjustment were to be performed because delivery from 2 PM to 3 PM exceeded 150% of the BBR, an adjustment may be made to the user-specific dosage parameters for the same time on a different day in the future (e.g., 2 PM to 3 PM on the next day) or a preceding diurnal period on a different day in the future (e.g., 1 PM to 2 PM on the next day or 12 PM to 1 PM on the next day, etc.). In some cases, modifying a preceding diurnal period may adjust more appropriately for variations in BBR and/or other user-specific dosage parameters because of the delay of effect after delivery of insulin and/or the delay of effect after consumption of carbohydrates (e.g., if a PWD repeatedly goes high between 2 PM and 3 PM, the PWD may need additional insulin during the 1 PM to 2 PM hour).

(102) In some cases, systems and methods disclosed herein can smooth adjustments to user-specific dosage parameters in one diurnal period relative to other diurnal periods. For example, in some cases, a proposed adjustment to a BBR for a first diurnal period may be compared to one or more preceding diurnal periods and one or more following diurnal periods. If the proposed adjustment is a threshold amount different from one or more of the preceding or following diurnal period values, the proposed adjustment may be modified to avoid drastic jumps between diurnal periods. For example, if a preceding diurnal period had a BBR of 1.06 U/hour and the proposed adjustment was from a BBR of 1.4 U/hour to a BBR of 1.90 U/hour, the adjustment may be reduced to smooth the transition from the preceding diurnal time period. In some cases, the smoothing may include adjusting preceding or following diurnal time periods in addition to the diurnal time period under consideration. In these and other cases, such adjustment may be performed once per day or at another periodic time such that following diurnal periods may have already occurred and the smoothing is not being performed based on projections. For example, the diurnal period from 1 PM to 2 PM may be analyzed for potential adjustment at 4 PM such that the diurnal periods from 11 AM to 12 PM and 12 PM to 1 PM and from 2 PM to 3 PM and 3 PM and 4 PM are available in considering any adjustment and/or smoothing to perform on the user-specific dosage parameters for the 1 PM to 2 PM diurnal period.

(103) In some cases, systems and methods disclosed herein can adjust user-specific dosage parameters in a diurnal period based on the FHI. For example, if the FHI is high (e.g., indicating a preference that the PWD not go low), the range for adjusting the BBR may be limited to a relatively small change (e.g., 0.5%, 1%, 1.5%, etc.). As another example, if the FHI is low (e.g., indicating that the PWD is not as concerned about going low), the range for adjusting the BBR may include a broader range of changes (e.g., up to a 5% change).

(104) Adjusting Blood Glucose Targets

(105) Methods and systems provided herein can make adjustments to the blood glucose targets. For example, FIG. 2 includes the block **283** for analyzing the variability of CGM and/or BGM data (e.g., data from the CGM **50** and/or the BGM **70** of FIG. 1), which can then be used to adjust blood glucose targets at the block **261**. In some cases, blood glucose targets are set for diurnal periods. In some cases, the diurnal periods for blood glucose targets are at least fifteen minutes long, at least thirty minutes long, at least one hour long, or at least two hours long. In some cases, blood glucose targets can have a constrained range. In some cases, blood glucose targets must be at least 80 mg/dL, at least 90 mg/dL, at least 100 mg/dL, at least 110 mg/dL, or at least 120 mg/dL. In some cases, blood glucose targets must be no greater than 200 mg/dL, no greater than 180 mg/dL, no greater than 160 mg/dL, no greater than 140 mg/dL, or no greater than 125 mg/dL. In some cases, a constrained range is between 100 mg/dL and 160 mg/dL. These updated blood glucose targets can then be used at block **264** to evaluate different basal delivery profiles.

(106) Updated blood glucose targets for a particular diurnal period can be based on historical blood glucose patterns for the PWD and the risk of hypoglycemia for the PWD over the course of a day. The updated blood glucose targets can also consider a set FHI. For example, based on an FHI selection, an initial blood glucose target at a conservative level (e.g., 120 mg/dl) can be set, and over the course of a period of days and/or weeks as more information is gained about variability patterns, the blood glucose target(s) can be adjusted. A slow adjustment can prevent the blocks **283** and **261** from overreacting to short term disturbances but still allow blood glucose target individualization to a PWD's lifestyle and habits over time.

(107) In some cases, blood glucose measurements (e.g., including CGM data and optionally BGM data) for diurnal periods can be analyzed for the variability of that data during that time block and modifications to the blood glucose target for that diurnal period can be made based on an assessment of a risk of the PWD having a blood glucose level below a threshold value during that diurnal period. In some cases, blood glucose data from that diurnal period is evaluated to assess and/or determine a measure of dispersion and/or a measure of central tendency. In some cases, the measure of a central tendency can be the geometric mean of the collected data. In some cases, the measure of a central tendency can be a geometric mean that weights the data based on the recency of the collected data (e.g., exponential weighting of data based on

the recency of the data). In some cases, the measure of a central tendency can be an arithmetic mean of the data (without or without time weighting). In some cases, the measure of dispersion can be a geometric standard distribution. In some cases, the measure of dispersion can be a geometric standard distribution that weights the data based on the recency of the collected data (e.g., exponential weighting of data based on the recency of the data). In some cases, the measure of dispersion can be an arithmetic standard distribution (without or without time weighting). In some cases, the measure of central tendency and the measure of dispersion can be evaluated based on a lognormal distribution. In some cases, a blood glucose target is increased if the measure of central tendency minus a multiple of the measure of dispersion (or some multiple of it) is below a threshold blood glucose value (e.g., a threshold value between 60 and 80 mg/dL) and decreased if the median blood glucose value minus the measure of dispersion (or some multiple of it) is above the same or a similar threshold blood glucose value. In some cases, methods and systems provided herein can disregard blood glucose data after a predetermined period of time and/or use a decay function so that more recent data is weighted more heavily. In some cases, each adjustment to a blood glucose target is limited to a predetermined amount (e.g., 5 mg/dL or less, 3 mg/dL or less, or 1 mg/dL) or to a predetermined percentage (e.g., 5%, 3%, or 1%). In some cases, increases to a blood glucose target can be immediate, but decreases be rate limited. In some cases, adjustments to blood glucose targets occur every hour, every day, or less frequently (e.g., every 3 days, every 5 days, every week). In some cases, blood glucose targets can be specified for certain days of the week (e.g., weekends can have different blood glucose targets) or during periodic intervals. In some cases, the amount of adjustment to the blood glucose target, the frequency of changes, the threshold considered, and/or the multiple of the standard deviation used may be based on the FHI. For example, for a low FHI (e.g., an aggressive PWD), larger adjustments may be made, adjustments may be made more frequently, etc.

(108) FIG. 5 illustrates an example chart **500** of various distributions **510a-510g** of blood glucose levels. As shown, the distributions are shown to be log normal. As illustrated in FIG. 5, the distribution **510a** has most common value **520a** of ninety-four mg/dL. For the given distribution **510a**, with a threshold level **530** of 70 mg/dL, approximately five percent of the distribution is below the threshold level **530**. For the distribution **510a**, for five percent of the distribution to be below the threshold level **530**, a most common value of **520b** may be observed. Stated another way, if the distribution **510b** were observed and five percent was the desired percentage below the threshold of seventy mg/dL (e.g., the median minus a multiple of the standard deviation was desired to be seventy mg/dL), methods and systems of the present disclosure may operate to shift the distribution toward a most common value **520b** of one hundred and eight mg/dL. Also, as observed between the distributions **510a** and **510b**, the distribution **510b** is more spread out than the distribution **510a**, and thus, has a higher corresponding median blood glucose level **520b** corresponding to the same percentage of the distribution falling below the threshold level **530**. The same trend can be observed with respect to the other distributions **510c-510g** and most common values **520c-520g**. As shown, the distributions are evaluated using a logarithmic scale.

(109) In some cases, methods and systems provided herein can also allow a user to temporarily or permanently adjust blood glucose targets by adjusting their fear of hypoglycemia index (FHI). In some cases, a user adjustment to FHI can result in blood glucose targets being temporarily or permanently adjusted to blood glucose targets based on the variability of CGM (and optionally BGM) data for multiple diurnal periods. In some cases, a user adjustment to FHI can add or subtract a predetermined value from a previously used blood glucose target (e.g., an adjustment from “prefer low” to “prefer medium” could add 20 mg/dL to each stored blood glucose target). In some cases, a temporary adjustment to FHI could analyze variability data for multiple time blocks and set a new blood glucose target for each diurnal period based on the variability data for that time block (e.g., an adjustment from “prefer low” to “prefer medium” could adjust the blood glucose target for each diurnal period from a level estimated to send the PWD below a threshold of 70 mg/dL about 5% of the time to a level estimated to send the PWD below a threshold of 70 mg/dL about 3% of the time).

(110) Allowing a PWD to change the FHI for temporary time periods or otherwise use some form of temporary override may allow a PWD to tell the system that the PWD is about to or is experiencing some activity or condition that might impact their blood glucose levels. For example, a PWD that is about to exercise might set a temporary FHI of “prefer high” to offset the risk that exercise will send the PWD low for that period of time. In some cases, a PWD might set a temporary FHI of “prefer low” if the PWD is feeling sick in order to offset the risk that the sickness will result in high blood glucose levels. In some embodiments, such a temporary override may be a separate setting or entry other than the FHI. In these and other cases, in addition to a preferred range (e.g., “high” or “low”), the user may be able to select a temporary override of a target blood glucose level or range (e.g., approximately 120 mg/dL or between 120 mg/dL and 200 mg/dL, etc.), or may select a particular activity or circumstance the PWD will participate in or is experiencing (e.g., exercising, sickness, menses, driving, etc.).

(111) In some cases, after a temporary override is input, methods and systems of the present disclosure can select a new profile to follow based on the profile more closely aligning with the temporary override. In these and other cases, a new set of profiles can be generated before selecting the new profile. Additionally or alternatively, after a temporary override is input, methods and systems of the present disclosure can temporarily modify the BBR. In some cases, after the BBR has been modified, a new set of profiles may be generated based on the temporarily modified BBR.

(112) In some cases a log of temporary overrides can be generated. For example, each time a user (e.g., the PWD) inputs an override, an entry can be created in the log that includes what override was selected, what starting and ending times, and/or what the reason for the override was. In these and other cases, the log can be periodically provided to a healthcare professional, for example, via email or some other electronic message. Additionally or alternatively, in some cases the log can be parsed for patterns. For example, the PWD may input a temporary override every Monday, Wednesday, and Friday from 6 PM to 7 PM when the PWD exercises. The log can be parsed to find such patterns of overrides. In these and other cases, methods and systems of the present disclosure can modify a BBR based on the patterns. Continuing the example, the BBR may be lowered for the diurnal period of 6 PM to 7 PM on Monday, Wednesday, and Friday because of a PWD repeatedly entering a temporary override during that diurnal period that the PWD is exercising and not to go low.

(113) Overall System

(114) Methods and systems provided herein can control basal insulin delivery over time and adjust basal user-specific dosage parameters and blood glucose targets for multiple diurnal periods to personalize the user-specific dosage parameters over time. For example, FIG. 6 illustrates various examples of user interfaces (e.g., **600**, **610**, **620**, and **630**) displaying various aspects of the present disclosure.

(115) In some cases, FIG. 6 illustrates a simulation of a method provided herein, showing how methods and systems provided herein may generate a user interface **600** that may illustrate BBRs **601**, CRs **602**, ISFs **603**, and a blood glucose targets **604** set for multiple time blocks. For example, after a system (e.g., the system **10** of FIG. 1) has run on a PWD after thirty days, user-specific dosage parameters may be personalized based on adjustments made to the user-specific dosage parameters. For example, the user interface **600** may align the various user-specific dosage parameters over various diurnal periods throughout a day. For example, the BBR **601** may be higher around meal times (e.g., nine AM, twelve PM, and seven PM), and lower while the PWD is sleeping (e.g., eleven PM to five AM). As an additional example, the CR **602** and ISF **603** may follow a similar trajectory of variation as illustrated for the BBR **601**. Additionally, the blood glucose target

may be lower for times of low variability and higher for times of higher variability (e.g., sleeping vs. active times of the day).

(116) In some cases, as illustrated in interface **610** of FIG. **6**, methods and/or systems of the present disclosure (including, for example, back-end computer systems) may monitor and/or track blood glucose levels over time. For example, the interface **610** may illustrate glucose levels for one hundred eighty days, with a bar indicating the last thirty days. In some cases, when adjusting user-specific dosage parameters, methods and systems of the present disclosure may disregard readings older than thirty days, or may weight more recent readings more heavily than older readings.

(117) In some cases, the interface **620** may include time aligned charts (including chart **621**, chart **622**, and chart **623**) that can show a six hour window of the timeline illustrated in interface **610**. As illustrated in FIG. **6**, chart **621** depicts the current blood glucose values as well as the predictions that have been made over time for that particular delivery time. For example, once the “current” bar **624** is reached, there may have been multiple predictions made for each time segment. As the window extends further into the future, the number of predictions may be lower. The chart **622** illustrates the calculated IOB and the calculated COB for the PWD. The chart **623** indicates whether the method or system delivered 0% of the BBR, 100% of the BBR, or 200% of the BBR for fifteen minute time segments.

(118) As illustrated in FIG. **6**, the user interface **630** depicts a possible user interface for a PWD showing some data that may be displayed on a mobile device of a PWD (e.g., the mobile computing device **60** of FIG. **1**). In some cases, only the data prior to the bar **624** (e.g., historic data) may be shown in the user interface **630**. In a first part **631** of the user interface **630**, historic blood glucose data can be displayed. In a second section **632**, announced meals and bolus insulin deliveries can be displayed. In a third section **633**, the rates of basal delivery can be displayed. The section **633** can differ from chart **623** by displaying the actual rates of basal delivery rather than a ratio of the rate delivered to the BBR. Section **634** can display a current blood glucose reading, a current IOB, and/or an indication of whether the system is automating. In some cases, more or less information can be displayed on the user interface **630** than illustrated in FIG. **6**. For example, the interface **630** may include any of the information from the user interfaces **600**, **610**, and/or **620** in any combination.

(119) Additional Details about Example Pump Assembly

(120) FIGS. **7A** and **7B** provide additional details about example pump assembly **15** as discussed above in regards to FIG. **1**. FIG. **7B** depicts the details of example reusable pump controller **200**.

(121) Referring now to FIG. **7A**, disposable pump **100** in this embodiment includes a housing structure **110** that defines a cavity **116** in which a fluid cartridge **120** can be received. Disposable pump **100** also can include a cap device **130** to retain the fluid cartridge **120** in the cavity **116** of the housing structure **110**. Disposable pump **100** can include a drive system (e.g., including a battery powered actuator, a gear system, a drive rod, and other items that are not shown in FIG. **7A**) that advances a plunger **125** in the fluid cartridge **120** so as to dispense fluid therefrom. In this embodiment, reusable pump controller **200** communicates with disposable pump **100** to control the operation of the drive system. For example, in some cases, the pump controller **200** can generate a message for the disposable pump **100** directing the disposable pump **100** to deliver a certain amount of insulin or deliver insulin at a certain rate. In some cases, such a message may direct the disposable pump **100** to advance the plunger **125** a certain distance. In some cases, not depicted, reusable pump controller **200** may include a user interface to control the operation of disposable pump **100**. In some cases, disposable pump **100** can be disposed of after a single use. For example, disposable pump **100** can be a “one-time-use” component that is thrown away after the fluid cartridge **120** therein is exhausted. Thereafter, the user can removably attach a new disposable pump **100** (having a new fluid cartridge) to the reusable controller device **200** for the dispensation of fluid from a new fluid cartridge. Accordingly, the user is permitted to reuse reusable pump controller **200** (which may include complex or valuable electronics, as well as a rechargeable battery) while disposing of the relatively low-cost disposable pump **100** after each use. Such a pump assembly **15** can provide enhanced user safety as a new pump device (and drive system therein) is employed with each new fluid cartridge.

(122) The pump assembly **15** can be a medical infusion pump assembly that is configured to controllably dispense a medicine from the cartridge **120**. As such, the fluid cartridge **120** can contain a medicine **126** to be infused into the tissue or vasculature of a targeted individual, such as a human or animal patient. For example, disposable pump **100** can be adapted to receive a fluid cartridge **120** in the form of a carpule that is preloaded with insulin or another medicine for use in the treatment of Diabetes (e.g., Exenatide (BYETTA®, BYDUREON®) and liraglutide (VICTOZA®) SYMLIN®, or others). Such a cartridge **120** may be supplied, for example, by Eli Lilly and Co. of Indianapolis, IN. The fluid cartridge **120** may have other configurations. For example, the fluid cartridge **120** may comprise a reservoir that is integral with the pump housing structure **110** (e.g., the fluid cartridge **120** can be defined by one or more walls of the pump housing structure **110** that surround a plunger to define a reservoir in which the medicine is injected or otherwise received).

(123) In some embodiments, disposable pump **100** can include one or more structures that interfere with the removal of the fluid cartridge **120** after the fluid cartridge **120** is inserted into the cavity **116**. For example, the pump housing structure **110** can include one or more retainer wings (not shown) that at least partially extend into the cavity **116** to engage a portion of the fluid cartridge **120** when the fluid cartridge **120** is installed therein. Such a configuration may facilitate the “one-time-use” feature of disposable pump **100**. In some embodiments, the retainer wings can interfere with attempts to remove the fluid cartridge **120** from disposable pump **100**, thus ensuring that disposable pump **100** will be discarded along with the fluid cartridge **120** after the fluid cartridge **120** is emptied, expired, or otherwise exhausted. In another example, the cap device **130** can be configured to irreversibly attach to the pump housing structure **110** so as to cover the opening of the cavity **116**. For example, a head structure of the cap device **130** can be configured to turn so as to threadably engage the cap device **130** with a mating structure along an inner wall of the cavity **116**, but the head structure may prevent the cap device from turning in the reverse direction so as to disengage the threads. Accordingly, disposable pump **100** can operate in a tamper-resistant and safe manner because disposable pump **100** can be designed with a predetermined life expectancy (e.g., the “one-time-use” feature in which the pump device is discarded after the fluid cartridge **120** is emptied, expired, or otherwise exhausted).

(124) Still referring to FIG. **7A**, reusable pump controller **200** can be removably attached to disposable pump **100** so that the two components are mechanically mounted to one another in a fixed relationship. In some embodiments, such a mechanical mounting can also form an electrical connection between the removable controller device **200** and disposable pump **100** (for example, at electrical connector **118** of disposable pump **100**). For example, reusable pump controller **200** can be in electrical communication with a portion of the drive system (not shown) of disposable pump **100**. In some embodiments, disposable pump **100** can include a drive system that causes controlled dispensation of the medicine or other fluid from the cartridge **120**. In some embodiments, the drive system incrementally advances a piston rod (not shown) longitudinally into the cartridge **120** so that the fluid is forced out of an output end **122**. A septum **121** at the output end **122** of the fluid cartridge **120** can be pierced to permit fluid outflow when the cap device **130** is connected to the pump housing structure **110**. For example, the cap device **130** may include a penetration needle that punctures the septum **121** during attachment of the cap device **130** to the housing structure **110**. Thus, when disposable pump **100** and reusable pump controller **200** are mechanically attached and thereby electrically connected, reusable pump controller **200** communicates electronic control signals via a hardwire-connection (e.g., electrical contacts along connector **118** or the like) to the drive system or other components of disposable pump **100**. In response to the electrical

control signals from reusable pump controller **200**, the drive system of disposable pump **100** causes medicine to incrementally dispense from the fluid cartridge **120**. Power signals, such as signals from a battery (not shown) of reusable pump controller **200** and from the power source (not shown) of disposable pump **100**, may also be passed between reusable pump controller **200** and disposable pump **100**.

(125) Referring again to FIGS. **1** and **7A**, the pump assembly **15** can be configured to be portable and can be wearable and concealable. For example, a PWD can conveniently wear the pump assembly **15** on the PWD's skin (e.g., skin adhesive) underneath the PWD's clothing or carry disposable pump **100** in the PWD's pocket (or other portable location) while receiving the medicine dispensed from disposable pump **100**. The pump assembly **15** is depicted in FIG. **1** as being held in a PWD's hand **5** so as to illustrate the size of the pump assembly **15** in accordance with some embodiments. This embodiment of the pump assembly **15** is compact so that the PWD can wear the portable pump assembly **15** (e.g., in the PWD's pocket, connected to a belt clip, adhered to the PWD's skin, or the like) without the need for carrying and operating a separate module. In such embodiments, the cap device **130** of disposable pump **100** can be configured to mate with an infusion set **146**. In general, the infusion set **146** can be a tubing system that connects the pump assembly **15** to the tissue or vasculature of the PWD (e.g., to deliver medicine into the tissue or vasculature under the PWD's skin). The infusion set **146** can include a flexible tube **147** that extends from disposable pump **100** to a subcutaneous cannula **149** that may be retained by a skin adhesive patch (not shown) that secures the subcutaneous cannula **149** to the infusion site. The skin adhesive patch can retain the cannula **149** in fluid communication with the tissue or vasculature of the PWD so that the medicine dispensed through the tube **147** passes through the cannula **149** and into the PWD's body. The cap device **130** can provide fluid communication between the output end **122** (FIG. **7A**) of the fluid cartridge **120** and the tube **147** of the infusion set **146**.

(126) In some embodiments, the pump assembly **15** can be pocket-sized so that disposable pump **100** and controller device **200** can be worn in the PWD's pocket or in another portion of the PWD's clothing. In some circumstances, the PWD may desire to wear the pump assembly **15** in a more discrete manner. Accordingly, the PWD can pass the tube **147** from the pocket, under the PWD's clothing, and to the infusion site where the adhesive patch can be positioned. As such, the pump assembly **15** can be used to deliver medicine to the tissues or vasculature of the PWD in a portable, concealable, and discrete manner.

(127) In some embodiments, the pump assembly **15** can be configured to adhere to the PWD's skin directly at the location in which the skin is penetrated for medicine infusion. For example, a rear surface of disposable pump **100** can include a skin adhesive patch so that disposable pump **100** can be physically adhered to the skin of the PWD at a particular location. In these embodiments, the cap device **130** can have a configuration in which medicine passes directly from the cap device **130** into an infusion set **146** that is penetrated into the PWD's skin. In some examples, the PWD can temporarily detach reusable pump controller **200** (while disposable pump **100** remains adhered to the skin) so as to view and interact with the user interface **220**.

(128) In some embodiments, the pump assembly **15** can operate during an automated mode to deliver basal insulin according the methods provided herein. In some cases, pump assembly **15** can operate in an open-loop mode to deliver insulin at the BBR. A basal rate of insulin can be delivered in an incremental manner (e.g., dispense 0.10 U every five minutes for a rate of 1.2 U per hour) according to a selected basal insulin delivery profile. A user can use the user interface on mobile computing device **60** to select one or more bolus deliveries, for example, to offset the blood glucose effects caused by food intake, to correct for an undesirably high blood glucose level, to correct for a rapidly increasing blood glucose level, or the like. In some circumstances, the basal rate delivery pattern may remain at a substantially constant rate for a long period of time (e.g., a first basal dispensation rate for a period of hours in the morning, and a second basal dispensation rate for a period of hours in the afternoon and evening). In contrast, the bolus dosages can be more frequently dispensed based on calculations made by reusable pump controller **200** or the mobile computing device **60** (which then communicates to reusable pump controller **200**). For example, reusable pump controller **200** can determine that the PWD's blood glucose level is rapidly increasing (e.g., by interpreting data received from the glucose monitoring device **50**), and can provide an alert to the user (via the user interface **220** or via the mobile computing device **60**) so that the user can manually initiate the administration of a selected bolus dosage of insulin to correct for the rapid increase in blood glucose level. In one example, the user can request (via the user interface of mobile computing device **60**) a calculation of a suggested bolus dosage (e.g., calculated at the mobile computing device **60** based upon information received from the user and from reusable pump controller **200**, or alternatively calculated at reusable pump controller **200** and communicated back to the mobile computing device **60** for display to the user) based, at least in part, on a proposed meal that the PWD plans to consume.

(129) Referring now to FIG. **7B**, reusable pump controller **200** (shown in an exploded view) houses a number of components that can be reused with a series of successive disposable pumps **100**. In particular, reusable pump controller **200** can include control circuitry **240** (e.g., a control device) and a rechargeable battery pack **245**, each arranged in the controller housing **210**. The rechargeable battery pack **245** may provide electrical energy to components of the control circuitry **240**, other components of the controller device (e.g., the display device **222** and other user interface components **230**, sensors, or the like), or to components of disposable pump **100**. The control circuitry **240** may be configured to communicate control or power signals to the drive system of disposable pump **100**, or to receive power or feedback signals from disposable pump **100**.

(130) The control circuitry **240** of reusable pump controller **200** can include one or more microprocessors **241** configured to execute computer-readable instructions stored on one or more memory devices **242** so as to achieve any of the control operations described herein. At least one memory device **242** of the control circuitry **240** may be configured to store a number of user-specific dosage parameters. One or more user-specific dosage parameters may be input by a user via the user interface **220**. Further, as described further below in connection with FIG. **7A**, various user-specific dosage parameters can be automatically determined and/or updated by control operations implemented by the control circuitry **240** of reusable pump controller **200**. For example, the control circuitry **240** can implement a secondary feedback loop to determine and/or update one or more user-specific dosage parameters in parallel with the infusion pump system **10** operating in a closed-loop delivery mode. Whether determined automatically or received via the mobile computing device **60** (or via the user interface **220** of reusable pump controller **200**), the control circuitry **240** can cause the memory device **242** to store the user-specific dosage parameters for future use during operations according to multiple delivery modes, such as closed-loop and open-loop delivery modes. Additionally, the control circuitry **240** can cause reusable pump controller **200** to periodically communicate the user-specific dosage parameters to the mobile computing device **60** for future use during operations by the mobile computing device **60** or for subsequent communication to a cloud-based computer network.

(131) Such user-specific dosage parameters may include, but are not limited to, one or more of the following: total daily basal dosage limits (e.g., in a maximum number of units/day), various other periodic basal dosage limits (e.g., maximum basal dosage/hour, maximum basal dosage/six hour period), insulin sensitivity (e.g., in units of mg/dL/insulin unit), carbohydrate ratio (e.g., in units of g/insulin unit), insulin onset time (e.g., in units of minutes and/or seconds), insulin on board duration (e.g., in units of minutes and/or seconds), and basal rate profile (e.g., an average basal rate or one or more segments of a basal rate profile expressed in units of insulin unit/hour). Also, the control circuitry **240** can cause the memory device **242** to store (and can cause reusable pump controller **200** to periodically communicate out to the

mobile computing device **60**) any of the following parameters derived from the historical pump usage information: dosage logs, average total daily dose, average total basal dose per day, average total bolus dose per day, a ratio of correction bolus amount per day to food bolus amount per day, amount of correction boluses per day, a ratio of a correction bolus amount per day to the average total daily dose, a ratio of the average total basal dose to the average total bolus dose, average maximum bolus per day, and a frequency of cannula and tube primes per day. To the extent these aforementioned dosage parameters or historical parameters are not stored in the memory device **242**, the control circuitry **240** can be configured to calculate any of these aforementioned dosage parameters or historical parameters from other data stored in the memory device **242** or otherwise input via communication with the mobile computing device **60**.

(132) FIG. **8** illustrates a flow diagram of an example method **800** of using insulin delivery profiles. The method **800** may be performed by any suitable system, apparatus, or device. For example, the system **10**, the pump assembly **15**, the mobile computing device **60** of FIG. **1**, and/or a remote server may perform one or more of the operations associated with the method **800**. Although illustrated with discrete blocks, the steps and operations associated with one or more of the blocks of the method **800** may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.

(133) At block **810**, a set of insulin delivery profiles can be generated, each having a series of insulin delivery actions. For example, the pump assembly **15** may generate a series of potential delivery actions that may include permutations based on one or more potential inflection points in the delivery actions (e.g., the permutations illustrated in the chart **300** of FIG. **3**).

(134) At block **820**, a prediction can be made of future blood glucose levels for each of the delivery profiles. For example, the pump assembly **15** and/or the mobile computing device **60** of FIG. **1** can generate a prediction of future blood glucose levels at various points in time if a particular profile is followed. Such prediction may be based on the effect of glucose, insulin, carbohydrates, and/or other disturbances projected for the blood glucose levels at the various points in time.

(135) At block **830**, a determination can be made as to variations from a target blood glucose level for each of the profiles. For example, the pump assembly **15** and/or the mobile computing device **60** of FIG. **1** may compare the predicted blood glucose levels to a target blood glucose level for each of the various points in time. In some cases, the target blood glucose level may be constant and in other cases, the target blood glucose level may vary over time. In these and other cases, the variation may be measured as a distance between the target blood glucose level and the projected blood glucose level, or a square of the difference, etc., as described above.

(136) At block **840**, the profile that approximates the target blood glucose level can be selected. In some cases, the profile that minimizes variation from the target blood glucose level may be selected. For example, a cost function can be utilized and the profile with the lowest cost can be selected as the profile that approximates the target blood glucose level.

(137) At block **850**, insulin may be delivered based on the next action in the selected profile. For example, control circuitry **240** of the pump assembly **15** may send a message to the pump portion of the pump assembly to deliver insulin based on the next action in the selected profile. For example, a next action may indicate that the pump is to deliver $0\times$, $1\times$, or $2\times$ of a BBR. The next action can be the first delivery action in the set of actions of the profile.

(138) In some cases, after the block **850**, the method **800** can return to the block **810** to generate another set of insulin delivery profiles, predict future blood glucose levels, determine variations from a target blood glucose level, etc. In some cases, the method **800** can be performed iteratively each time a PWD is to receive a dose of basal insulin. In these and other cases, the method **800** can routinely update delivery actions based on a repeatedly updated projection of the blood glucose levels of the PWD and the effect a particular delivery action may have on the blood glucose levels. In some cases, methods and systems provided herein can change modes if there is a lack of reliable CGM data at this point in time (e.g., the system can change modes to a mode where BBR is delivered and potentially provide notice that the system has exited the automation mode).

(139) Modifications, additions, or omissions may be made to the method **800** without departing from the scope of the present disclosure. For example, the operations of the method **800** may be implemented in differing order. Additionally or alternatively, two or more operations may be performed at the same time. Furthermore, the outlined operations and actions are provided as examples, and some of the operations and actions may be optional, combined into fewer operations and actions, or expanded into additional operations and actions without detracting from the essence of the disclosed embodiments.

(140) FIG. **9** illustrates a flow diagram of an example method **900** of adjusting insulin delivery rates. The method **900** may be performed by any suitable system, apparatus, or device. For example, the system **10**, the pump assembly **15**, the mobile computing device **60** of FIG. **1**, and/or a remote server may perform one or more of the operations associated with the method **900**. Although illustrated with discrete blocks, the steps and operations associated with one or more of the blocks of the method **900** may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.

(141) At block **910**, insulin can be delivered over a diurnal time period. For example, the pump assembly **15** of FIG. **1** can deliver insulin to a PWD based on a BBR for the diurnal time period. In some cases, the insulin may be actually delivered at multiple points in time throughout the diurnal time period as a ratio of the BBR, such as $0\times$, $1\times$, and $2\times$.

(142) At block **920**, variations between actual insulin delivered values and the BBR for the diurnal time period can be determined. For example, if the delivery actions throughout the diurnal time period deliver a ratio of the BBR, the actual delivery actions may be averaged over the diurnal time period to find an average ratio for the diurnal time period. In these and other cases, the actual insulin delivered values can be based on periodically projected blood glucose levels and the BBR. For example, a set of insulin delivery profiles can be generated and a delivery action selected as described in the present disclosure (e.g., as described in FIG. **8**).

(143) At block **930**, a determination is made as to whether the variations between the actual insulin delivered values and the baseline basal insulin rate exceeds a threshold. If the variations do exceed the threshold, the method **900** may proceed to the block **940**. If the variations do not exceed the threshold, the method **900** may proceed back to the block **910**. In some cases, the threshold may be based on a ratio of the baseline basal delivery rate. For example, the threshold may include that the average rate over the diurnal period be above 150% of the BBR or below 50% of the BBR for the actual delivery values over the diurnal time period.

(144) At block **940**, the baseline basal insulin rate can be adjusted for a related diurnal time period. For example, the BBR can be adjusted higher by a certain amount (e.g., 1%, 2%, or 5%) if the variations went above a threshold and can be adjusted lower by a certain amount (e.g., 1%, 2%, or 5%) if the variations went below a threshold. In some cases, the related diurnal time period can be the same block of time (e.g., if the variations exceeded the threshold during the 2 PM to 3 PM diurnal period, then the BBR from 2 PM to 3 PM of the next day may be adjusted) on another day in the future, and in some cases, the related diurnal time period can be a different time on another day (e.g., if the variations exceeded the threshold during the 2 PM to 3 PM diurnal period, then the BBR from 1 PM to 2 PM of the next day may be adjusted). In some cases, such an adjustment may be performed once per day for all the diurnal periods of that day.

(145) In some cases, the adjustment at block **940** can include smoothing of the adjustment. For example, a potential modification can be compared to the BBR of the preceding diurnal time period or the following diurnal time period, and may modify the adjustment to be closer

to other diurnal time periods. Alternatively, the BBR can be smoothed by comparing the potential modification to BBRs of the same time of day for preceding days to determine whether the potential modification may be responsive to an unusual day.

(146) In some cases the adjustment at block **940** can consider other factors. For example, the adjustment can be based on penalizing a modification that increases the probability of the PWD having a hypoglycemic event (e.g., by penalizing modifications that may increase the probability of the blood glucose levels of the PWD falling below a threshold low blood glucose level). In these and other cases, in addition to or in place of adjusting the BBR, other user-specific dosage-guidelines can be adjusted. For example, ISF and CR can also be adjusted according to the present disclosure. In some cases, if BBR is adjusted higher, ISF may be adjusted higher by the same or an approximately proportional percentage amount and CR may be adjusted lower by the same or an approximately proportional percentage amount of the BBR.

(147) At block **950**, insulin may be delivered during the related diurnal time period based on the adjusted baseline basal insulin rate. For example, the insulin pump can deliver insulin based on the adjusted baseline basal insulin rate. In some cases, such delivery can include a control device (e.g., the control circuitry **240** of FIG. 7B) sending a message to the insulin pump to deliver insulin.

(148) Modifications, additions, or omissions may be made to the method **900** without departing from the scope of the present disclosure. For example, the operations of the method **900** may be implemented in differing order. Additionally or alternatively, two or more operations may be performed at the same time. Furthermore, the outlined operations and actions are provided as examples, and some of the operations and actions may be optional, combined into fewer operations and actions, or expanded into additional operations and actions without detracting from the essence of the disclosed embodiments.

(149) FIG. **10** illustrates a flowchart of an example method **1000** of utilizing a fear of hypoglycemia index. The method **1000** may be performed by any suitable system, apparatus, or device. For example, the system **10**, the pump assembly **15**, the mobile computing device **60** of FIG. **1**, and/or a remote server may perform one or more of the operations associated with the method **1000**. Although illustrated with discrete blocks, the steps and operations associated with one or more of the blocks of the method **1000** may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.

(150) At block **1010**, an interface can be displayed to a user to input an FHI. For example, an interface can be displayed on a mobile computing device (e.g., the mobile computing device **60** of FIG. **1**) and/or to a terminal connected over a network such as the Internet to a remote server. In some cases, the user (e.g., a PWD or a healthcare professional) can be presented with an interactive feature from which the user can select the FHI. In these and other cases, the interface can include a variety of ways that the user can input the FHI, such as a preferred blood glucose level, a preferred probability of going above or below a certain threshold, a textual description of a blood glucose level (e.g., “prefer high”), etc. In these and other cases, the FHI can correspond to a threshold blood glucose level and an acceptable probability of crossing the threshold blood glucose level. For example, “prefer high” may designate a low threshold blood glucose level as 100 mg/dl, with a target blood glucose level of 150 mg/dl, and a high threshold blood glucose level of 220 mg/dl, and an acceptable probability of 5% for exceeding either the low or the high threshold values.

(151) At block **1020**, a probability of a PWD crossing a threshold blood glucose level is calculated. For example, a calculation can be made as to how likely the PWD is to cross the threshold blood glucose level corresponding to the FHI. In these and other cases, the probability of crossing the threshold can also be compared to the acceptable probability of crossing the threshold. For example, if the FHI indicates that a 5% probability of exceeding a threshold is acceptable, the calculated probability of exceeding the threshold can be compared to the 5% acceptable probability.

(152) At block **1030**, target blood glucose level can be modified to more closely align the probability of crossing the threshold with the FHI. For example, if the probability of dropping below a threshold is higher than the acceptable probability, the target blood glucose level may be adjusted higher such that the probability is closer to the acceptable probability. In some cases, the target blood glucose level can be adjusted such that the probability of crossing the threshold is the same as the acceptable probability. In these and other cases, the modification of the baseline basal insulin rate can also be based on the actual insulin delivered compared to the BBR for a diurnal period. For example, if four delivery actions occur during a diurnal time period and each of them deliver 2× the BBR, the BBR can be modified based on both the FHI and the 2× delivered. Continuing the example, if a user had selected a low FHI (e.g., the PWD is not as concerned about going low), the target blood glucose level can be changed by a large amount (e.g., between 0% and 5%) while if the user had selected a high FHI (e.g., the PWD is concerned about going low), the BBR can be changed by a smaller amount (e.g., between 0% and 2%). In these and other cases, the change amount can vary depending on whether it is adjusting up or down. For example, for a PWD that prefers high blood glucose levels, methods and systems of the present disclosure can use a larger change when adjusting the BBR upwards and a lower change when adjusting the BBR downwards. In some cases, increases to the target blood glucose level can be unconstrained, but decreases constrained to 5% or less, 3% or less, 2% or less, or 1% or less.

(153) At block **1040**, insulin can be delivered based on the modified target blood glucose level. For example, a control device can determine insulin delivery profiles or rates based the target blood glucose level(s) using any suitable method, including the methods described above. In some cases, the delivery of insulin can be based off of one or more insulin delivery profiles that can be generated, and selecting one of the profiles that most closely approximates a target blood glucose level. In these and other cases, the actions of the delivery profiles can be a ratio of the modified BBR. For example, the delivery actions can include one of delivering 0×, 1×, or 2× the modified BBR.

(154) In some cases, the delivery actions of the delivery profiles can be based off of the FHI as well. For example, for a first FHI (e.g., the PWD is concerned about going low), the possible ratios used in the delivery actions of the profile can include 0×, 0.5×, 1× and 1.5× the BBR (e.g., for a PWD that prefers low), while for a second FHI, the possible ratios used in the delivery actions of the profile can include 0×, 1×, 2×, and 3× (e.g., for a PWD that prefers high).

(155) Modifications, additions, or omissions may be made to the method **1000** without departing from the scope of the present disclosure. For example, the operations of the method **1000** may be implemented in differing order. Additionally or alternatively, two or more operations may be performed at the same time. Furthermore, the outlined operations and actions are provided as examples, and some of the operations and actions may be optional, combined into fewer operations and actions, or expanded into additional operations and actions without detracting from the essence of the disclosed embodiments.

(156) FIG. **11** illustrates a flowchart of an example method **1100** of utilizing a temporary override. The method **1100** may be performed by any suitable system, apparatus, or device. For example, the system **10**, the pump assembly **15**, the mobile computing device **60** of FIG. **1**, and/or a remote server may perform one or more of the operations associated with the method **1100**. Although illustrated with discrete blocks, the steps and operations associated with one or more of the blocks of the method **1100** may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.

(157) At block **1110**, a set of insulin delivery profiles may be generated, each having a series of insulin delivery actions. For example, an electronic device (e.g., the pump assembly **15**, the mobile computing device **60** of FIG. **1** and/or a remote server) may generate a set of

profiles in accordance with the present disclosure.

(158) At block **1120**, an input indicating a temporary override may be received. The temporary override can indicate a user-preferred blood glucose level for one or more diurnal periods. For example, a user (e.g., a PWD) may be presented with a field or other entry component where the user can enter a numerical blood glucose level for a set period of time. As another example, the user may be presented with multiple activities (e.g., exercising, driving a car for an extended period of time, etc.) and when the activity will be performed. As another example, the user may be presented with a series of textual descriptions of preferred blood glucose levels (e.g., “do not go low,” or “do not go high”). In these and other cases, the user may be limited in selecting a temporary override for a period of time some point in the future (e.g., at least thirty minutes in the future).

(159) At block **1130**, a log of the temporary override can be generated. For example, the electronic device can record what was selected for the temporary override (e.g., a target blood glucose level, a particular activity, etc.), when, and/or for how long. In some cases, the log may be updated each time the user inputs a temporary override.

(160) At block **1140**, a baseline basal insulin rate (BBR) can be temporarily modified based on the temporary override. For example, the BBR can be modified to more closely align the BBR with the user-preferred blood glucose level. For example, the BBR can be adjusted higher if the temporary override indicates a lower than normal blood glucose level. As another example, the BBR can be adjusted lower if the temporary override indicates a higher than normal blood glucose level. In some cases, the temporary override from the block **1120** can be received and the BBR can be modified prior to generating the set of profiles, or the set of profiles can be updated after the temporary override is received and/or the BBR is modified.

(161) At block **1150**, a determination can be made as to which profile from the set of profiles approximates the user-preferred blood glucose level during the diurnal period. For example, a predicted blood glucose level for various points in time can be projected based on each of the profiles. The variation from the user-preferred blood glucose level can be analyzed, for example, by accumulating the variation over time and finding the profile with the lowest variation from the user-preferred blood glucose level. In these and other cases, the profile that most closely approximates the user-preferred blood glucose level can be selected as the basis for delivery actions of insulin.

(162) At block **1160**, insulin can be delivered based on the next action in the selected profile. For example, a given profile that was selected might have sixteen delivery actions spanning four hours, and the first of sixteen actions may be taken to deliver insulin. In some cases, the block **1160** can include control circuitry or another control device generating a message to be provided to a pump to deliver insulin in accordance with the next action in the selected profile.

(163) At block **1170**, the log can be periodically provided to a healthcare professional. For example, the log generated and/or updated at block **1130** can be sent to a healthcare professional using email, text message, via an app, etc., such that the healthcare professional can review the overrides that have occurred for a PWD.

(164) At block **1180**, the log can be parsed to determine if a pattern is present in the temporary overrides. For example, the PWD may input a temporary override every Monday, Wednesday, and Friday from 6 PM to 7 PM when they exercise. As another example, the PWD may input a temporary override Monday through Friday from 5:30 PM until 6:15 PM while the PWD drives home from work. The log can be parsed to find such patterns of overrides.

(165) At block **1190**, the baseline basal insulin rate can be modified for a given diurnal period based on the pattern. Following the first example given at block **1180**, methods and systems of the present disclosure can adjust the BBR for 6 PM to 7 PM on Monday, Wednesday and Friday based on the repeated overrides occurring at those times. Following the second example given at block **1180**, methods and systems of the present disclosure can adjust the BBR from 5:30 PM to 6:15 PM Monday through Friday based on the repeated overrides for that span of time.

(166) Modifications, additions, or omissions may be made to the method **1100** without departing from the scope of the present disclosure. For example, the operations of the method **1100** may be implemented in differing order (e.g., the block **1120** can be performed the block **1110**, and/or the blocks **1170** and/or **1180** can be performed any time after the block **1130**). Additionally or alternatively, two or more operations may be performed at the same time. Furthermore, the outlined operations and actions are provided as examples, and some of the operations and actions may be optional (e.g., the blocks **1130**, **1140**, **1170**, **1180**, and/or **1190**), combined into fewer operations and actions, or expanded into additional operations and actions without detracting from the essence of the disclosed embodiments.

(167) FIG. **12** illustrates a flowchart of an example method **1200** of modifying target blood glucose levels. The method **1200** may be performed by any suitable system, apparatus, or device. For example, the system **10**, the pump assembly **15**, the mobile computing device **60** of FIG. **1**, and/or a remote server may perform one or more of the operations associated with the method **1200**. Although illustrated with discrete blocks, the steps and operations associated with one or more of the blocks of the method **1200** may be divided into additional blocks, combined into fewer blocks, or eliminated, depending on the desired implementation.

(168) At block **1210**, blood glucose level readings over a diurnal period may be obtained for multiple days. For example, a continuous glucose monitor (e.g., the CGM **50** of FIG. **1**) may generate blood glucose level readings and a control device (e.g., the pump assembly **15** or the mobile computing device **60** of FIG. **1** or a remote server) may obtain blood glucose levels for a particular diurnal period (e.g., from two PM to three PM).

(169) At block **1220**, a determination may be made as to the rate of variability for the particular diurnal period. For example, the control device may create a distribution of the blood glucose levels observed over the diurnal time period (e.g., as illustrated in FIG. **5**). The distributions can include a geometric median blood glucose value and a geometric standard deviation for the diurnal period when plotted using a log normal distribution. In some cases, the determination of the block **1220** may be performed using logarithmic relationships, such that the median and/or standard deviation may be logarithmically based.

(170) At block **1230**, a determination can be made as to whether the rate of variability is above one threshold and/or below another threshold (or the same threshold). For example, the control device may determine whether the median blood glucose level minus a multiple of the standard deviation is above or below a minimum blood glucose level. In some cases, another rate of variability can be used and another threshold may be used. If the rate of variability is does not cross the threshold (e.g., the median blood glucose level minus the multiple of the standard deviation is at the threshold), the method **1200** may proceed back to the block **1210**. If the threshold is crossed, the method **1200** may proceed to the block **1240**.

(171) At block **1240**, the target blood glucose level may be modified based on the rate of variability. For example, if the rate of variability is high (e.g., the rate of variability exceeds a threshold), the target blood glucose level may be raised to decrease the probability of the blood glucose level of a PWD dropping below a minimum threshold. As another example, if the rate of variability is low (e.g., the rate of variability falls below a threshold), the target blood glucose level may be lowered to more closely align the probability of the blood glucose level of a PWD dropping below the minimum threshold with an acceptable probability. As another example, if the median blood glucose value minus a multiple of the standard deviation of the distribution is below the minimum blood glucose level, the target blood glucose level

may be increased. As an additional example, if the median blood glucose value minus a multiple of the standard deviation of the distribution is above the minimum blood glucose level, the target blood glucose level may be lowered.

(172) At block **1250**, insulin may be delivered during the diurnal period based on the modified target blood glucose level. For example, a set of delivery profiles may be generated based on projected blood glucose levels and variations of projected blood glucose levels from the modified target blood glucose level. A delivery profile that most closely approximates the modified target blood glucose level may be selected and insulin may be delivered according to one or more delivery actions in the delivery profile.

(173) Modifications, additions, or omissions may be made to the method **1200** without departing from the scope of the present disclosure. For example, the operations of the method **1200** may be implemented in differing order. Additionally or alternatively, two or more operations may be performed at the same time. Furthermore, the outlined operations and actions are provided as examples, and some of the operations and actions may be optional, combined into fewer operations and actions, or expanded into additional operations and actions without detracting from the essence of the disclosed embodiments.

(174) The embodiments described herein may include the use of a special-purpose or general-purpose computer including various computer hardware or software modules, as discussed in greater detail below.

(175) Embodiments described herein may be implemented using computer-readable media for carrying or having computer-executable instructions or data structures stored thereon. Such computer-readable media may be any available media that may be accessed by a general-purpose or special-purpose computer. By way of example, and not limitation, such computer-readable media may include non-transitory computer-readable storage media including Random Access Memory (RAM), Read-Only Memory (ROM), Electrically Erasable Programmable Read-Only Memory (EEPROM), Compact Disc Read-Only Memory (CD-ROM) or other optical disk storage, magnetic disk storage or other magnetic storage devices, flash memory devices (e.g., solid state memory devices), or any other storage medium which may be used to carry or store desired program code in the form of computer-executable instructions or data structures and which may be accessed by a general-purpose or special-purpose computer. Combinations of the above may also be included within the scope of computer-readable media.

(176) Computer-executable instructions comprise, for example, instructions and data which cause a general-purpose computer, special-purpose computer, or special-purpose processing device (e.g., one or more processors) to perform a certain function or group of functions. Although the subject matter has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.

(177) As used herein, the terms “module” or “component” may refer to specific hardware implementations configured to perform the operations of the module or component and/or software objects or software routines that may be stored on and/or executed by general-purpose hardware (e.g., computer-readable media, processing devices, etc.) of the computing system. In some embodiments, the different components, modules, engines, and services described herein may be implemented as objects or processes that execute on the computing system (e.g., as separate threads). While some of the system and methods described herein are generally described as being implemented in software (stored on and/or executed by general-purpose hardware), specific hardware implementations or a combination of software and specific hardware implementations are also possible and contemplated. In the present description, a “computing entity” may be any computing system as previously defined herein, or any module or combination of modules running on a computing system.

(178) Any ranges expressed herein (including in the claims) are considered to be given their broadest possible interpretation. For example, unless explicitly mentioned otherwise, ranges are to include their end points (e.g., a range of “between X and Y” would include X and Y). Additionally, ranges described using the terms “approximately” or “about” are to be understood to be given their broadest meaning consistent with the understanding of those skilled in the art. Additionally, the term approximately includes anything within 10%, or 5%, or within manufacturing or typical tolerances.

(179) All examples and conditional language recited herein are intended for pedagogical objects to aid the reader in understanding the disclosure and the concepts contributed by the inventor to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Although embodiments of the present disclosure have been described in detail, it should be understood that the various changes, substitutions, and alterations could be made hereto without departing from the spirit and scope of the disclosure.

Claims

1. A method comprising: obtaining glucose value readings over a period for each of a plurality of days; analyzing variability of the glucose values over the period for the plurality of days to determine a measurement of the variability of the glucose values over the period for the plurality of days, wherein determining the measurement of the variability comprises: determining a measurement of dispersion of the glucose value readings; determining a measurement of central tendency of the glucose value readings; and subtracting a multiple of the measurement of dispersion from the measurement of central tendency to determine the measurement of variability of the glucose values; comparing the measurement of the variability of the glucose values over the period for the plurality of days to a first threshold glucose value and a second threshold glucose value, wherein the first threshold glucose value is lower than the second threshold glucose value; determining that the measurement of variability either falls below the first threshold glucose value or falls above the second threshold glucose value, responsive to determining that the measurement of the variability of the glucose values over the period for the plurality of days falls below the first threshold glucose value, increasing a target glucose value to an increased modified target glucose value; responsive to determining that a measurement of the variability of the glucose values over the period for the plurality of days falls above the second threshold glucose value, decreasing the target glucose value to a decreased modified target glucose value; and delivering insulin, using an insulin pump, based on one of the increased or decreased modified target glucose values.
2. The method of claim 1, wherein increasing a target glucose value comprises incrementally increasing the target glucose value to the increased modified target glucose value, with the provision that the increased modified target glucose value is capped at a maximum glucose value.
3. The method of claim 2, wherein the first threshold glucose value is at least partially determined by a fear of hypoglycemia index (FHI) set by a user.
4. The method of claim 2, wherein the increase between the increased modified target glucose value and the target glucose value is determined based at least partially on the determined measurement of central tendency and the determined measurement of dispersion of the glucose value readings for each of the plurality of days.
5. The method of claim 1, wherein the increased modified target glucose value is capped at a maximum target glucose value.

6. The method of claim 1, wherein decreasing the target glucose value comprises incrementally decreasing the target glucose value to the decreased modified target glucose value, with the provision that the decreased modified target glucose value is limited by a minimum target glucose value.
7. The method of claim 6, wherein the second threshold glucose value is at least partially determined by a fear of hypoglycemia index (FHI) set by a user.
8. The method of claim 6, wherein the decrease between the decreased modified target glucose value and the target glucose value is determined based at least partially on a determined measurement of central tendency and a determined measurement of dispersion of glucose values.
9. The method of claim 8, wherein the target glucose value is decreased by no more than 2 mg/dL per day.
10. The method of claim 9, further comprising delivering insulin during an adjacent period in the same direction based at least partially on one of the increased or decreased modified target glucose values and to smooth changes in target glucose values between adjacent periods.
11. The method of claim 1, wherein delivering insulin based on the increased or decreased modified target glucose value includes: generating a first plurality of insulin delivery profiles, each of the first plurality of insulin delivery profiles including a first series of insulin delivery actions spanning a first time interval extending over the period and subsequent periods; projecting a first plurality of future blood glucose values for each insulin delivery profile of the first plurality of insulin delivery profiles for a plurality of times spanning the first time interval, each projected future blood glucose values being projected using at least one up-to-date glucose value for a person with diabetes (PWD); selecting a first profile of the first plurality of insulin delivery profiles based at least in part upon a comparison between the first plurality of future blood glucose values for each insulin delivery profile and a plurality of increased or decreased modified target glucose values for each period overlapping with the first time interval; and delivering a first dose of insulin using the insulin pump for a second time interval after a previous dose of insulin, the first dose of insulin corresponding to a first action in the first series of insulin delivery actions of the first profile, the second time interval being equal to or shorter than the period.
12. The method of claim 1, wherein analyzing the variability in the glucose values over the period for the plurality of days includes weighting the glucose values from more recent days of the plurality of days more heavily than the glucose values from older days of the plurality of days.
13. The method of claim 1, wherein analyzing variability in the glucose values over the period for the plurality of days includes excluding from the plurality of days glucose values from days older than a cutoff date.
14. A system comprising: a glucose sensor configured to generate glucose value readings; an insulin pump configured to deliver insulin based on a message; and a control device comprising: at least one processor; and at least one non-transitory computer-readable storage medium storing instructions thereon that, when executed by the at least one processor, cause the control device to: obtain glucose value readings over a period for each of a plurality of days; analyze variability in the glucose values over the period for the plurality of days to determine a measurement of the variability of the glucose values over the period for the plurality of days, wherein determining the measurement of the variability comprises: determining a measurement of dispersion of the glucose value readings; determining a measurement of central tendency of the glucose value readings; and subtracting a multiple of the measurement of dispersion from the measurement of central tendency to determine the measurement of variability of the glucose values; compare the measurement of the variability of the glucose values over the period for the plurality of days to a first threshold glucose value and a second threshold glucose value, wherein the first threshold glucose value is lower than the second threshold glucose value; determine that the measurement of variability either falls below the first threshold glucose value or falls above the second threshold glucose value, responsive to determining that the measurement of the variability of the glucose values over the period for the plurality of days falls below the first threshold glucose value, increase a target glucose value to an increased modified target glucose value; responsive to determining that a measurement of the variability of the glucose values over the period for the plurality of days falls above the second threshold glucose value, decrease the target glucose value to a decreased modified target glucose value; generate a message to deliver insulin based on the increased or decreased modified target glucose value; and send the generated message to the insulin pump to cause the insulin pump to deliver insulin based on one of the increased or decreased modified target glucose values.
15. The system of claim 14, wherein the control device is one of a mobile computing device, a remote server, and control circuitry.
16. The system of claim 15, wherein the message includes instructions to control circuitry to utilize the increased or decreased modified target glucose value in controlling delivery of insulin.
17. The system of claim 14, wherein the glucose sensor includes a continuous glucose monitor (CGM).
18. A system comprising: a glucose sensor configured to generate glucose value readings; an insulin pump configured to deliver insulin based on a message; and a control device comprising: at least one processor; and at least one non-transitory computer-readable storage medium storing instructions thereon that, when executed by the at least one processor, cause the control device to: receive glucose value readings from a blood glucose monitor over a period for each of a plurality of days; analyze variability in the glucose values over the period for the plurality of days to determine a measurement of the variability of the glucose values over the period for the plurality of days, wherein determining the measurement of the variability comprises: determining a measurement of dispersion of the glucose value readings; determining a measurement of central tendency of the glucose value readings; and subtracting a multiple of the measurement of dispersion from the measurement of central tendency to determine the measurement of variability of the glucose values; compare the measurement of the variability of the glucose values over the period for the plurality of days to a first threshold glucose value and a second threshold glucose value, wherein the first threshold glucose value is lower than the second threshold glucose value; determine that the measurement of variability either falls below the first threshold glucose value or falls above the second threshold glucose values, responsive to determining that the measurement of the variability of the glucose values over the period for the plurality of days falls below the first threshold glucose value, increase a target glucose value to an increased modified target glucose value; responsive to determining that the measurement of the variability of the glucose values over the period for the plurality of days falls above the second threshold glucose value, decrease the target glucose value to a decreased modified target glucose value; generate a message to deliver insulin based on the one of the increased or decreased modified target glucose value; and transmit the message to an insulin pump and causing the insulin pump to deliver insulin based at least partially on one of the increased or decreased modified glucose values.
-